

Withdrawal/Redaction Sheet

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001a. form	re: Information for New Drug Product (partial) (1 page)	n.d.	P6/b(6)
001b. form	re: Information for New Drug Product (partial) (1 page)	n.d.	P6/b(6)
001c. note	re:phone number (partial) (1 page)	12/30/1991	P6/b(6)

COLLECTION:

Clinton Presidential Records
Domestic Policy Council
Devorah Adler
OA/Box Number: 20468

FOLDER TITLE:

Fraud and Drugs

2012-0463-S

rc754

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

TOM BLUREY, VIRGINIA, CHAIRMAN

W.J. BILLY TAUBIN, LOUISIANA
 MICHAEL G. OXLEY, OHIO
 MICHAEL BILMAGIS, FLORIDA
 JOE BARTON, TEXAS
 FRED LITTON, MICHIGAN
 CLIFF STAMMS, FLORIDA
 PAUL E. GILLMOR, OHIO
 JAMES C. GREENWOOD, PENNSYLVANIA
 CHRISTOPHER COX, CALIFORNIA
 NATHAN DEAL, GEORGIA
 STEVE LARGENT, OKLAHOMA
 RICHARD BURR, NORTH CAROLINA
 BRIAN P. BILBRAY, CALIFORNIA
 TO WHITFIELD, KENTUCKY
 GREG GANSKE, IOWA
 CHARLIE NORWOOD, GEORGIA
 TOM COBURN, OKLAHOMA
 RICK LAZIO, NEW YORK
 BARBARA CUBIN, WYOMING
 JAMES E. ROGAN, CALIFORNIA
 JOHN SHIMKUS, ILLINOIS
 HEATHER WILSON, NEW MEXICO
 JOHN B. SHADEGG, ARIZONA
 CHARLES W. "CHIP" PICKERING, MISSISSIPPI
 VITO FOSSELLA, NEW YORK
 HOY BLUNT, MISSOURI
 ED BRYANT, TENNESSEE
 ROBERT L. EHRLICH, JR., MARYLAND

JOHN D. WINGELL, MICHIGAN
 HENRY A. WAXMAN, CALIFORNIA
 EDWARD J. MARKEY, MASSACHUSETTS
 RALPH M. HALL, TEXAS
 NICK BOUCHER, VIRGINIA
 FIDELPHUS TOWNS, NEW YORK
 FRANK PALLONE, JR., NEW JERSEY
 SHERROD BROWN, OHIO
 RART GORDON, TENNESSEE
 PETER DEUTSCH, FLORIDA
 BOBBY L. RUSH, ILLINOIS
 ANNA C. ESHOO, CALIFORNIA
 RON KLING, PENNSYLVANIA
 BART STUPAK, MICHIGAN
 ELIOT L. ENGEL, NEW YORK
 THOMAS C. SAWYER, OHIO
 ALBERT R. WYNN, MARYLAND
 GENE GREEN, TEXAS
 KAREN MCCARTHY, MISSOURI
 TED STRICKLAND, OHIO
 DIANA DEGETTE, COLORADO
 THOMAS M. BARRETT, WISCONSIN
 BILL LUTHER, MINNESOTA
 LOIS CAPPS, CALIFORNIA

U.S. House of Representatives
Committee on Commerce
 Room 2125, Rayburn House Office Building
 Washington, DC 20515-6115

May 5, 2000

JAMES E. DERDERIAN, CHIEF OF STAFF

The Honorable Donna E. Shalala
 Secretary
 Department of Health and Human Services
 200 Independence Avenue, S.W.
 Washington, D.C. 20201

Dear Secretary Shalala:

I am writing to express my concerns over the excessive reimbursements that the Medicare program is paying for certain covered pharmaceuticals and other related products. Further, I wish to learn what actions the Health Care Financing Administration (HCFA) and the Department of Health and Human Services (HHS) have taken to address this problem.

As you know, the Office of Inspector General at HHS has issued a series of reports that have identified significant discrepancies between the prices Medicare pays for certain drugs and the prices that are available to private sector purchasers of these same drugs. In its December 1997 report, the Office of Inspector General (OIG) estimated that, in 1996 alone, Medicare could have saved \$447 million by reducing the Medicare-allowed price for just 22 drugs to the actual prices available in the private wholesale sector. The OIG also found that Medicare could have saved at least 40 percent of the current allowance for almost half of the 22 drugs, and 93 percent for one particular drug, by limiting reimbursement to the available private sector prices for those drugs. As you know, Medicare is supposed to pay only 95 percent of the Average Wholesale Price (AWP) of these drugs under Federal law.

These findings are supported by additional investigative work that the Committee on Commerce has conducted. The Committee has written to several drug manufacturers, inquiring about the prices they charge to wholesale purchasers. The responses the Committee received confirmed that Medicare does in fact pay considerably more for certain drugs than the actual average price paid by such wholesalers. In addition, the Committee is continuing to investigate the practices of certain drug manufacturers relating to allegations that they manipulated the AWP of particular drugs in order to increase the sales of these drugs. I have enclosed for your review letters that the Committee has recently sent to several drug manufacturers regarding this investigation.

THE HONORABLE DONNA E. SHALALA

Page 2

The information revealed in the OIG report and through the Committee's investigation is particularly troubling. I firmly believe that improper expenditures in the Medicare program, whether due to waste, abuse or fraud, are unacceptable. In the time that I have been Chairman of the Committee, we have held numerous hearings that have sought to prevent the payment of such improper expenditures throughout the Medicare and Medicaid programs. As Congress considers ways to expand the scope of Medicare's coverage of prescription drugs, it is essential that this Administration be able to assure Congress, the beneficiaries of the Medicare program, and the American people that it has done all that it can to prevent waste and abuse in the current limited Medicare drug program.

The December 1997 OIG report contained several specific recommendations relating to actions HCFA could take to address this problem, including requiring all Medicare carriers to reimburse a uniform allowed amount for each HCFA Common Procedure Coding System (HCPCS) drug code. In response to this report, then-Deputy Administrator Nancy-Ann Min DeParle wrote to the Inspector General, indicating that HCFA had convened a workgroup to develop an electronic file consisting of the AWP for drugs covered by Medicare. She further stated that HCFA would then distribute this file to Medicare contractors for their use in paying claims for drugs.

To date, it appears that these efforts have not been implemented. The Committee has learned that HCFA submitted a Request for Proposal to develop a solution to the problem of price variances between Medicare carriers, but no contract was ever entered into, and it does not appear that the issue has been resolved. The December 1997 OIG report noted, "[t]he rate at which physicians and suppliers are paid for drugs should not depend on which carrier providers bill." I strongly concur with this statement, and am deeply disturbed that it appears that HCFA has failed to remedy this problem in the two and a half years since it was first identified by the Inspector General.

In her response to the OIG report, then-Deputy Administrator Min DeParle also stated that HCFA would pursue other "appropriate ways" to eliminate the markup for drugs billed to Medicare, beyond those legislative initiatives contained in the President's budget. I understand that a rulemaking was initiated, but never completed, to utilize your authority to adjust Medicare reimbursements that are not inherently reasonable. I wish to learn by what other "appropriate ways" HCFA has attempted to address the problem of excessive reimbursements for Medicare-covered drugs. Accordingly, I request that, pursuant to Rules X and XI of the U.S. House of Representatives, you provide the following information to the Committee no later than May 26, 2000.

1. Please identify all actions taken by HCFA to date to independently investigate and assess the accuracy of the AWP as a measurement of wholesale drug prices.
2. Please identify all actions taken by HCFA to date to independently investigate and assess the discrepancies between the prices paid by Medicare and other non-governmental entities for Medicare-covered drugs.

The Honorable Donna E. Shalala

Page 3

3. Please identify the other "appropriate ways," mentioned in then-Deputy Administrator Min DeParle's response to the OIG report, that HCFA has utilized to address the problem of excessive reimbursements for Medicare-covered drugs. In your answer, please describe all actions that have been taken relating to these efforts.
4. Please identify whether the electronic file, also identified in then-Deputy Administrator Min DeParle's response to the OIG report, has been developed and is now operational. If the electronic file is not yet operational, please identify whether other actions have been taken to insure that all Medicare carriers are now reimbursing a uniform allowed amount for each HCPCS drug code.

If you should have any questions, please have your staff contact Mr. Charles Clapton, Committee Counsel, at (202) 226-2424. I appreciate your cooperation in this matter.

Sincerely,


Tom Bliley
Chairman

Attachments

cc: The Honorable John D. Dingell, Ranking Member



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

The Honorable Tom Bliley
Chairman, Commerce Committee
House of Representatives
Washington, D.C. 20515

Thank you for your letter regarding pricing for the drugs that Medicare currently covers. As you know, the law requires Medicare to pay physicians 95 percent of the average wholesale price for the handful of drugs that are covered by Medicare. We share your concern about the significant discrepancies between the prices that Medicare is required by law to pay to physicians for these drugs based on the average wholesale price and the prices that physicians themselves pay. Since 1997, the Clinton Administration has four times proposed taking steps to pay more appropriately. I appreciate the opportunity to explain what we have done and the challenges we face in ensuring that Medicare pays fair prices.

We are aware that the Department of Justice and HHS Inspector General have been conducting investigations in this area and the HCFA Administrator has asked the Justice Department to keep her apprised of developments. We are reviewing new pricing data developed for Medicaid and considering appropriate steps to enable Medicare to benefit from it, as well. We also have been consulting with the Department of Justice and HHS Inspector General to seek advice and recommendations on changes to Medicare policy that would ensure Medicare pays a fair price.

HCFA has been actively addressing this issue, both legislatively and through administrative actions, for many years. In 1991, the agency established a policy (through notice and comment) to pay physicians for drugs based on the lower of the estimated acquisition cost or the average wholesale price. However, due to difficulties in acquiring data from physicians to accurately estimate acquisition costs, we had to rely instead on the average wholesale price.

Because the estimated acquisition cost approach proved unworkable, the President in 1997 proposed legislation to pay physicians their actual acquisition cost for drugs. However, the Balanced Budget Act instead reduced Medicare payment for covered drugs from 100 percent to 95 percent of average wholesale price, reducing only a fraction of the excessive payment amounts. In 1998 the President again proposed paying physicians their actual acquisition cost to "ensure that doctors are reimbursed no more, and no less, than the price they themselves pay for the medicines they give Medicare patients."

In 1999 and again this year, the President proposed a different legislative approach to the problem -- that Medicare pay 83 percent of the average wholesale price. We estimate that this method would substantially reduce the pricing discrepancy, as well as any administrative burden on physicians and the agency associated with determining the costs of drugs. The HCFA actuaries project that this legislative proposal would save \$2.1 billion over 10 years.

Page 2 - The Honorable Tom Bliley

Based on our recent discussion with the Department of Justice and HHS Inspector General, we have concluded that payments based on actual acquisition cost is a much more effective way to ensure that Medicare is paying fairly. We therefore are now changing our FY 2001 budget to propose paying physicians their actual acquisition costs. We also plan to work with physician groups to review payment rates for chemotherapy administration.

In addition to changing our legislative proposal, we are taking advantage of a more accurate source of average wholesale price data than has been available to date. This data are from catalogs of drug wholesalers, whom the Department of Justice says account for a significant portion of the market. The Department of Justice has compiled data for 379 products, each with its unique national drug code representing 46 different chemical compounds. Many of these drugs are covered by Medicare, and they represent about one-third of Medicare spending for drugs.

To apply this new information in Medicare right away, the Administration is calculating the average of the wholesale catalog prices, just as has been done by First Data Bank, a company specializing in the compilation of drug pricing data (the Blue Book). We are sending this information to Medicare carriers so they can use it when they determine average wholesale prices for their next quarterly update of Medicare drug allowances, which will become effective on October 1, 2000. This is the most immediate action we can take without going through the formal rule-making process.

We also are consulting with the Department of Justice and HHS Inspector General on the possibility of developing a proposed rule that could require carriers to use an average wholesale price based on data from wholesalers. To monitor carrier activities, we are requiring carriers to send to HCFA by September 15, 2000, a written explanation of the data source used for determining payment allowances for the 46 drugs.

In addition to the proposed legislation and our most recent administrative activity discussed above, we have taken several other steps over the last several years to try to address Medicare drug pricing inequities.

- We proposed using the inherent reasonableness authority secured in the Balanced Budget Act of 1997 to reduce excessive charges on several items – including albuterol sulfate. Our contractors who process durable medical equipment claims surveyed retailers in 16 states and found that Medicare was paying substantially more than other payers. A September 1998 proposed rule to reduce payments is on hold by Congressional mandate until a GAO study of our use of the inherent reasonableness authority is published and we issue a final rule. We have just received the draft final report from the GAO, and are looking forward to their final report so that we can move forward.

- We are using market forces and competition to set fairer prices for albuterol sulfate as part of a competitive bidding demonstration for durable medical equipment supplies in Texas. A similar demonstration in Florida, while not including drugs, is saving an average of 17 percent for beneficiaries and Medicare through the bidding process. We hope to be able to use the results from these demonstrations more generally in the Medicare program.
- We have proposed legislation to reduce payments for Epogen, the most common and costly drug that Medicare covers, by 10 percent. This was based on a November 23, 1997 report by the HHS Inspector General which found that Medicare payments for Epogen exceed the cost of purchasing it by approximately 10 percent.
- And we are developing the electronic file of prices for Medicare covered drugs, as recommended by the HHS Inspector General. A contractor has been working on numerous technical issues, including the components necessary for appropriate drug pricing (e.g., route of administration, drug strength concentrations, available package size and most commonly used dosage ranges). We are hopeful that a report on this first phase of the project will be available by this summer. A report on a second phase of work on issues relating to mapping between codes Medicare currently uses (the HCFA Common Procedure Coding System) and national drug codes, compatibility with the Health Insurance Portability and Accountability Act administrative simplification standards that are being developed, generic and brand name mapping, new drug entries, drug deletions, and updates, is expected by the end of the year. We believe this work will help us ensure that Medicare payments are appropriate and consistent across the country.

We have also taken actions to help State Medicaid programs obtain fair prices for drugs.

- We have proposed sharing average manufacturer price data with States so they can accurately set Medicaid reimbursement rates. Current law requires drug manufacturers to report average manufacturer price data to HHS but prohibits disclosure of the data by States, who instead must rely on average wholesale price or wholesale acquisition cost data that, like average wholesale price, can be substantially inflated.
- We have proposed applying the consumer price index-urban (CPI-U) adjustment to generic drugs. Brand name drug manufacturers must pay an additional dollar-for-dollar rebate to Medicaid if they increase prices in excess of CPI-U. But it is now clear that generic drug prices also sometimes are rising faster than inflation.
- And State Medicaid programs should also benefit from First Data Bank's announcement that it will revise the way it collects and reports average wholesale price data to them, based on information in wholesaler catalogs.



Page 4 - The Honorable Tom Bliley

Again, I thank you for your inquiry into this important matter. We would be very interested in receiving the data the Commerce Committee has compiled on Medicare drug pricing to assist our efforts. We hope Congress will enact the President's proposal for improving Medicare drug payments. And I look forward to working further with you and your Committee as we proceed.

Sincerely,

Donna Shalala



DEPARTMENT OF HEALTH & HUMAN SERVICES

Health Care Financing Administration

The Administrator
Washington, D.C. 20201

MAY 31 2000

The Honorable Fortney "Pete" Stark
Ranking Member, House Ways & Means Health Subcommittee
House of Representatives
Washington, D.C. 20515

Dear Mr. Stark:

Thank you for your April 6 letter about the Clinton Administration's efforts to obtain fair prices for the limited number of drugs that Medicare currently covers, and thank you for the leadership role you have taking in addressing the need to ensure that both Medicare and Medicaid pay appropriately for prescription drugs.

We have closely monitored the investigations of drug pricing conducted by the Department of Justice, the HHS Inspector General, and the State Medicaid Fraud Control Units. Let me assure you that I share your concern about the significant discrepancies between the prices that Medicare must pay by law and the significantly lower prices at which physicians may obtain these drugs. I appreciate the opportunity to explain what we have done and the challenges we face in ensuring that Medicare pays fair prices.

History: The Health Care Financing Administration has been actively working to address this issue, both legislatively and through administrative actions, for many years. In 1991, the agency issued regulations to pay for these drugs based on the lower of the estimated acquisition cost or the average wholesale price. To implement this policy, HCFA developed a survey to get the necessary information from physicians. However, given the wide range of drugs used in different amounts at different frequencies by different types of physicians in different geographic areas of the country, we would have had to survey virtually all physicians in order to get a statistically valid estimate of acquisition costs. Because that would have been burdensome and unfeasible, the Administration therefore determined that it would rely instead on the average wholesale price.

Because the estimated acquisition cost approach had proved unworkable, in 1997, the President proposed legislation to pay physicians their actual acquisition costs. Physicians would tell Medicare what they pay for drugs and be reimbursed that amount, rather than the Administration developing an estimate of acquisition costs and basing payment on the estimate. Unfortunately, Congress did not adopt the Administration's proposal. Instead, the Balanced Budget Act reduced Medicare payment for covered drugs from 100 percent to 95 percent of average wholesale price. This recaptures only a fraction of the excessive Medicare payment amounts because, until recently, available average wholesale price data did not correlate to actual wholesale prices for certain Medicare-covered drugs.

Page 2 - The Honorable Fortney "Pete" Stark

Indeed, the HHS Inspector General found payments based on average wholesale price data to be 11 to 900 percent greater than the prices available to the physician community. Therefore, in 1998, the President again proposed paying physicians their actual acquisition cost to "ensure that doctors are reimbursed no more, and no less, than the price they themselves pay for the medicines they give Medicare patients." However, no Congressional action was taken.

Because Congress failed to act on the Administration's 1997 and 1998 proposals, in 1999 and again this year, the President proposed a different legislative approach to achieve a similar result -- paying 83 percent of the average wholesale price instead of the 95 percent allowed by the Balanced Budget Act. We estimate that this would substantially reduce the pricing discrepancy, as well as any administrative burden associated with surveying vast numbers of physicians to estimate acquisition costs. The HCFA actuaries project that this legislative proposal would save Medicare \$2.9 billion over 10 years.

Current Activity: We are now moving administratively to take advantage of the newly available, more accurate data on average wholesale prices developed for Medicaid as a result of Department of Justice investigations. These data are from catalogs of drug wholesalers, which the Department of Justice says account for a significant portion of the wholesale market. The Department of Justice and the State Medicaid Fraud Control Units have compiled data for about 400 national drug codes, representing about 50 different chemical compounds. The Department of Justice provided this information to First Data Bank, a company specializing in the compilation of drug pricing data (formerly known as the "Blue Book") that is used to determine prices paid by State Medicaid programs. These drugs represent about one-third of Medicare spending for drugs.

To obtain the benefits of this new information for Medicare right away, we will provide to the insurance companies that, by law, Medicare must contract with to pay Part B claims (known as "carriers") the average of the wholesale catalog prices, just as has been calculated by First Data Bank. In June, we will send this information to Medicare carriers so they can use it when they determine average wholesale prices for their next quarterly update of Medicare drug allowances, which will become effective on October 1, 2000. According to the HHS General Counsel, this is the most immediate action we can take without undergoing the formal rule-making process.

We also are consulting with the Department of Justice and HHS Inspector General on the feasibility of developing additional means to ensure that accurate drug pricing data is used in setting Medicare rates. To monitor carrier activities, we are requiring carriers to send to HCFA by September 15, 2000, a written explanation of the data sources used for determining payment allowances for these drugs. And we are attempting to meet with the company that publishes the "Red Book," which is the source of average wholesale price data that most carriers have used to date, to discuss recent developments and the need for accurate data. Furthermore, we are considering whether to change our current legislative proposal from paying 83 percent of average wholesale prices to instead propose paying physicians their actual acquisition costs.

Page 3 - The Honorable Fortney "Pete" Stark

Based on our recent discussions with the Department of Justice and HHS Inspector General, we believe that the Administration's original approach -- to base Medicare's payment for drugs on the physician's actual acquisition costs, perhaps adjusted for a reasonable handling fee -- is probably the most effective means to ensure that Medicare is paying fairly. As part of this effort, we plan to work with physician groups to review physicians' ability to provide acquisition cost data, and to review payment rates for chemotherapy administration to ensure that they are adequate as we reduce payments for the drugs themselves to the prices that physicians pay.

Other Efforts: In addition to the proposed legislation and administrative activity discussed above, we are taking several other steps to try to address Medicare drug pricing inequities.

- We are developing an electronic file of prices for Medicare covered drugs, as recommended by the HHS Inspector General in her December 1997 report. A contractor has been working on numerous technical issues, including the components necessary for appropriate drug pricing (e.g., route of administration, drug strength concentrations, available package size and most commonly used dosage ranges). We are hopeful that a report on this first phase of the project will be available by this summer. A report on a second phase of work on issues relating to mapping between codes Medicare currently uses (the HCFA Common Procedure Coding System) and national drug codes, compatibility with the Health Insurance Portability and Accountability Act administrative simplification standards that are being developed, generic and brand name mapping, new drug entries, drug deletions, and updates, is expected by the end of the year. We believe this work will help us ensure that all carriers across the country have access to the most accurate average wholesale price data and will reimburse a uniform allowed amount for each drug code.
- We are using market forces and competition to set fairer prices for one drug -- albuterol sulfate -- as part of a competitive bidding demonstration for durable medical equipment supplies in Texas. A similar demonstration in Florida, while not including drugs, is saving an average of 17 percent for beneficiaries and Medicare through the bidding process. We hope to be able to use the results from these demonstrations more generally in the Medicare program.
- Finally, we are awaiting a final General Accounting Office report on use of the "inherent reasonableness" authority contained in the Balanced Budget Act of 1997. In September 1998, we proposed reducing excessive charges on several items, including albuterol sulfate. Our contractors who process durable medical equipment claims surveyed retailers in 16 states and found that Medicare was paying substantially more than other payers.

Page 4 - The Honorable Fortney "Pete" Stark

Congress, however, in the Balanced Budget Refinement Act of 1999, mandated that we not take action to finalize the proposed rule until a GAO study of our use of the inherent reasonableness authority is published. We just received the draft final report from the GAO and look forward to its final report so we can move forward to reduce these payments to reasonable levels.

We have also taken actions to help State Medicaid programs obtain fair prices for drugs.

- We have proposed sharing average manufacturer price data with States so they can accurately set Medicaid reimbursement rates. Current law only requires drug manufacturers to report average manufacturer price data to HHS.
- We have proposed applying the consumer price index-urban (CPI-U) adjustment to generic drugs. Brand name drug manufacturers must pay an additional dollar-for-dollar rebate to Medicaid if they increase prices in excess of CPI-U. But it is now clear that generic drug prices also sometimes increase faster than inflation.
- We plan to work with all State Medicaid programs regarding First Data Bank's announcement that it will revise the way it collects and reports average wholesale price data to them, based on information in wholesaler catalogs. This should create immediate benefit for all State Medicaid programs.

As you know, the President has proposed a voluntary, comprehensive Medicare outpatient drug benefit available to all Medicare beneficiaries. A critical element of this proposal is the use of private pharmacy benefit managers who will negotiate prices with pharmaceutical companies, as they do now for most private insurance plans. This will help keep the benefit affordable without any statutory price setting, and avoid the types of concerns addressed in this letter.

Again, I thank you for your inquiry into this important matter. We hope Congress will enact the President's proposal for improving Medicare drug payments, and I look forward to working further with you and your Committee as we proceed.

Sincerely,



Nancy-Ann Min DeParle
Administrator



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

MAY 31 2000

The Honorable Tom Bliley
Chairman, Commerce Committee
House of Representatives
Washington, D.C. 20515

Dear Mr. Chairman:

Thank you for your May 5 letter about the Clinton Administration's efforts to obtain fair prices for the limited number of drugs that Medicare currently covers. We have closely monitored the investigations of drug pricing conducted by the Department of Justice, the HHS Inspector General, and the State Medicaid Fraud Control Units. Let me assure you that I share your concern about the significant discrepancies between the prices that Medicare must pay by law and the significantly lower prices at which physicians may obtain these drugs. I appreciate the opportunity to explain what we have done and the challenges we face in ensuring that Medicare pays fair prices.

History: The Health Care Financing Administration has been actively working to address this issue, both legislatively and through administrative actions, for many years. In 1991, the agency issued regulations to pay for these drugs based on the lower of the estimated acquisition cost or the average wholesale price. To implement this policy, HCFA developed a survey to get the necessary information from physicians. However, given the wide range of drugs used in different amounts at different frequencies by different types of physicians in different geographic areas of the country, we would have had to survey virtually all physicians in order to get a statistically valid estimate of acquisition costs. Because that would have been burdensome and unfeasible, the Administration therefore determined that it would rely instead on the average wholesale price.

Because the estimated acquisition cost approach had proved unworkable, in 1997, the President proposed legislation to pay physicians their actual acquisition costs. Physicians would tell Medicare what they pay for drugs and be reimbursed that amount, rather than the Administration developing an estimate of acquisition costs and basing payment on the estimate. Unfortunately, Congress did not adopt the Administration's proposal. Instead, the Balanced Budget Act reduced Medicare payment for covered drugs from 100 percent to 95 percent of average wholesale price. This recaptures only a fraction of the excessive Medicare payment amounts because, until recently, available average wholesale price data did not correlate to actual wholesale prices for certain Medicare-covered drugs.

Page 2 - The Honorable Tom Bliley

Indeed, the HHS Inspector General found payments based on average wholesale price data to be 11 to 900 percent greater than the prices available to the physician community. Therefore, in 1998, the President again proposed paying physicians their actual acquisition cost to "ensure that doctors are reimbursed no more, and no less, than the price they themselves pay for the medicines they give Medicare patients." However, no Congressional action was taken.

Because Congress failed to act on the Administration's 1997 and 1998 proposals, in 1999 and again this year, the President proposed a different legislative approach to achieve a similar result -- paying 83 percent of the average wholesale price instead of the 95 percent allowed by the Balanced Budget Act. We estimate that this would substantially reduce the pricing discrepancy, as well as any administrative burden associated with surveying vast numbers of physicians to estimate acquisition costs. The HCFA actuaries project that this legislative proposal would save Medicare \$2.9 billion over 10 years.

Current Activity: We are now moving administratively to take advantage of the newly available, more accurate data on average wholesale prices developed for Medicaid as a result of Department of Justice investigations. These data are from catalogs of drug wholesalers, which the Department of Justice says account for a significant portion of the wholesale market. The Department of Justice and the State Medicaid Fraud Control Units have compiled data for about 400 national drug codes, representing about 50 different chemical compounds. The Department of Justice provided this information to First Data Bank, a company specializing in the compilation of drug pricing data (formerly known as the "Blue Book") that is used to determine prices paid by State Medicaid programs. These drugs represent about one-third of Medicare spending for drugs.

To obtain the benefits of this new information for Medicare right away, we will provide to the insurance companies that, by law, Medicare must contract with to pay Part B claims (known as "carriers") the average of the wholesale catalog prices, just as has been calculated by First Data Bank. In June, we will send this information to Medicare carriers so they can use it when they determine average wholesale prices for their next quarterly update of Medicare drug allowances, which will become effective on October 1, 2000. According to the HHS General Counsel, this is the most immediate action we can take without undergoing the formal rule-making process.

We also are consulting with the Department of Justice and HHS Inspector General on the feasibility of developing additional means to ensure that accurate drug pricing data is used in setting Medicare rates. To monitor carrier activities, we are requiring carriers to send to HCFA by September 15, 2000, a written explanation of the data sources used for determining payment allowances for these drugs. And we are attempting to meet with the company that publishes the "Red Book," which is the source of average wholesale price data that most carriers have used to date, to discuss recent developments and the need for accurate data. Furthermore, we are considering whether to change our current legislative proposal from paying 83 percent of average wholesale prices to instead propose paying physicians their actual acquisition costs.

Page 3 - The Honorable Tom Bliley

Based on our recent discussions with the Department of Justice and HHS Inspector General, we believe that the Administration's original approach -- to base Medicare's payment for drugs on the physician's actual acquisition costs, perhaps adjusted for a reasonable handling fee -- is probably the most effective means to ensure that Medicare is paying fairly. As part of this effort, we plan to work with physician groups to review physicians' ability to provide acquisition cost data, and to review payment rates for chemotherapy administration to ensure that they are adequate as we reduce payments for the drugs themselves to the prices that physicians pay.

Other Efforts: In addition to the proposed legislation and administrative activity discussed above, we are taking several other steps to try to address Medicare drug pricing inequities.

- We are developing an electronic file of prices for Medicare covered drugs, as recommended by the HHS Inspector General in her December 1997 report. I understand your concern about the speed with which our efforts have proceeded, but I want to assure you that HCFA has moved as quickly as was administratively feasible to put this system in place. A contractor has been working on numerous technical issues, including the components necessary for appropriate drug pricing (e.g., route of administration, drug strength concentrations, available package size and most commonly used dosage ranges). We are hopeful that a report on this first phase of the project will be available by this summer. A report on a second phase of work on issues relating to mapping between codes Medicare currently uses (the HCFA Common Procedure Coding System) and national drug codes, compatibility with the Health Insurance Portability and Accountability Act administrative simplification standards that are being developed, generic and brand name mapping, new drug entries, drug deletions, and updates, is expected by the end of the year. We believe this work will help us ensure that all carriers across the country have access to the most accurate average wholesale price data and will reimburse a uniform allowed amount for each drug code.
- We are using market forces and competition to set fairer prices for one drug -- albuterol sulfate -- as part of a competitive bidding demonstration for durable medical equipment supplies in Texas. A similar demonstration in Florida, while not including drugs, is saving an average of 17 percent for beneficiaries and Medicare through the bidding process. We hope to be able to use the results from these demonstrations more generally in the Medicare program.
- Finally, we are awaiting a final General Accounting Office report on use of the "inherent reasonableness" authority contained in the Balanced Budget Act of 1997. In September 1998, we proposed reducing excessive charges on several items, including albuterol sulfate. Our contractors who process durable medical equipment claims surveyed retailers in 16 states and found that Medicare was paying substantially more than other payers.

Page 4 - The Honorable Tom Bliley

Congress, however, in the Balanced Budget Refinement Act of 1999, mandated that we not take action to finalize the proposed rule until a GAO study of our use of the inherent reasonableness authority is published. We just received the draft final report from the GAO and look forward to its final report so we can move forward to reduce these payments to reasonable levels.


We have also taken actions to help State Medicaid programs obtain fair prices for drugs.

- We have proposed sharing average manufacturer price data with States so they can accurately set Medicaid reimbursement rates. Current law only requires drug manufacturers to report average manufacturer price data to HHS.
- We have proposed applying the consumer price index-urban (CPI-U) adjustment to generic drugs. Brand name drug manufacturers must pay an additional dollar-for-dollar rebate to Medicaid if they increase prices in excess of CPI-U. But it is now clear that generic drug prices also sometimes increase faster than inflation.
- We plan to work with all State Medicaid programs regarding First Data Bank's announcement that it will revise the way it collects and reports average wholesale price data to them, based on information in wholesaler catalogs. This should create immediate benefit for all State Medicaid programs.

As you know, the President has proposed a voluntary, comprehensive Medicare outpatient drug benefit available to all Medicare beneficiaries. A critical element of this proposal is the use of private pharmacy benefit managers who will negotiate prices with pharmaceutical companies, as they do now for most private insurance plans. This will help keep the benefit affordable without any statutory price setting, and avoid the types of concerns addressed in this letter.

Again, I thank you for your inquiry into this important matter. We would be very interested in receiving the data the Commerce Committee has compiled on Medicare drug pricing to assist our efforts. We hope Congress will enact the President's proposal for improving Medicare drug payments, and I look forward to working further with you and your Committee as we proceed.

Sincerely,



Donna E. Shalala

Jim Sheehan
Assistant U.S. Attorney
615 Chestnut St.
Philadelphia, Pa. 19106
215 861-8301
Jim.Sheehan@USDOJ.gov

EXECUTIVE SUMMARY
ISSUES IN PHARMACY BENEFIT MANAGEMENT
KICKBACKS, FRAUD, AND PATIENT HARM

BACKGROUND: Pharmacy Benefit Management firms(PBMs) provide their customers(health plans, employers, and government agencies) with five basic services with significant benefits to customers and opportunities for expansion of drug benefits for beneficiaries:

- 1) real-time claims processing, reducing administrative costs per transaction
- 2) access to large networks of retail pharmacies, at reduced prices
- 3) control of use of expensive drugs(prior approval, exclusion)
- 4) data about usage, trends, growth areas
- 5) formulary management-maintaining lists of covered drugs

Over time, PBMs have expanded from these services to five other service areas, each with potential to reduce costs and improve benefits :

- 1) drug utilization review,minimizing harmful interactions for patients
- 2) brand to generic substitution, reducing therapy costs
- 3) mail order pharmacies,reducing prices per prescription
- 4) disease management programs, improving patient compliance and outcomes
- 5) solicitation of payments and rebates from manufacturers, some of which are returned to their customers.

PBMs compete with each other on the following bases:

- 1) Price(usually expressed as discount off AWP("average wholesale price")).
Typical PBM price to customers: AWP-12% plus \$3 dispensing fee, less for mail order.
- 2) payments from manufacturers passed through to customers
- 3) Network retail pharmacy access-convenience for members
- 4) on-time delivery of mail order prescriptions
- 5) brand to generic drug ratios

PBMs make their profits from five primary sources:

- 1) the spread between their price to customers and the price paid to pharmacies.
- 2) the spread between their costs and mail order payments.

- 3) fees from add-on services(utilization review, disease management)
- 4) sales of data about patient, physician utilization to drug information wholesalers
- 5) payments from drug manufacturers

Of these profit areas, by far the most important are payments from drug manufacturers and data sales.(the other profit areas are minimally above break-even). Both manufacturer payments and data sales depend primarily on the number of "covered lives" controlled by the PBM, so that the PBM will "loss lead" on claim processing to get access to covered lives. According to information we have received, some PBMs allegedly also engage in illegal acts to increase their payments from drug manufacturers, and to avoid passing on discounts and rebates to customers or beneficiaries.

WHAT DO SOME PBMS DO THAT IS WRONG?

1. They solicit, accept, and retain payments from manufacturers to influence their discretion about providing the right drug, at the right price, to the right patient, and to influence their advice to health plans..

- "we can kill your drug"

- "we control x doctors, and x patients"

- we agree to use best efforts to cause each health plan "to add all Pfizer Products to the Plan's formulary" and to "cause each Plan to treat each Pfizer product in a favorable manner"(Pfizer vs. PCS).

2. They solicit, accept and retain payments from manufacturers to influence their discretion as an agent for customers and beneficiaries, and do not disclose the payments received.

- counterdetailing fees *pushing one drug*

- information collection fees

- market share movement payments *rebates, disease mgmt prog*

- disease management fees

- intervention cost participation *call mbs & get them to switch drugs*

3. They make false statements to manufacturers and customers in order to obtain rebates and retain them.(lie-up, lie-down) *up to man down to plan*

- secret rebate agreements

Health Plan - ~~customers~~ and manufacturers not permitted to directly review records of payments, or rebate agreements(must use selected auditors who sign confidentiality agreements)

- aggregate reports to manufacturers which double-count sales, fail to exclude Medicare/Medicaid.

4. PBMs use professional pharmacists to contact physician offices seeking changes in prescriptions.

These pharmacists do not exercise independent professional judgment in providing their best recommendation to the physician office based upon appropriate professional review of the

patient; rather, they are either paid by the PBM to influence their recommendation, or (if employees) they are given scripts and quotas to “move” market share in the desired direction. Often, they are forbidden from deviating from the scripts, and forbidden from contacting the patient to determine if a switch involves risks or problems for the patient. The scripts often mislead the physician about the coverage for the drugs, and the likelihood of adverse outcomes.

5. The PBM payments to influence pharmacist recommendations, and the quotas for successful switches, result in false statements and false records by pharmacists of physician approval for drug switches.

6. The calls from pharmacists to physician offices results in delivery of products to beneficiaries by mail other than what they ordered, paid for, expected, and need to take to continue their treatment.

7. The “therapeutic interventions” (industry term) by pharmacists to change prescriptions put many patients at risk for adverse outcomes resulting from the change, a risk that PBMs are either aware of and ignore, or fail to follow.

- most “drug switches” involve drugs taken for chronic conditions, by patients taking multiple drugs for multiple medical problems-blood pressure, gastric reflux disease, high cholesterol
- failure to counsel with patients, or even advise them of switch efforts, increases risk of harm
- some patients fail to continue drug regimen after switch because of side effects
- bad reactions to switched drugs
- failure of new drug to control condition
- failure of PBM or doctor to monitor results of change

8. The “therapeutic interventions” in some cases, result in higher costs to customers or beneficiaries:

- higher priced drugs are the switched-to drugs
- switch is made from product going off patent to newer, patented version
- added costs of monitoring, lab work, dosage adjustment

9. PBMs make payments to other fiduciaries of rebate funds to obtain and retain their patient base:

- “advance rebates”
- asset purchases (e.g., buildings)
- aggregated rebate checks-not passed on to ultimate customer.
- “disease management payments

POTENTIAL VIOLATIONS

- Anti-Kickback Act, 41 U.S.C. 51
- Mail, Wire and Health Care Fraud 18 U.S.C. 1341, 1345, 1346
- False Claims Act 31 U.S.C. 3729

- Travel Act(interstate travel to commit commercial bribery)
- False Statements 18 U.S.C. 1001
- breach of duty as ERISA fiduciary under 29 U.S.C. 1104

THIS DOCUMENT CONTAINS AN ANALYSIS OF ALLEGATIONS PRESENTED BY VARIOUS PERSONS CONCERNING VARIOUS PBM's. IT DOES NOT DISCLOSE ALLEGATIONS OR CONCLUSIONS RELATING TO ANY PARTICULAR INVESTIGATION OR ANY PARTICULAR PBM.

DOD - CHAMPUS

~~FEBHP~~

MCare mgd care
Mcaid

NASA

Amtrak

Managed Care Operations

Table Definitions


Chart Calculations

Week Ending 08/28/99

Overall Performance Report


Action	Overall Rate	Personal Plan	Actual % of Plan Rate
Switches:	48%	48%	100%
Contacts:	92%	90%	102%

Contact Rate



06/14/1999 thru 08/28/1999, Days

Switch Rate



06/14/1999 thru 08/28/1999, Days

Intervention Results by Drug

CLASS FROM

NO. 1000

FolEST →

Service	Drug	Handled	Serious	Callable	Contacts	Contract Rate	Switches	Switching Rate	Ratio Switch
MATL	1 ACCOLATE	2	—	2	1	50	1	100	50
MATL	1 ALTACE	1	—	1	1	100	—	—	52
MATL	1 AVAPRO	2	—	2	2	100	—	—	35
MATL	1 CAPOTEN	1	—	1	1	100	—	—	12
MATL	1 LESCOL	1	—	1	1	100	—	—	50
MATL	1 LIPITOR	21	6	15	13	86	8	23	22
MATL	1 MEVACOR	1	—	1	1	100	—	—	52
MATL	1 MONORIL	1	—	1	1	100	—	—	55
MATL	1 PRUVACHOL	4	1	3	3	100	1	33	45
MATL	1 ZESTORETC	1	—	1	1	100	—	—	79
MATL	1 ZESTATL	2	—	2	2	100	2	100	78
MATL	2 ADALAT	1	—	1	1	100	1	100	66
MATL	2 AEROBID	2	—	2	2	100	2	100	53
MATL	2 BECONASE	1	—	1	1	100	—	—	73
MATL	2 CARDENE SR	2	—	2	2	100	1	50	25
MATL	2 ESTROGENS	1	—	1	1	100	1	100	37
MATL	2 INSULIN SYRINGE	3	1	2	2	100	2	100	67
MATL	2 NASAL STEROIDS	1	—	1	1	100	1	100	75
MATL	2 ORAL CONTRACEPT	3	—	3	3	100	2	55	60
MATL	2 OTHER TIER 2	10	—	10	9	90	5	55	63
MATL	2 PRUVACHOL	1	—	1	1	100	1	100	100
MATL	2 PROCARDIA XL	7	1	6	6	100	1	16	34
MATL	2 SULAR	1	—	1	1	100	1	100	40
MATL	3 KIGNOPEN	2	—	2	1	50	1	100	58
MATL	3 OTHER TIER 3	5	—	5	4	80	3	—	73
RETATL	1 ARITHROTEC	25	6	19	19	100	10	—	48
RETATL	1 AVAPRO	1	—	1	1	100	1	100	36
RETATL	1 LIPITOR	2	2	—	—	—	—	—	22
RETATL	2 PREVACID	1	—	1	1	100	—	—	55
RETATL	2 VANCEASE	1	—	1	—	—	—	—	70
	TOTALS	107	17	90	83	92.86	40	43.96	

30 August 1999

Managed Care Operations

These materials are the confidential property of [REDACTED] and are intended for the internal use of authorized employees only. These materials may not be duplicated or distributed without authorization.

Service	Drug	Handled	Samcat	Calistr	Constr	Constr	Constr	Constr	Constr
MAIL 1	AGGOLATE	1	1	1	1	100	1	1	50
MAIL 1	ALTACE	2	2	2	2	100	1	1	52
MAIL 1	AVAPRO	2	2	2	2	100	1	1	85
MAIL 1	IBTOR	12	8	8	8	88	4	50	22
MAIL 1	OTHER TIER 1	1	1	1	1	100	1	1	50
MAIL 1	PRAVACHOL	7	1	6	6	100	1	16	45
MAIL 2	AEROBID	4	1	3	3	100	1	1	58
MAIL 2	BECONASE	2	2	2	2	100	2	1	78
MAIL 2	CARDENE SR	1	1	1	1	100	1	1	25
MAIL 2	OTHER TIER 2	20	1	19	16	84	7	43	62
MAIL 2	PREVACID	3	1	3	2	56	1	50	50
MAIL 2	PROCARDIA XL	6	1	5	3	50	1	33	34
MAIL 2	SULAR	2	2	2	2	100	1	50	40
MAIL 2	TAZAC	3	1	3	3	100	2	50	58
MAIL 2	VANCENASE	1	1	1	1	100	1	1	70
MAIL 3	CORGARD	1	1	1	1	100	1	1	50
MAIL 3	IMURAN	1	1	1	1	100	1	1	54
MAIL 3	LOZOL	1	1	1	1	100	1	1	52
MAIL 3	OTHER TIER 3	3	3	3	3	100	2	66	72
MAIL 3	TENORMIN	2	2	2	2	100	1	1	55
RETAIL	VANCENASE	1	1	1	1	100	1	1	70
TOTALS		77	8	69	60	8686	25	4106	

23 August 1999

Managed Care Operations

These materials are the confidential property of [REDACTED] and are intended for the internal use of authorized employees only. These materials may not be duplicated or distributed without authorization.

A Recent Example: 12 Weeks of Performance Drug Program Opportunities by State

	#Stores w/ Opportunities	Completed Interventions
AK	23	10%
AL	692	14%
AR	252	15%
AZ	359	19%
CA	2196	32%
CO	432	16%
CT	433	22%
DC	80	8%
DE	113	16%
FL	1648	22%
GA	1233	18%
HI	5	33%
IA	360	18%
ID	113	14%
IL	1118	19%
IN	764	15%
KS	313	19%
KY	534	25%

	#Stores w/ Opportunities	Completed Interventions
LA	489	25%
MA	584	15%
MD	764	18%
ME	168	11%
MI	1167	26%
MN	432	26%
MO	580	28%
MS	438	8%
MT	75	19%
NC	1223	11%
ND	35	20%
NE	136	14%
NH	160	27%
NJ	1061	18%
NM	121	19%
NV	187	19%
NY	1827	17%

	#Stores w/ Opportunities	Completed Interventions
OH	1465	23%
OK	457	18%
OR	294	21%
PA	1631	21%
RI	81	25%
SC	617	12%
SD	90	13%
TN	680	21%
TX	2018	23%
UT	227	22%
VA	908	15%
VT	53	26%
WA	484	31%
WI	383	28%
WV	318	17%
WY	50	17%
Totals:	29842	19%

TOM BLUKEY, VIRGINIA, CHAIRMAN

W. J. BILLY TAUZIN, LOUISIANA
 MICHAEL G. OXLEY, OHIO
 MICHAEL BILIRAKIS, FLORIDA
 JOE BARTON, TEXAS
 FRED LITTON, MICHIGAN
 CLIFF STEAMNS, FLORIDA
 PAUL E. GILLMOR, OHIO
 JAMES C. GREENWOOD, PENNSYLVANIA
 CHRISTOPHER COX, CALIFORNIA
 NATHAN DEAL, GEORGIA
 STEVE LARGENT, OKLAHOMA
 RICHARD BURR, NORTH CAROLINA
 BRIAN P. BILBRAY, CALIFORNIA
 ED WHITFIELD, KENTUCKY
 GREG GANGS, IOWA
 CHARLIE NORWOOD, GEORGIA
 TOM COBURN, OKLAHOMA
 RICK LAZIO, NEW YORK
 BARBARA CUBIN, WYOMING
 JAMES E. ROGAN, CALIFORNIA
 JOHN SHIMKUS, ILLINOIS
 HEATHER WILSON, NEW MEXICO
 JOHN B. SHADEGG, ARIZONA
 CHARLES W. "CHIP" PICKERING, MISSISSIPPI
 VITO FOSSELLA, NEW YORK
 MOY BLUNT, MISSOURI
 ED BRYANT, TENNESSEE
 ROBERT L. EHRLICH JR., MARYLAND

JOHN D. LINGELL, MICHIGAN
 HENRY A. WAXMAN, CALIFORNIA
 EDWARD J. MARKEY, MASSACHUSETTS
 RALPH M. HALL, TEXAS
 RICK BOUCHER, VIRGINIA
 EDOLPHUS TOWNS, NEW YORK
 FRANK PALLONE, JR., NEW JERSEY
 SHERROD BROWN, OHIO
 RART GORDON, TENNESSEE
 PETER DEUTSCH, FLORIDA
 BOBBY L. RUSH, ILLINOIS
 ANNA C. ESHOO, CALIFORNIA
 RON KLICK, PENNSYLVANIA
 BART STUPAK, MICHIGAN
 ELIOT L. ENGEL, NEW YORK
 THOMAS C. SAWYER, OHIO
 ALBERT R. WYNN, MARYLAND
 GENE GREEN, TEXAS
 KAREN MCCARTHY, MISSOURI
 TED STRICKLAND, OHIO
 DIANA DIGETTE, COLORADO
 THOMAS M. BARRETT, WISCONSIN
 BILL LUTHER, MINNESOTA
 LOIS CAPPS, CALIFORNIA

**U.S. House of Representatives
 Committee on Commerce**

Room 2125, Rayburn House Office Building
 Washington, DC 20515-6115

May 5, 2000

JAMES E. DERDERIAN, CHIEF OF STAFF

The Honorable Donna E. Shalala
 Secretary
 Department of Health and Human Services
 200 Independence Avenue, S.W.
 Washington, D.C. 20201

Dear Secretary Shalala:

I am writing to express my concerns over the excessive reimbursements that the Medicare program is paying for certain covered pharmaceuticals and other related products. Further, I wish to learn what actions the Health Care Financing Administration (HCFA) and the Department of Health and Human Services (HHS) have taken to address this problem.

As you know, the Office of Inspector General at HHS has issued a series of reports that have identified significant discrepancies between the prices Medicare pays for certain drugs and the prices that are available to private sector purchasers of these same drugs. In its December 1997 report, the Office of Inspector General (OIG) estimated that, in 1996 alone, Medicare could have saved \$447 million by reducing the Medicare-allowed price for just 22 drugs to the actual prices available in the private wholesale sector. The OIG also found that Medicare could have saved at least 40 percent of the current allowance for almost half of the 22 drugs, and 93 percent for one particular drug, by limiting reimbursement to the available private sector prices for those drugs. As you know, Medicare is supposed to pay only 95 percent of the Average Wholesale Price (AWP) of these drugs under Federal law.

These findings are supported by additional investigative work that the Committee on Commerce has conducted. The Committee has written to several drug manufacturers, inquiring about the prices they charge to wholesale purchasers. The responses the Committee received confirmed that Medicare does in fact pay considerably more for certain drugs than the actual average price paid by such wholesalers. In addition, the Committee is continuing to investigate the practices of certain drug manufacturers relating to allegations that they manipulated the AWP of particular drugs in order to increase the sales of these drugs. I have enclosed for your review letters that the Committee has recently sent to several drug manufacturers regarding this investigation.

THE HONORABLE DONNA E. SHALALA
Page 2

The information revealed in the OIG report and through the Committee's investigation is particularly troubling. I firmly believe that improper expenditures in the Medicare program, whether due to waste, abuse or fraud, are unacceptable. In the time that I have been Chairman of the Committee, we have held numerous hearings that have sought to prevent the payment of such improper expenditures throughout the Medicare and Medicaid programs. As Congress considers ways to expand the scope of Medicare's coverage of prescription drugs, it is essential that this Administration be able to assure Congress, the beneficiaries of the Medicare program, and the American people that it has done all that it can to prevent waste and abuse in the current limited Medicare drug program.

The December 1997 OIG report contained several specific recommendations relating to actions HCFA could take to address this problem, including requiring all Medicare carriers to reimburse a uniform allowed amount for each HCFA Common Procedure Coding System (HCPCS) drug code. In response to this report, then-Deputy Administrator Nancy-Ann Min DeParle wrote to the Inspector General, indicating that HCFA had convened a workgroup to develop an electronic file consisting of the AWP's for drugs covered by Medicare. She further stated that HCFA would then distribute this file to Medicare contractors for their use in paying claims for drugs.

To date, it appears that these efforts have not been implemented. The Committee has learned that HCFA submitted a Request for Proposal to develop a solution to the problem of price variances between Medicare carriers, but no contract was ever entered into, and it does not appear that the issue has been resolved. The December 1997 OIG report noted, "[t]he rate at which physicians and suppliers are paid for drugs should not depend on which carrier providers bill." I strongly concur with this statement, and am deeply disturbed that it appears that HCFA has failed to remedy this problem in the two and a half years since it was first identified by the Inspector General.

In her response to the OIG report, then-Deputy Administrator Min DeParle also stated that HCFA would pursue other "appropriate ways" to eliminate the markup for drugs billed to Medicare, beyond those legislative initiatives contained in the President's budget. I understand that a rulemaking was initiated, but never completed, to utilize your authority to adjust Medicare reimbursements that are not inherently reasonable. I wish to learn by what other "appropriate ways" HCFA has attempted to address the problem of excessive reimbursements for Medicare-covered drugs. Accordingly, I request that, pursuant to Rules X and XI of the U.S. House of Representatives, you provide the following information to the Committee no later than May 26, 2000.

1. Please identify all actions taken by HCFA to date to independently investigate and assess the accuracy of the AWP as a measurement of wholesale drug prices.
2. Please identify all actions taken by HCFA to date to independently investigate and assess the discrepancies between the prices paid by Medicare and other non-governmental entities for Medicare-covered drugs.

The Honorable Donna E. Shalala
Page 3

3. Please identify the other "appropriate ways," mentioned in then-Deputy Administrator Min DeParle's response to the OIG report, that HCFA has utilized to address the problem of excessive reimbursements for Medicare-covered drugs. In your answer, please describe all actions that have been taken relating to these efforts.
4. Please identify whether the electronic file, also identified in then-Deputy Administrator Min DeParle's response to the OIG report, has been developed and is now operational. If the electronic file is not yet operational, please identify whether other actions have been taken to insure that all Medicare carriers are now reimbursing a uniform allowed amount for each HCPCS drug code.

If you should have any questions, please have your staff contact Mr. Charles Clapton, Committee Counsel, at (202) 226-2424. I appreciate your cooperation in this matter.

Sincerely,


Tom Bliley
Chairman

Attachments

cc: The Honorable John D. Dingell, Ranking Member



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

202 690 6262 P.01/07

The Honorable Tom Bliley
Chairman, Commerce Committee
House of Representatives
Washington, D.C. 20515

Thank you for your letter regarding pricing for the drugs that Medicare currently covers. As you know, the law requires Medicare to pay physicians 95 percent of the average wholesale price for the handful of drugs that are covered by Medicare. We share your concern about the significant discrepancies between the prices that Medicare is required by law to pay to physicians for these drugs based on the average wholesale price and the prices that physicians themselves pay. Since 1997, the Clinton Administration has four times proposed taking steps to pay more appropriately. I appreciate the opportunity to explain what we have done and the challenges we face in ensuring that Medicare pays fair prices.

We are aware that the Department of Justice and HHS Inspector General have been conducting investigations in this area and the HCFA Administrator has asked the Justice Department to keep her apprised of developments. We are reviewing new pricing data developed for Medicaid and considering appropriate steps to enable Medicare to benefit from it, as well. We also have been consulting with the Department of Justice and HHS Inspector General to seek advice and recommendations on changes to Medicare policy that would ensure Medicare pays a fair price.

HCFA has been actively addressing this issue, both legislatively and through administrative actions, for many years. In 1991, the agency established a policy (through notice and comment) to pay physicians for drugs based on the lower of the estimated acquisition cost or the average wholesale price. However, due to difficulties in acquiring data from physicians to accurately estimate acquisition costs, we had to rely instead on the average wholesale price.

Because the estimated acquisition cost approach proved unworkable, the President in 1997 proposed legislation to pay physicians their actual acquisition cost for drugs. However, the Balanced Budget Act instead reduced Medicare payment for covered drugs from 100 percent to 95 percent of average wholesale price, reducing only a fraction of the excessive payment amounts. In 1998 the President again proposed paying physicians their actual acquisition cost to "ensure that doctors are reimbursed no more, and no less, than the price they themselves pay for the medicines they give Medicare patients."

In 1999 and again this year, the President proposed a different legislative approach to the problem -- that Medicare pay 83 percent of the average wholesale price. We estimate that this method would substantially reduce the pricing discrepancy, as well as any administrative burden on physicians and the agency associated with determining the costs of drugs. The HCFA actuaries project that this legislative proposal would save \$2.1 billion over 10 years.

Page 2 - The Honorable Tom Bliley

Based on our recent discussion with the Department of Justice and HHS Inspector General, we have concluded that payments based on actual acquisition cost is a much more effective way to ensure that Medicare is paying fairly. We therefore are now changing our FY 2001 budget to propose paying physicians their actual acquisition costs. We also plan to work with physician groups to review payment rates for chemotherapy administration.

In addition to changing our legislative proposal, we are taking advantage of a more accurate source of average wholesale price data than has been available to date. This data are from catalogs of drug wholesalers, whom the Department of Justice says account for a significant portion of the market. The Department of Justice has compiled data for 379 products, each with its unique national drug code representing 46 different chemical compounds. Many of these drugs are covered by Medicare, and they represent about one-third of Medicare spending for drugs.

To apply this new information in Medicare right away, the Administration is calculating the average of the wholesale catalog prices, just as has been done by First Data Bank, a company specializing in the compilation of drug pricing data (the Blue Book). We are sending this information to Medicare carriers so they can use it when they determine average wholesale prices for their next quarterly update of Medicare drug allowances, which will become effective on October 1, 2000. This is the most immediate action we can take without going through the formal rule-making process.

We also are consulting with the Department of Justice and HHS Inspector General on the possibility of developing a proposed rule that could require carriers to use an average wholesale price based on data from wholesalers. To monitor carrier activities, we are requiring carriers to send to HCFA by September 15, 2000, a written explanation of the data source used for determining payment allowances for the 46 drugs.

In addition to the proposed legislation and our most recent administrative activity discussed above, we have taken several other steps over the last several years to try to address Medicare drug pricing inequities.

- We proposed using the inherent reasonableness authority secured in the Balanced Budget Act of 1997 to reduce excessive charges on several items – including albuterol sulfate. Our contractors who process durable medical equipment claims surveyed retailers in 16 states and found that Medicare was paying substantially more than other payers. A September 1998 proposed rule to reduce payments is on hold by Congressional mandate until a GAO study of our use of the inherent reasonableness authority is published and we issue a final rule. We have just received the draft final report from the GAO, and are looking forward to their final report so that we can move forward.

- We are using market forces and competition to set fairer prices for albuterol sulfate as part of a competitive bidding demonstration for durable medical equipment supplies in Texas. A similar demonstration in Florida, while not including drugs, is saving an average of 17 percent for beneficiaries and Medicare through the bidding process. We hope to be able to use the results from these demonstrations more generally in the Medicare program.
- We have proposed legislation to reduce payments for Epogen, the most common and costly drug that Medicare covers, by 10 percent. This was based on a November 23, 1997 report by the HHS Inspector General which found that Medicare payments for Epogen exceed the cost of purchasing it by approximately 10 percent.
- And we are developing the electronic file of prices for Medicare covered drugs, as recommended by the HHS Inspector General. A contractor has been working on numerous technical issues, including the components necessary for appropriate drug pricing (e.g., route of administration, drug strength concentrations, available package size and most commonly used dosage ranges). We are hopeful that a report on this first phase of the project will be available by this summer. A report on a second phase of work on issues relating to mapping between codes Medicare currently uses (the HCFA Common Procedure Coding System) and national drug codes, compatibility with the Health Insurance Portability and Accountability Act administrative simplification standards that are being developed, generic and brand name mapping, new drug entries, drug deletions, and updates, is expected by the end of the year. We believe this work will help us ensure that Medicare payments are appropriate and consistent across the country.

We have also taken actions to help State Medicaid programs obtain fair prices for drugs.

- We have proposed sharing average manufacturer price data with States so they can accurately set Medicaid reimbursement rates. Current law requires drug manufacturers to report average manufacturer price data to HHS but prohibits disclosure of the data by States, who instead must rely on average wholesale price or wholesale acquisition cost data that, like average wholesale price, can be substantially inflated.
- We have proposed applying the consumer price index-urban (CPI-U) adjustment to generic drugs. Brand name drug manufacturers must pay an additional dollar-for-dollar rebate to Medicaid if they increase prices in excess of CPI-U. But it is now clear that generic drug prices also sometimes are rising faster than inflation.
- And State Medicaid programs should also benefit from First Data Bank's announcement that it will revise the way it collects and reports average wholesale price data to them, based on information in wholesaler catalogs.

Page 4 - The Honorable Tom Bliley

Again, I thank you for your inquiry into this important matter. We would be very interested in receiving the data the Commerce Committee has compiled on Medicare drug pricing to assist our efforts. We hope Congress will enact the President's proposal for improving Medicare drug payments. And I look forward to working further with you and your Committee as we proceed.

Sincerely,

Donna Shalala

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

1

Divider Title: _____

VANCOMYCIN HYDROCHLORIDE

PROD/MFR	NDC	Wholesale	(GPO) DP	1999 AWP Red Book
(Abbott Hosp)				
PDI, IJ, (ADD-VANTAGE)				
500 mg, 10s ea.....	00074-6534-01	3.60 /FI 5.80 /MK 5.87 /BB		13.10
(VIAL, FLIPTOP)				
500 mg, 10s ea	00074-4332-01	3.75 /FI 3.25 /OTN 7.10 /MK 6.90 /BB 3.92 /OS		36.40
1 gm, 10s ea.....	00074-6533-01	7.60 /FI,ASD,OS 11.22 /MK,BB		72.78
(VIAL, FLIPTOP)				
1gm, 10s ea.....	00074-6535-01	7.40 /FI 12.90 /OTN 14.18 /MK,BB		26.18
(BULK VIAL)				
5 gm, ea.....	00074-6509-01	36.00 /FI 43.86 /MK,BB		163.72
(Fujisawa) LYPHOCIN				
PDI IJ (VIAL)				
500 mg, ea.....	00469-2210-30	7.00 /BB,MK		10.97
	63323-2210-30			
1 gm, ea.....	00469-2840-40	13.00 /BB, MK		20.35
	63323-0284-20			
5 gm, ea.....	00469-2951-00	71.50 /BB		136.32
	63323-0295-41			
10 gm, ea.....	63323-0314-61	143.00/MK		272.64
(Lederle Std Prod) VANCOLED				
PDI INJ, IJ				
500 mg, 10s ea.....	00205-3154-88	4.64 /MK 4.37 /BB		5.47
1 gm, 10s ea.....	00205-3154-15	9.29 /MK 8.75 /BB		10.94
5 gm, ea.....	00205-3154-05	46.42 /MK 43.75 /BB		54.69
(Schein)				
PDI, IJ (S.D.V.)				
500 mg, 10s ea.....	00364-2472-33	3.84 /MK		none
(M.D.V.)				
1 gm, 10s ea.....	00364-2473-91	12.90 /OTN		14.82

NDC	MFG	Item #	Description	U/M	EXP	NET	AWP	J Code
00004-2011-09	ROC	550-820	ROFERON-A 18MIL ALPHA 2A	EA	Jul-00	180.00	208.56	
00004-2012-09	ROC	550-825	ROFERON-A 36MIL ALPHA 2A	EA	Jan-00	360.00	417.17	
00004-2009-09	ROC	550-810	ROFERON-A 3MIL ALPHA 2A	EA	Mar-00	30.00	33.94	J9213
00004-2007-09	ROC	550-812	ROFERON-A 6MIL ALPHA 2A	EA	May-00	60.00	69.56	
00004-2010-09	ROC	550-815	ROFERON-A 9MIL ALPHA 2A	EA	Oct-00	85.00	97.94	
00078-0110-22	NOV	420-043	SANDIMMUNE SOLN 100MG 50ML	EA	Jan-01	274.40	330.04	
00078-0244-93	NOV	420-048	SANDOGLOBULIN 12GM	EA	May-01	1,320.00		
00078-0244-19	NOV	420-051	SANDOGLOBULIN 12GM 10'S	EA		13,200.00		
00079-0120-94	NOV	420-040	SANDOGLOBULIN 1GM	EA	Dec-00	110.00		
00078-0122-59	NOV	420-041	SANDOGLOBULIN 3GM	EA		330.00		
00078-0124-60	NOV	420-042	SANDOGLOBULIN 6GM	EA	Apr-01	660.00		
00078-0124-19	NOV	420-046	SANDOGLOBULIN 6GM 10'S	EA		6,600.00		
00078-0181-03	NOV	420-044	SANDOSTATIN .1MG 20'S	EA	Mar-03	215.00	214.33	
00078-0182-03	NOV	420-045	SANDOSTATIN .5MG 20'S	EA	Aug-00	998.00	1,033.74	
00078-0184-25	NOV	420-049	SANDOSTATIN 1000MCG 5CC	EA	Mar-00	550.00		
00078-0183-25	NOV	420-047	SANDOSTATIN 200MCG 5CC	EA	Feb-01	110.00		
00078-0340-84	NOV	420-010	SANDOSTATIN LAR DEPOT 10MG	EA	Oct-00	1,152.63	1,368.75	
00078-0341-84	NOV	420-020	SANDOSTATIN LAR DEPOT 20MG	EA	Oct-00	1,152.63	1,368.75	
00078-0342-84	NOV	420-030	SANDOSTATIN LAR DEPOT 30MG	EA	Oct-00	1,728.42	2,053.12	
00074-6625-02	ABB	110-706	SODIUM BICARBONATE 8.4% 50ML	EA	Dec-99	1.05	195.90	
00517-1019-05	ARL	130-108	SODIUM THIOSULFATE 10% VIAL	EA	Apr-00	7.95		
00009-0900-13	PHA	500-810	SOLU-CORTEF 100MG 2ML	EA	Aug-03	1.50	3.34	J1720
00009-0912-05	PHA	500-816	SOLU-CORTEF 500MG 4ML	EA	Jan-03	6.00		
00009-0190-09	PHA	500-812	SOLU-MEDROL 125MG 2ML	EA	Oct-01	2.50	5.64	J2930
00009-2289-01	PHA	500-813	SOLU-MEDROL 1GM 8ML	EA	Oct-01	12.75	34.13	
00009-0113-12	PHA	500-811	SOLU-MEDROL 40MG/ML VIAL	EA	Oct-00	1.50	2.13	J2920
00009-0758-01	PHA	500-817	SOLU-MEDROL 500MG VIAL	EA	Nov-02	7.25		
00026-8131-20	BAY	165-062	STILPHOSTROL 250MG 20'S	EA	Aug-01	255.78		
60574-4111-01	MED	888-981	SYNAGIS 100MG PWD VL	EA	Apr-00	940.00		
00015-3476-30	BMS	195-446	TAXOL 100MG MDV	EA	Nov-00	496.75	608.76	J9265
00015-3479-11	BMS	195-447	TAXOL 300MG MDV	EA	Nov-00	1,490.82		
00015-3475-30	BMS	195-445	TAXOL 30MG MULTI	EA	Oct-00	149.02	182.63	J9265
00075-8001-20	RPR	530-020	TAXOTERE 20MG VIAL	EA	Oct-99	224.00	284.36	J9170
00075-8001-80	RPR	530-080	TAXOTERE 80MG VIAL	EA	Nov-99	896.00	1,137.43	
00005-2720-25	LED	888-263	TB TINE TEST	EA	Jul-00	1.23	1.79	
00173-0880-25	GLX	290-256	THIOGUANINE 40MG 25'S TABS	EA	May-00	86.00	87.90	
58406-0661-31	IMM	320-672	THIOPLEX 15MG 6'S	EA	Mar-99	525.00	541.40	J9340
00013-7336-91	PHA	500-060	TOPOSAR 100MG	EA	May-99	9.00	143.31	J9182
00013-7346-94	PHA	500-061	TOPOSAR 200MG	EA	Apr-99	18.00	286.63	
00013-7356-88	PHA	500-062	TOPOSAR 500MG	EA	Dec-98	44.00	698.65	
00054-4748-25	ROX	888-080	TORCAN 10MG TAB 100'S	EA	Jan-02	48.50	54.30	
00054-1701-07	ROX	888-081	TORCAN AMPS 10MG/2ML 20'S	EA	Jul-02	93.40	105.63	J3280
00049-3890-28	PZR	888-234	TROVAN IV 200MG	EA	Oct-99	34.60		
00074-6533-01	ABB	110-704	VANCOMYCIN 1GM 10'S ABBOTT	EA	May-00	75.95	735.48	
00074-4332-01	ABB	110-702	VANCOMYCIN 500MG 10'S ABBOTT	EA	Feb-00	39.20	367.80	
00002-1452-01	ELI	888-152	VELBAN 10MG INJ	EA	Aug-00	34.39	40.54	
49669-1623-01	ALP	122-604	VENO-S 10% 10GM	EA		1,250.00		
49669-1624-01	ALP	122-605	VENO-S 10% 20GM	EA		2,500.00		
669-1622-01	ALP	122-603	VENO-S 10% 5GM	EA		625.00		
49669-1614-01	ALP	122-602	VENO-S 5% 10GM	EA		1,250.00		
49669-1624-01	ALP	122-613	VENO-S 5% 10GM 200ML	EA		1,250.00		

ITEM NUMBER	ITEM DESCRIPTION	R X	REGULAR COST	LIST / SUGGTD RETAIL	MIM ORD	UNIT	PKG QTY	ITEM NUMBER	ITEM DESCRIPTION	R X	REGULAR COST	LIST / SUGGTD RETAIL	MIM ORD	UNIT	PKG QTY
168-9837	TUBERSOL VIAL STU-50 TEST 5ML		54.08				50	172-2214	URO BLUE TAB	100	32.83				12
198-7262	TUBEX INJECTOR 9145-01 R		3.00				100	181-6335	URO-KP-NEUTRAL TAB 0.25GM	100	27.25				36
368-8100	TUBING EXTEN BUR ET-04TS CS100		152.50					140-1447	UROBLOTIC-250 CAP	60	89.11*				24
328-5004	TUBING EXTEN BUR ET-08L CS100		89.60					270-0250	UROCIT-K TAB 100MG 10MG	100	18.80				12
110-3888	TUBING EXTEN BUR ET-118L CS100		211.00					181-1408	UROCIT-K TAB 540MG 5MG	100	15.24				12
121-8229	TUBOCUR FTV 60MG 20ML AB8	25	185.00				2	320-7990	URODOL CAP	100	18.87				60
178-0297	TUBOCUR SYR 15MG 5ML AB8	10	80.80				5	197-8788	UROGESIC-BLUE TAB	100	24.50				12
110-3001	TUBOCUR VIAL 30MG 1L 10ML R	10	10.11				270	178-8231	UROLOGIC G SOL 7188-09 AB8	12	31.44				CS
148-3827	TUBOCUR VIAL 30MG 10ML SQ 10	10	48.00				10	278-7881	UROLOGIC 500 CHL 9% IRR BAX	12	28.92				CS
188-5140	TUINAL PULVULE 100MG 303	100	25.78*				138	215-8188	UROQID-ACID TAB 500/500MG	100	19.80				12
327-8884	TUSS-OS SYRP	160Z B	19.95				12	110-3187	URSO CAP 250MG	100	165.71				12
327-8528	TUSS-PD SYRP	160Z B	24.77				12	173-4854	USEPT TAB BRECK	100	5.96				24
138-3630	TUSS-TAN PED SUSP EXP	160Z B	22.50				12	142-8036	VALIUM AMP 10MG 2ML	10	36.22				120
138-3465	TUSS-TAN TAB EXP	100	24.25				12	271-8185	VALIUM DISP SYR 10MG 2ML	10	47.88				40
132-4838	TUSSEND EXP	160Z B	50.53				12	170-4815	VALIUM TAB 10MG	100	94.89				48
132-3559	TUSSEND SYRP	160Z B	47.31				12	170-4899	VALIUM TAB 2MG	100	38.22				48
121-7710	TUSSEND TAB	100	59.44				12	142-8061	VALIUM TAB 2MG	500	179.99				48
147-1705	TUSSI-ORGAN DM NR WALL	160Z R	60.48				12	180-8736	VALIUM TAB 5MG	100	66.33				48
143-9785	TUSSI-ORGAN DM-S NR WALL 4X40Z	R	57.88				12	142-8077	VALIUM TAB 5MG	500	280.49				48
147-2489	TUSSI-ORGAN DM NR WALL	160Z E	82.35				12	142-8101	VALIUM TAB 10MG	500	473.28				48
143-6930	TUSSI-ORGAN DM-S NR WALL 4X40Z	E	59.41				12	224-4432	VALIUM VIAL 50MG	10ML D	16.65				360
211-1088	TUSSION TAB 5MG	100	28.56				12	243-3589	VALPROIC CAP 250MG G/L	100	13.79*				144
343-6718	TUSSION TAB 5MG	600	121.10				12	381-3775	VALPROIC CAP 250MG GEN	100	9.97				12
138-0867	TUSSION V SYRP EXP	160Z B	11.50				12	389-5004	VALPROIC CAP 250MG MMR	100	8.85				24
148-9956	TUSSIONEX E/R SUSP	160Z B	77.40				8	118-8466	VALPROIC CAP 250MG Q/P	100	13.28*				24
228-1428	TUSSOGEST T/R CAP MWP	100	17.65				24	137-8817	VALPROIC CAP 250MG SCHE	100	8.42*				12
134-3755	TYLENOL+COD #2 TAB	100	26.91				144	227-5873	VALPROIC CAP 250MG URL	100	9.22*				24
134-3783	TYLENOL+COD #3 TAB	100	29.25				144	228-8445	VALPROIC CAP 250MG ROSE	100	9.58				24
171-4278	TYLENOL+COD #3 TAB	500	128.57				12	242-7880	VALPROIC CAP 250MG UD	100	21.10				10
148-5294	TYLENOL+COD #3 TAB	1000	230.08				12	164-4137	VALPROIC SFTGL 250MG NAT	100	10.44*				144
110-8745	TYLENOL+COD #3 TAB UD	500	139.35				8	141-3541	VALPROIC SFTGL 250MG MWP	100	11.26				144
134-3771	TYLENOL+COD #4 TAB	100	51.68				144	277-8256	VALPROIC SFTGL 250MG S/D	100	12.89*				96
137-4081	TYLENOL+COD #4 TAB	500	223.25				12	143-1818	VALPROIC SYR 250MG URL	160Z	25.10*				12
121-0343	TYLENOL+COD ELIX	160Z E	48.47				12	270-8331	VALPROIC SYR 250MG G/L	160Z	28.58*				12
189-7818	TYLOX CAP 5/500MG	100	83.27*				144	142-3334	VALPROIC SYR 250MG GEN	160Z	23.65				12
189-7828	TYLOX CAP 5/500MG UD	100	109.49*				48	115-8585	VALPROIC SYR 250MG Q/P	160Z	19.98*				12
181-6255	TYMPAGESIC+DROPPER	13ML R	12.13				38	138-1847	VALPROIC SYR 250MG SCHE	160Z	23.61*				12
178-3010	TYPHIM VI VACC 5ML	20DOSE R	680.70				50	322-8945	VALPROIC SYR 250MG NAT	160Z	22.74*				12
178-6585	TYPHIM VI VACC SYR	0.5ML R	31.80				50	340-5388	VALPROIC SYR 250MG MOR	160Z	21.43				12
188-1655	TYPHIM VACC VIAL	WY 5ML R	9.41				100	212-0857	VALPROIC SYR 250MG COP	160Z	25.79*				12
140-1413	TYZINE NASAL SOL 0.1%	10Z R	10.98				144	110-4124	VALTREX CAPL 1GM	20	80.89				24
140-1406	TYZINE NASAL SPR 0.1%	15ML R	9.84				144	122-7838	VALTREX CAPL 500MG UD	100	240.97				10
140-1397	TYZINE PED NASAL DROPS	0.50Z R	9.49				144	122-8915	VALTREX CAPL 500MG UD	42	99.05				48
228-8421	ULR-LA TAB	GEN 100	3.40				116	388-8035	VALVE BACKCHECK BUR BC0017	100	116.00				24
182-3483	ULTANE USP	250ML R	250.90				6	228-8243	VALVE BACKCHECK BUR BC1000	100	109.00				10
278-3405	ULTIVA INJ 1MG/3ML	10 X	117.00*				8	195-7547	VANCENASE AD-DS NASAL SPR 19CM	R	40.19				36
278-4838	ULTIVA INJ 2MG/5ML	10 X	228.00*				8	249-8424	VANCENASE ROCKWATER NASAL 70CM	R	32.82				72
278-4965	ULTIVA INJ 5MG/10ML	10 X	540.00*				8	128-8998	VANCERIL DS INHALER	84MG R	40.73				72
188-8120	ULTRA NATAL CAP TB ETH	100Z R	14.00*				12	133-0083	VANCERIL INHALER	16.8CM R	31.89				72
184-5130	ULTRAM TAB 50MG	100	59.18				144	220-8217	VANOCIN AVY 1GM	10	134.00				10
189-8485	ULTRAM TAB 50MG	500	295.89				12	328-5129	VANOCIN AVY 500MG	10	69.00				10
184-5155	ULTRAM TAB 50MG UD	100	65.09				48	168-2467	VANOCIN Q/S 1GM	8	185.37				8
181-5487	ULTRASE CAP	100	28.82				72	183-4340	VANOCIN Q/S 10GM	M208	261.98				36
352-8294	ULTRASE MT-12 CAP	100	69.00				38	227-9529	VANOCIN PULVULE 12MG UD	20	89.63				20
119-8801	ULTRASE MT-18 CAP	100	92.49				84	227-9689	VANOCIN PULVULE 250MG UD	20	179.27				20
352-8377	ULTRASE MT-20 CAP	100	102.22				72	278-2175	VANOCIN VIAL 1GM 20ML	26	325.00				4
133-2428	ULTRASE MT-20 CAP	500	488.29				12	388-7110	VANOCIN VIAL 10GM	100ML	130.00				12
188-8033	ULTRAVATE CRM 0.05%	15GM R	19.85				24	243-8592	VANOCIN VIAL 500MG 10ML	26	182.50				4
279-8781	ULTRAVATE CRM 0.05%	50GM R	48.83				24	211-7380	VANOCIN ADV 1GM	AB8	112.20				4
189-2734	ULTRAVATE OINT 0.05%	15GM R	19.85				24	211-7257	VANOCIN ADV 500MG	AB8	68.70				10
279-8822	ULTRAVATE OINT 0.05%	50GM R	48.83				24	280-8428	VANOCIN FTV 1GM	AB8	141.80				8
117-8272	UNASYN AVY 1.5GM	10	64.84*				24	280-8428	VANOCIN FTV 500MG	AB8	71.40				10
389-1388	UNASYN AVY 3GM	10	118.70*				24	341-8888	VANOCIN SDV 1GM 20ML	FUJ	130.00				10
389-7028	UNASYN PBV 1.5GM	10	70.20*				8	228-7418	VANOCIN VL 500MG LED	10	48.42*				18
389-7083	UNASYN PBV 3GM	10	125.24*				8	221-7388	VANOCIN VL 500MG LED	10	38.33*				18
389-8980	UNASYN VIAL 1.5GM	10	60.91*				10	138-8891	VANOCIN VL 1GM	LED	82.85*				10
164-8070	UNASYN VIAL 15GM BULK	185Z R	57.50*				25	181-8271	VANOCIN VL 10GM	FUJ 100ML	143.00				60
389-8895	UNASYN VIAL 3GM	10	114.99*				10	382-8542	VANOCIN VL 50MG 10ML	FUJ 26	175.00				4
123-7197	UNGUENTUM BOSSI	20Z R	7.38				24	389-8895	VANOCIN VL 5GM	FUJ 100ML	71.50				50
277-2135	UNI-DECON TAB	URL 100Z	9.88*				24	122-2388	VANOCIN VL 5GM	LED	48.42*				50
277-2143	UNI-DECON TAB	URL 1000Z	35.43*				12	382-8898	VANOCIN VL 5GM BULK	AB8	43.88				10
250-1144	UNI-DUR E/R TAB 400MG	100	88.84				38	243-3720	VANEX LIO GRAPE	180Z	82.45				12
250-0700	UNI-DUR E/R TAB 600MG	100	97.12				38	244-8827	VANEX LIO LIO	180Z	30.84				12
183-8010	UNI-BLATTIN CS SYRP	URL 160Z	14.88*				38	113-0343	VANOCIN LOTION	30GM R	13.15				12
113-2189	UNI-BLATTIN D SYRP	URL 100Z	22.11*				12	123-3857	VANOCIDE-HC LOT 5/0.5%	25GM R	28.45				144
134-6329	UNI-BLATTIN D ELIX	URL 160Z	5.58*				12	177-4033	VANTIN O/S 100MG/BAL	50ML	28.10				24
115-8358	UNI-NATALONE IMP TAB	URL 100Z	4.37*				24	177-4396	VANTIN O/S 100MG/BAL	75ML	39.06				24
175-8113	UNI-6ERP SALMON TAB	URL 100Z	8.29*				72	120-3581	VANTIN O/S 100MG/BAL	100ML	49.85				24
175-8170	UNI-6ERP SALMON TAB	URL 1000Z	35.36*				24	177-3332	VANTIN O/S 50MG/BAL	50ML	13.72				24
133-8488	UNI-TUSS HC SYRP	URL 160Z	10.03*				12	177-3753	VANTIN O/S 50MG/BAL	75ML	20.63				24
181-3878	UNIPHYL CR TAB 600MG	100	95.51				24	120-1815	VANTIN O/S 50MG/BAL	100ML	26.10				24
218-7949	UNIPHYL TAB 400MG	100	88.11				24	123-7383	VANTIN TAB 100MG	20	47.59				48
222-0814	UNIPHYL TAB 400MG	500	328.28				4	123-8237	VANTIN TAB 100MG	100	228.49				48
344-4734	UNIRETIC TAB 15/25MG	100	44.24				12	123-8888	VANTIN TAB 100MG UD	100	234.07				24
213-3452	UNIRETIC TAB 7.5/12.5MG	100	44.24				12	123-8278	VANTIN TAB 200MG	20	86.81				48
224-2564	UNIVASC TAB 15MG	100	44.24				12	123-8488	VANTIN TAB 200MG	100	318.73				24
177-1874	UNIVASC TAB 15MG UD	90	39.82				12	123-8979	VANTIN TAB 200MG UD	100	324.84				24
224-2972	UNIVASC TAB 7.5MG	100	44.24				12	180-8181	VAQTA PRF SYR 50L/1ML	5	228.17				36
177-1419	UNIVASC TAB 7.5MG UD	90	39.82				12	180-3331	VAQTA SDP SYR PED 25L/1ML	5	114.08				36
138-8189	URECHOLINE TAB 10MG	100	59.19				144	180-82							

ASD ITEM #	MFG	NDC #	ONCOLOGY PHARMACEUTICALS	PKG SIZE	PKG PRICE	EACH PRICE	REDBOOK AWP	J CODE
291-181	PUJ	00009-0825-01	Solu Cortef 100mg vl	1	\$1.75	\$1.75	\$3.28	
291-179	PUJ	00009-0900-13	Solu Cortef 100 mg vl 2 ml	1	\$1.75	\$1.75	\$3.34	
291-187	PUJ	00009-0909-08	Solu Cortef 250 mg vl 2 ml	1	\$2.65	\$2.65	\$7.56	
291-153	PUJ	00009-0912-05	Solu Cortef 500 mg vl 4 ml	1	\$5.55	\$5.55	\$14.71	
291-344	PUJ	00009-0190-09	Solu Medrol 125 mg vl 2ml	1	\$2.65	\$2.65	\$5.31	
291-211	PUJ	00009-0887-01	Solu Medrol 500 mg vl	1	\$6.17	\$6.17	\$20.06	
291-260	PUJ	00009-0113-12	Solu Medrol 40 mg ADV 1 ml	1	\$1.60	\$1.60	\$2.00	
291-286	PUJ	00009-3389-01	Solu Medrol 1 g ADV 8 ml	1	\$11.02	\$11.02	\$32.19	
039-032	SKB	00108-5022-11	Tagamet 150mg/ml 8ml	10	\$111.00	\$11.10	\$128.60	J9999*
979-583	BMS	00015-3475-30	Taxol 8mg/ml 5ml	1	\$149.02	\$149.02	\$182.63	J9265
074-450	BMS	00015-3476-27	Taxol 100mg/17ml	1	\$496.75	\$496.75	\$608.78	J9265
587-691	BMS	00015-3479-11	Taxol 300mg MDV 50ml	1	\$1,490.22	\$1,490.22	\$1,826.30	J9265
665-885	RPR	00075-8001-20	Taxotere 20mg SDV	1	\$220.50	\$220.50	\$284.36	J9170
665-000	RPR	00075-8001-80	Taxotere 80mg SDV	1	\$882.00	\$882.00	\$1,137.43	J9170
034-637	LIL	00002-7241-16	Tazidime 6gm vl	6	\$434.70	\$72.45	NA	
978-472	SHN	00364-6810-54	Testost Cyp 200 mg vl 10 ml	1	\$13.99	\$13.99	\$26.15	J1080
978-498	SHN	00364-6817-54	Testost Ena 200mg vl 10ml	1	\$14.65	\$14.65	\$42.10	
324-319	CNN	49281-0800-83	Tetanus Tox A MDV 5 ml	1	\$23.08	\$23.08	\$20.75	J1870
873-840	IMM	58406-0681-31	Thioplex 15MG/2ML	6	\$460.00	\$76.67	\$514.44	J9340
023-788	PUJ	00013-7338-91	Toposar 100mg	1	\$9.00	\$9.00	\$143.31	J9182
023-796	PUJ	00013-7338-94	Toposar 200mg	1	\$18.00	\$18.00	\$286.63	J9182
023-812	PUJ	00013-7338-88	Toposar 500mg	1	\$44.00	\$44.00	\$698.65	J9182
393-827	ROX	00054-4748-25	Torecan 10 mg Tabs	100	\$48.50	\$0.49	\$54.30	
393-835	ROX	00054-1701-07	Torecan 10 mg amp 2 ml	20	\$93.40	\$4.67	\$105.63	
241-497	PFI	00049-3900-28	Trovan IV 300mg SDV 60ml	1	\$48.06	\$48.06	NA	
535-559	CNN	11793-7522-01	Tubersol 5 TU 10 Test vl 1ml	1	\$15.23	\$15.23	\$22.08	J9999*
428-177	J+J	00045-0449-10	Tylenol X/S Disp Pack Cpl 2 UD	50	\$10.48	\$0.21	\$6.29	
763-409	ABB	00074-6533-01	Vancomycin 1 gm Add Vantage	10	\$76.00	\$7.60	\$663.14	
279-059	ALP	49669-1614-01	Venoglobul S 5%/ 10 mg vl 200 ml	1	CALL	CALL	\$900.00	
097-253	ALP	49669-1623-01	Venoglobulin-S 10% 10gm	1	CALL	CALL	\$950.00	J1562
097-311	ALP	49669-1624-01	Venoglobulin-S 10% 20gm	1	CALL	CALL	\$1,900.00	J1562
106-112	ROC	00004-1999-01	Versed 1mg/ml vl 5 ml	10	\$153.76	\$15.38	\$104.23	
481-564	BED	55390-0091-10	Vinblastine 10mg	10	\$72.80	\$7.28	\$212.50	J9360
955-666	FAU	81703-0310-18	Vinblastine 10mg	1	\$7.95	\$7.95	\$37.50	J9360
980-870	FUJ	00469-2780-30	Vinblastine 10mg Solution	1	\$9.00	\$9.00	\$43.23	J9360
312-439	PUJ	00013-7458-88	Vincasar 1mg	10	\$45.00	\$4.50	\$37.08	J9370
312-447	PUJ	00013-7468-86	Vincasar 2mg	10	\$70.00	\$7.00	\$74.13	J9375
955-718	FAU	81703-0309-06	Vincristine 1mg/ml 1ml	1	\$3.95	\$3.95	\$31.75	J9370
955-724	FAU	81703-0309-16	Vincristine 1mg/ml 2ml	1	\$6.95	\$6.95	\$38.25	J9375
313-593	GLS	81958-0101-1	Visibid 375mg 5ml	1	\$670.73	\$670.73	\$706.80	
062-224	ABB	00074-9158-01	Vit K10mg Amp 1ml	25	\$174.17	\$6.97	\$137.16	
080-418	BER	58337-0003-01	Vivotif Berna Capsule 4	1	\$31.02	\$31.02	\$34.17	
388-777	BMS	00015-3075-19	Vumon 50mg/ml	1	\$156.67	\$156.67	\$181.01	J9999*
083-998	NAB	60492-0081-01	WinRHo SDF 800iu 120mcg	1	\$59.02	\$59.02	\$120.00	J2790
086-892	NAB	60492-0082-01	WinRHo SDF 1500iu 300mcg	1	\$135.26	\$135.26	\$306.00	J2790
829-907	NAB	60492-0024-01	WinRHo SDF 8000iu 1000mcg	1	\$450.95	\$450.95	NA	J2790
140-079	ESI	00008-0170-01	Wydase Stabl 150 un vl 1 ml	1	\$8.00	\$8.00	\$8.26	J3470
457-822	ROC	00004-1100-51	Xeloda 150mg Tab	120	\$203.69	\$1.70	\$230.59	J9999
457-830	ROC	00004-1101-16	Xeloda 500mg Tab	240	\$1,357.92	\$5.66	\$1,537.27	J9999
560-441	AST	00188-0110-01	Xylocaine 1% MDV 20 ml	1	\$2.34	\$2.34	\$2.11	J2000
560-468	AST	00188-0120-01	Xylocaine 2% MDV 20 ml	1	\$2.61	\$2.61	\$2.39	J2000
292-136	PUJ	00009-0844-01	Zanosar 1gm	1	\$80.00	\$80.00	\$96.51	J9320
718-098	GLX	00173-0362-38	Zantac 25mg/ml 2ml	10	\$36.75	\$3.68	\$39.91	J9999*
489-740	GLX	00173-0363-01	Zantac 25mg/ml 6ml	1	\$8.90	\$8.90	\$9.26	J9999*
023-838	PUJ	00013-8715-82	Zinecard 250mg	1	\$125.00	\$125.00	\$152.39	J1190
023-846	PUJ	00013-8725-99	Zinecard 500mg	1	\$250.00	\$250.00	\$304.76	J1190
708-844	GLX	00173-0442-00	Zofran MDV 2mg/ml 20ml	1	\$167.09	\$167.09	\$244.43	J2405
593-780	GLX	00173-0461-00	Zofran pre-mix bags 32mg/50ml	6	\$756.00	\$126.00	\$208.41	J2405
762-807	GLX	00173-0469-00	Zofran oral sol 4 mg/5 ml sol 50 ml	1	\$120.00	\$120.00	\$134.80	
450-247	GLX	00173-0446-00	Zofran 4 mg Tab 30	1	\$350.00	\$350.00	\$398.30	
450-312	GLX	00173-0447-00	Zofran 8mg Tab 30	1	\$575.00	\$575.00	\$660.20	
303-586	ZNC	00310-0960-36	Zoladex Implant 3.6mg	1	\$383.51	\$383.51	\$451.18	J9202
036-855	ZNC	00310-0961-30	Zoladex Implant 10.8mg	1	\$1,150.54	\$1,150.54	\$1,353.57	J9202



INVENTORY EXCEPTION UPDATES AWP SUMMARY SHEET HELP

Catalog Search Results

You searched for vancomycin, product name Vancomycin. Listed below are all of the Vancomycin products available through OTN. Click on the catalog number to find more information on each product. (AWPs, HCPCS Codes, etc.)


CAT NO	DISTRIBUTOR OR MANUFACTURER	BRAND NAME	ITEM	UNIT SIZE	UNIT PRICE	NET PRICE
860-351	Abbott Laboratories		Vancomycin, powder	500 mg	3.25	3.22
860-360	Abbott Laboratories		Vancomycin, powder	1 g	12.90	12.77

[New Search](#)

* Net price reflects the amount charged if purchased under your payment terms of **1% 30 NET 60**.

Items found in your contracts through OTN are listed in blue.

The prices shown above reflect all contracts and marketing programs in which you participated through OTN and are subject to the terms stipulated therein.



COPYRIGHT 1999 © OTN

FLORIDA INFUSION |

CATALOG '98

Nations Drug

MULTI-SPECIALTY
PHARMACEUTICAL
DISTRIBUTOR

CHEMOTHERAPY DRUGS

PHARMACEUTICALS

VACCINES

I.V. SOLUTIONS

ADMINISTRATION SETS

INJECTABLE DILUENTS

ANTIBIOTICS

SYRINGES & NEEDLES

VENIPUNCTURE

GLOVES

TAPES & DRESSINGS

BONE MARROW BIOPSY

SAFE HANDLING PRODUCTS

INSIDE:

ONCOLOGY 10

UROLOGY 47


DIALYSIS 62

GENERAL PRACTICE 48

PEDI 48

Strong. Independent. Better.

ANTIBIOTICS



Rocephin® ROCHE

Roche Laboratories offers through FloridaInfusion prompt nationwide distribution of Rocephin, America's leading once-a-day I.V. antibiotic.


250MG	10/box	\$102 ⁴⁵
500MG	10/box	\$185 ⁷⁵
1GM	10/box	\$317 ⁹⁰
2GM	10/box	\$631 ⁷⁵
1GM ADD-VANTAGE	10/box	\$328 ²⁰
2GM ADD-VANTAGE	10/box	\$648 ²⁰
10GM BULK	each	\$309 ⁹⁰
500MG	CONVENIENCE KIT	\$20 ⁷⁰
1GM	CONVENIENCE KIT	\$33 ⁸⁵




VANCOMYCIN
500mg \$3.75
1gm \$7.40




AMPICILLIN
250mg \$1.50
500mg \$1.60
1gm \$1.70
2gm \$1.08




CEFOBID
1gm .. \$14.45




CEFAZOLIN
500mg \$1.99
1gm .. \$1.50
10gm \$10.99




UNASYN
1.5gm \$6.48
3gm ... \$11.62




TIMENTIN
3.1gm \$12.80



MONOCID
1gm . \$20.00



GENTAMICIN
8. 2mL .. \$1.56




PRIMAXIN
500mg . \$23.75



FORTAZ
1gm \$13.04
2gm \$26.09



CLAFORAN
500mg \$6.34
1gm .. \$10.58
2gm .. \$19.56



ZOSYN
3.375gm .. \$13.48
4.5gm \$17.97



TOBRAMYCIN
80mg \$3.00
12gm \$36.90



AMIKACIN
500mg ... \$11.00
1gm ... \$11.60

PRICE LIST

TABLE PAPER, CREPE 18"X125'12"RL CASE	31.15	TOURNOUQUET, LATEX DISPOSABLE 100/C'S	24.60	VERSED 5MG/ML 10ML VIAL 10/BOX C4	74.45
TABLE PAPER, CREPE 21"X125'12"RL CASE	33.45	TOWEL, SCOTT-C-FOLD 16PACKS/CASE 150'S	42.00	VERSED 5MG/ML 1ML VIAL 10/BOX C4	42.40
TABLE PAPER, WARM 11121 X225'12"RL CASE	49.60	TOWELS, LOW LINT 9"X9"100/C'S	38.40	VERSED 5MG/ML 2ML VIAL 10/BOX C4	166.10
TAGAMET 400MG 2ML VIAL 25/BOX	88.73	TRACE MTE-4 COMC 10ML 25/BOX	19.00	VERSED 5MG/ML 5ML VIAL 10/BOX C4	192.85
TAGAMET 400MG 2ML VIAL MDV 10/BOX	113.15	TRANSFER EXT SET W/MINI SPIKE 50/BOX	147.50	YESANOID 10MG CAP 100'S	1039.40
TALWIN 30MG 1ML 10ML VIAL C4	32.80	TRANSPORE TAPE 1X10Y 12/BOX 15271	15.40	VESTALLOTION SOAP QUART	10.20
TAMOXIFEN CITRATE 10MG TABLETS 250/BTL	332.80	TRANSPORE TAPE 1X10Y 24/BOX 15270	15.40	VIDEX (100) 100MG TABLETS 60 BTL	43.70
TAMOXIFEN CITRATE 10MG TABLETS 60/BTL	80.30	TRANSPORE TAPE 2X10Y 6/BOX 15272	15.40	VINBLASTINE LIQUID MDV 10MG	9.40
TAPAZOLEF 5MG TAB 100/BTL	23.45	TRANSPORE TAPE 3X10Y 4/BOX 15273	15.40	VINBLASTINE LYOPH POWDER 10MG VIAL	7.90
TAXOL (PACLITAXEL) 100MG 5ML SDV	150.00	TREATOR-SC 250MG TABLETS 100/BTL	175.00	VINCISTINE SOLUTION 1MG VIAL	1.05
TAXOL (PACLITAXEL) 100MG 17ML SDV	499.00	TRIAMCINOLONE ACETONIDE 40MG/ML 5ML MDV	9.40	VINCISTINE SOLUTION 2MG VIAL	6.95
TAXOTER 20MG SDV WITH DILUENT	202.00	TRIAMCINOLONE DIACETATE 40MG/ML 5ML VIAL	8.90	VIRACEPT 250MG TABLETS 270 BT	520.10
TAXOTER 40MG SDV WITH DILUENT	404.00	TRITOPHYTON SKIN TEST 1/500 1ML VIAL	20.25	VIRAHOL LIQUID DISINFECTANT 1 GALLON	44.85
TAZICEF 1GM VIAL 20ML 25/BOX	270.00	TRISURALIN 5MG TAB 100'S	188.90	VIRAMUNE 300MG TABS 100/BTL	178.40
TAZICEF 1GM VIAL ADD-VANTAGE 25 BX	250.00	TUBERCULIN (DMON) VACC TEST 25/BOX	35.40	VISTARIL 25MG/ML 10ML MDV	11.35
TAZICEF 3GM VIAL 60ML 10/BOX	199.50	TUBERCULIN PPD TIME TEST 25'S	32.30	VISTARIL 50MG/ML 10ML MDV	17.70
TEGADERM 2-3.8 X 2-3.4 100/BOX 1624	48.00	TUBERCULIN PPD TIME TEST 100'S	122.40	VISTIDE 375MG 5ML VIAL	624.35
TEGADERM 4 X 4-14 50/BOX 1626	64.80	TUBERCULIN APLISOL STU 10 TEST 1ML VIAL	14.60	VUMON 50MG 5ML AMPULE	146.25
TEGADERM 4 X 4-14 6/BOX 401	10.80	TUBERCULIN TUBERSOL STU 10 TEST 1ML VIAL	12.90	WALKMED 350 PUMP W/BATTERY, BFL1 & PPK111	1099.00
TEGADERM 6 X 8 10/BOX 1628	44.00	TUBERCULIN TUBERSOL STU 50 TEST 5ML VIAL	24.80	WARM GEL PACK 6 X 6 40-CASE	64.50
TEGADERM 8 X 12 10/BOX 1629	52.00	TUBEX INJECTOR	3.75	WELLBUTRIN 100MG TABS 100/BTL	100.45
TEGADERM HIP 1-1/2 X 4 50/BOX 9546	104.70	TUMS ASSORTED FLAVOR 150/BTL	4.15	WINRHOD SF 1500U (1300MG) SDV	119.40
TELEFA 2 X 3 OUCHLESS PADS 100/BOX 1961	9.80	TUSSIGON TABLETS 100/BTL C3	27.75	WINRHOD SF 5000U (1000MG) SDV	190.50
TELEFA 3 X 4 OUCHLESS PADS 100/BOX 2132	16.95	TYLENOL COD PIKOS 42 15MG 100-BTL C3	27.75	WINRHOD SF 600U (120MG) SDV	59.70
TEMPA-DOT, STERILE 100/BOX	12.39	TYLENOL COD PHOS 43 30MG 100-BTL C3	30.55	WYCILLIN 1,200,000U TUBEX 10X2ML	46.50
TERRAMYCIN 50MG 5X10ML	42.27	TYLENOL EXTRA STRENGTH CAPLETS 100/BTL	8.75	WYCILLIN 2,000,000U SYRINGE 10X4ML	97.45
TESLAC TABLETS 100'S C3	127.65	TYLENOL EXTRA STRENGTH CAPLETS 175/BTL	14.40	WYCILLIN 600,000U TUBE-X 10X1ML	27.85
TEST STRIPS, ACCU-CHEK EASY 50/BTL	35.40	TYLENOL LIQUID EXTRA STRENGTH BOX	6.45	WYDASE SOLUTION 150 USP 1ML VIAL	7.40
TEST STRIPS, CHEM STRIPS BG+502 50/BTL	38.70	TYPHOID, ORAL VIVOTIF BERNA 4/PACK	22.95	WYDASE SOLUTION 150 USP 10ML VIAL	20.85
TEST STRIPS, GLUCOSTIX #263 100/BTL	73.65	ULTRAVIST 200MG 50ML 10/BX	340.00	XANAX 1.0MG TABLETS 100/BOTTLE C4	97.15
TEST STRIPS, GLUCOCLIM #2582 50/BTL	35.35	ULTRAVIST 240MG 100ML 10/BX	680.00	XYLOCAINE 0.5% 50ML MDV	4.40
TEST STRIPS, ONE TOUCH 50/BTL	33.70	ULTRAVIST 300MG 50ML 10/BX	390.00	XYLOCAINE 1% 10CC MDV 5/BOX	18.10
TESTOSTERONE 50/BX C3	70.80	ULTRAVIST 300MG 100ML 10/BX	778.00	XYLOCAINE 1% 10ML SDV 5'S	32.50
TESTOSTERONE 6MG W/ADHESIVE 30/BX C3	74.35	ULTRAVIST 370MG 50ML 10/BX	427.00	XYLOCAINE 1% 30ML MDV	2.45
TESTOSTERONE AQ SUSP 100MG/ML 10ML C3	8.25	ULTRAVIST 370MG 100ML 10/BX	851.00	XYLOCAINE 1% 50ML MDV	4.40
TESTOSTERONE AQ SUSP 100MG/ML 30ML C3	12.85	ULTRAVIST 370MG 200ML 10/BX	1706.00	XYLOCAINE 1% 50' VIALS 10/BOX	21.25
TESTOSTERONE CYPINATE 200MG/ML 10ML C3	11.25	UNASYN 1.5GM VIAL 10/BOX	64.80	XYLOCAINE 1% W/EP 50ML MDV	4.40
TESTOSTERONE ENANTHATE 200MG/ML 10ML C3	11.75	UNASYN 3.0GM VIAL 10/BOX	116.20	XYLOCAINE 1% W/EP 30ML AMP 5/BX	46.10
TESTOSTERONE PROPIONATE 100MG/ML 10ML C3	10.50	UNASYN 3.0GM VIAL ADD-VANTAGE 10/BOX	123.85	XYLOCAINE 2% 30ML MDV	2.75
TETANIS DIPHTEHRIA ADULT 5ML VIAL LEDER	27.40	VACUTAINER COLLECTION SET 50'S BD7251	45.00	XYLOCAINE 2% 50ML MDV	5.70
TETANIS DIPHTEHRIA ADULT TOXOID 10 TUBEX	33.90	VACUTAINER COLLECTION SET 50'S BD7252	32.40	XYLOCAINE 2% JELLY 30ML TUBE	15.40
TETANIS TOXOID ADSORBED TUBEX 10 DOSES	26.40	VACUTAINER COLLECTION SET 50'S BD7253	40.50	XYLOCAINE 2% W/EP 30ML MDV	5.70
TETANIS TOXOID ADSORBED 5ML VIAL CONNAU	20.50	VACUTAINER COLLECTION SET 50'S BD7255	45.00	XYLOCAINE 4% 5ML AMP 10/BOX	64.40
TETANIS TOXOID ADSORBED 5ML VIAL BERNA	14.85	VACUTAINER LUER ADAPTER 50'S BD7231	20.10	XYLOCAINE 4% TOPICAL SOLUTION 50ML	15.75
TETANIS TOXOID FLUID 7.5ML VIAL	31.30	VACUTAINER LUER ADAPTER 45 100'S BD7290	29.60	XYLOCAINE BU AMPULE 1% 5ML	0.55
TETANIS DIPHTEHRIA TOXOID ADULT 5ML VIAL	27.30	VACUTAINER NEEDLE 22X1 100'S BD7210	13.10	XYLOCAINE BU 0.5% 50ML SDV	10.85
THERACYS, BCG VACCINE, 3VIAL SET	146.80	VACUTAINER NEEDLE 21X1 100'S BD7212	13.10	XYLOCAINE VISCOSUS 2% 100ML	20.85
THERMOMETER, DIGITAL RD4030	8.35	VACUTAINER, BLUE TOP 4.5ML 100'S BD6418	10.50	XYLOCAINE W/EP 100 1% 30ML MDV	2.75
THERMOMETER, ELECTRONIC FILAC 1500	185.80	VACUTAINER, BLUE TOP 4.5ML 100'S BD6419	10.50	ZANOSAR (STREPTOCYTIN) 1GM VIAL	62.10
THERMOMETER, ORAL, RD3905	2.00	VACUTAINER, GREEN TOP 10ML 100'S BD6480	17.50	ZANTAC 150MG TABLETS 60 BTL	90.40
THERMOMETER, THERMOSCAN PRO-1 MODEL LR-1	335.00	VACUTAINER, PURPLE TOP 3ML 100'S BD64385	10.75	ZANTAC 1.5 50MG 2ML 5ML MDV	2.75
THIAMINE 100MG/ML 1ML VIAL 25/BOX	18.10	VACUTAINER, PURPLE TOP 7ML 100'S BD6450	10.50	ZANTAC PRE-MIX 50MG 50ML 24 CASE	104.00
THIOGUANINE TABLETS 40MG 25-BTL	74.00	VACUTAINER, PURPLE TOP 5ML 100'S BD6452	11.30	ZERIT 20MG CAPSULES 60 BTL	202.85
THIOPLEX 15MG VIAL 6/BOX	434.95	VACUTAINER, RED TOP 10ML 100'S BD6441	10.50	ZERIT 30MG CAPSULES 60 BTL	211.35
THORACENTESIS SET, ABBOTT #453 48-CASE	276.00	VACUTAINER, RED TOP 7ML 100'S BD6442	10.25	ZERIT 40MG CAPSULES 60 BTL	214.20
THORACENTESIS TRAY W/CATHE #431A 10/C'S	264.00	VACUTAINER, RED SST 4.5ML 100'S BD6510	29.50	ZINACEF 1.5GM VIAL 25/BOX	408.40
THORAZINE 25MG/ML 1ML AMPULE 10/BOX	70.10	VALIUM 10MG TABLETS 100'S C4	102.30	ZINACEF 750MG VIAL 25/BOX	155.00
THORAZINE 25MG/ML 10ML MDV	45.30	VALIUM 10MG 2ML SYRINGE 10/BOX C4	59.30	ZINCARD 50MG VIAL	112.40
TICARCILLIN (TICAR) 3GM VIAL 10/BOX	85.80	VALIUM 5MG/ML 10ML MDV C4	19.10	ZINCARD 100MG VIAL	220.00
TIGAN 100MG ML 10X2ML AMPULE	29.75	VALTREL 500MG CAPLETS 42/BTL	100.46	ZOFIRAN 4MG TABLETS 30/BTL	140.10
TIGAN 100MG ML 30ML MDV	21.15	VANCOCCIN 1GRAM LILLY	143.00	ZOFIRAN 8MG TABLETS 30/BTL	58.20
TIMENTIN 1.1GM 50ML VIAL 10/BOX	128.00	VANCOCCIN 1GRAM LILLY 25/BOX	357.50	ZOFIRAN 8MG TABLETS 5PK	44.40
TIMENTIN 1.1GM 50ML ADD-VANTAGE 10/BOX	124.15	VANCOMYCIN 100MG VIAL	7.40	ZOFIRAN INJECTION 5MG/ML 30ML MDV	167.40
TOBRAMYCIN 1.5GM 10ML VIAL	36.90	VANCOMYCIN 1GRAM ADD-VANTAGE 10/BOX	76.00	ZOFIRAN INJECTION 2ML VIAL 5/BOX	114.15
TOBRAMYCIN 60MG/NS 50ML PREMIX 24/C'S	122.50	VANCOMYCIN 300MG VIAL	36.00	ZOFIRAN PRE-MIXED 12MG 50ML D/W 5/C'S	244.40
TOBRAMYCIN 80MG 2ML VIAL APOTHECON	3.80	VANCOMYCIN 500MG VIAL	3.75	ZOLADEX 100MG SYRINGE	1014.00
TOBRAMYCIN 80MG/NS 50ML PREMIX 24/C'S	136.15	VANCOMYCIN 500MG ADD-VANTAGE 10/BOX	35.95	ZOLADEX 30MG SYRINGE	134.25
TOILET LID MASKING DEVICE	1.00	VARI-VAX 5ML SDV (CHICKEN POX)	47.10	ZOMAS TAPE 1 X 10 YARDS 12/BOX 5104	11.45
TONGUE DEPRESSOR, N.S. 500/BOX	5.32	VARI-VAX 5ML SDV (CHICKEN POX) 10/BOX	459.95	ZOMAS TAPE 2 X 10 YARDS 6/BOX 5106	11.45
TONGUE DEPRESSOR, STERILE 100/BOX	3.80	VASELINE GAUZE 7 X 9 50'S	79.60	ZOMAS TAPE 3 X 10 YARDS 4/BOX 5107	11.45
TOPOSAR (ETOPOSIDE) 100MG MDV	18.00	VELBAN 10MG VIAL LILLY	35.67	ZOSTRIX CREAM 40GRAM TUBE	11.80
TOPOSAR (ETOPOSIDE) 300MG MDV	36.00	VENI-GARD, LV DRESSING #7504181 25/BX	28.80	ZOSTRIX 100 CREAM 20Z. TUBE	16.80
TOPOSAR (ETOPOSIDE) 500MG MDV	82.00	VENI-GARD, LV DRESSING #7504311 100/BX	59.50	ZOSYN 3.375GM VIAL 10/BOX	154.75
TOPOSAR (ETOPOSIDE) 1000MG	165.00	VENTOLIN SOLUTION (INHALANT) 30ML	16.60	ZOSYN 4.5GM VIAL 10/BOX	179.45
TOPPER SPONGE, STERILE 4X3 50/BOX 2435	4.25	VEPESID (VP-16) 1GRAM VIAL	1088.00	ZOVIRAX 1000MG VIAL 10/BOX	190.00
TOPPER SPONGE, STERILE 4X4 50/BOX 2436	4.95	VEPESID (VP-16) 100MG VIAL	95.00	ZOVIRAX 300MG CAPSULES 100 BTL	100.40
TORADOL 10MG TABLETS 100/BTL	120.65	VEPESID 50MG CAPS 20'S	666.85	ZOVIRAX 400MG TABLETS 100/BTL	202.40
URADOL 30MG/ML 1ML TUBEX 10/BOX	80.65	VERAPAMIL 2ML SDV 5/BOX	2.45	ZOVIRAX 500MG 10ML VIAL 10/BOX	515.70
URADOL 60MG/ML 2ML TUBEX 10/BOX	84.60	VERSED 1MG/ML 10ML VIAL 10/BOX C4	166.10	ZOVIRAX 800MG TABLETS 100/BTL	562.40
URECAN 10MG/ML 100'S	48.90	VERSED 1MG/ML 2ML VIAL 10/BOX C4	42.30	ZOVIRAX UBITMENT 5% 3GM TUBE	16.75
URECAN 5MG/ML 2ML AMPULE	4.62				

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

2

Divider Title: _____

ZOFRAN

PROD/MFR	NDC	Wholesale	(GPO) DP	1999 AWP Red Book
(Cerenex)				
INJ, IJ (S.D.V.)				
2 mg/ml, 2 ml	000173-0442-02	22.83 /FI 22.00 /OTN 23.00/OS		24.45
(M.D.V.)				
2 mg/ml, 20 ml.....	000173-0442-00	170.43 /FI 169.95 /OTN 167.09 /ASD 168.77/OS		244.43
(PREMIXED BAG)				
30 mg/50ml, 50 ml.....	000173-0461-00	127.98 /FI 131.64 /OTN 126.00 /FI 126.73 /OS		206.41

C:\MyFiles\update\Zofran.wpd

NDC	MFG	Item #	Description	U/M	EXP	NET	AWP	J Code
9-1613-01	ALP	122-601	VENO-S 5% 5GM	EA		625.00		
15-3084-20	BMS	195-429	VEPESID 150MG	EA	Jun-00	51.45	196.55	
55390-0091-10	BED	170-006	VINBLASTINE 10MG POWDER	EA	Mar-00	7.28		
00469-2780-30	APP	150-001	VINBLASTINE 10MG SOL FUJI	EA	Nov-99	9.00	43.23	J9360
00013-7456-86	PHA	500-040	VINCASAR 1MG	EA	Aug-99	6.00	37.08	J9370
00013-7466-86	PHA	500-041	VINCASAR 2MG	EA	Dec-99	7.25	74.15	J9375
61703-0309-06	FAU	230-805	VINCRISTINE 1MG	EA	Apr-00	3.95		J9370
61703-0309-16	FAU	230-806	VINCRISTINE 2MG	EA	May-00	6.95	-	J9375
00049-5460-74	PZR	888-180	VISTARIL 50MG 10ML	EA	Aug-01	16.37		
61958-0101-01	GIL	888-198	VISTIDE 375MG 5ML	EA	Jun-99	650.00	706.80	
00074-9158-01	ABB	110-707	VITAMIN K1 10MG 5'S	EA	Feb-99	22.00		
00015-3095-20	BMS	195-428	VP 16 100MG	EA	Jun-00	34.30	131.03	
00015-3091-45	BMS	195-432	VP 16 CAPS 50MG 20'S	EA	Sep-00	653.00	776.63	J8560
00015-3075-19	BMS	195-435	VUMON 50MG/5ML	EA	Jul-00	155.00	180.72	
00469-2249-25	APP	150-500	WATER PARABEN BASE 25'S	EA	Oct-99	22.81		
60492-0023-10	NAB	888-164	WINRHO SD 1500IU 300MCG 2.5ML	EA	Nov-99	150.00	324.50	
60492-0024-10	NAB	888-165	WINRHO SD 5000IU 1000MCG 8.5ML	EA	Apr-00	499.00	1,081.50	
60492-0021-01	NAB	888-166	WINRHO SDF 600IU 120MCG 2.5ML	EA	May-00	65.00	142.00	
00008-0170-01	WYT	888-105	WYDASE 150 UNITS 1ML	EA	Aug-01	7.35		
00004-1100-51	ROC	550-828	XELODA 150MG 120'S	EA	Apr-00	203.69		
00004-1101-16	ROC	550-829	XELODA 500MG 240'S	EA	Sep-00	1,357.92		
00186-0145-01	AST	888-160	XYLOCAINE 1% 50CC VIAL	EA	Apr-02	3.97	3.65	J2000
00186-0155-01	AST	888-161	XYLOCAINE 2% 50CC VIAL	EA	Sep-02	4.79	4.58	
00009-0844-01	PHA	500-814	ZANOSAR 1GM SDV	EA	Mar-00	80.00	96.51	J9320
13-0363-00	GLX	290-242	ZANTAC 25MG 40ML	EA	Feb-00	55.86	60.54	
00173-0363-01	GLX	290-240	ZANTAC 25MG 6ML VIAL	EA	May-00	8.92	9.26	
00173-0362-38	GLX	290-241	ZANTAC 25MG/ML 10X2ML	EA	Dec-00	36.75	39.91	
00013-8715-62	PHA	500-070	ZINECARD 250MG	EA	Feb-01	130.00	152.39	J1190
00013-8725-89	PHA	500-071	ZINECARD 500MG	EA	Jan-01	260.00	304.76	
00173-0442-00	GLX	290-220	ZOFRAN 2MG/CC 20CC	EA	Oct-99	167.09	244.43	J2405
00173-0461-00	GLX	290-225	ZOFRAN 32MG BAGS 6'S	EA	May-00	752.82	1,238.46	
00173-0447-02	GLX	290-232	ZOFRAN 8MG 100'S	EA	Aug-01	2,200.00	2,302.61	
00173-0447-04	GLX	290-230	ZOFRAN 8MG 3'S	EA	Feb-03	66.00		
00173-0447-00	GLX	290-231	ZOFRAN 8MG 30'S	EA	Dec-02	650.00		
00310-0961-30	ZEN	888-114	ZOLADEX 10.8 IMPLANT	EA	Jul-00	885.00	1,317.74	J9202
00310-0960-36	ZEN	888-113	ZOLADEX 3.6 IMPLANT	EA	May-00	295.00	439.24	J9202

MONTHLY CHEMO SPECIALS

Valid from 8/10/98 to 9/30/98

ADRIAMYCIN®	50mg RDF (powder)	\$38 ⁰⁰	KYTRIL®	1mg/mL 1mL	\$125 ⁹⁰
	50mg PFS (liquid)	\$39 ⁹⁵		1mg/mL 4mL	\$503 ⁶⁰
	200mg PFS (liquid)	\$149 ⁵⁰			
ANZEMET	20mg/ml 5ml SDV	\$71 ⁹⁰	LEUCOVORIN	100mg	\$3 ²⁵
			POWDER	200mg	\$8 ⁵⁰
				350mg	\$15 ²⁵
AREDIA®	30mg (4/box)	\$742 ⁰⁰	MITOMYCIN	5mg	\$49 ⁹⁵
	60mg (vial)	\$362 ⁹⁰		20mg	\$152 ⁹⁵
	90mg (vial)	\$525 ⁹⁰			
BLEOMYCIN	15unit	\$158 ⁰⁰	NAVELBINE®	10mg/mL 1mL	\$53 ^{63**}
	30unit	\$330 ⁰⁰		10mg/mL 5mL	\$270 ^{22**}
CAMPTOSAR®	40mg Vial	\$174 ⁰⁰	NEOSAR®	500mg	\$7 ²⁵
	100mg Vial	\$434 ⁰⁰		1000mg	\$10 ⁹⁵
				2000mg	\$21 ⁹⁰
CYTARABINE®	500mg (powder)	\$8 ²⁵	NEUMEGA	5mg SVD	\$185 ⁰⁰
	1gm (powder)	\$18 ⁷⁰			
	2gm (powder)	\$35 ²⁰	NOVANTRONE®	20mg	\$664 ⁸⁵
DOXORUBICIN	50mg (powder)	\$33 ⁰⁰		30mg	\$1,004 ⁶⁰
	50mg (liquid)	\$34 ⁰⁰	RITUXAN®	100mg	\$331 ²⁵
	200mg (liquid)	\$149 ⁰⁰		500mg	\$1,656 ²⁵
ETHYOL	500mg Vial 3/Box	\$872 ⁶⁰	TAXOL®	30mg	\$149 ⁹⁰
ETOPOSIDE	100mg	\$7 ⁹⁵		100mg	\$499 ⁰⁰
	500mg	\$39 ⁷⁵		300mg	\$1,497 ⁵⁰
	1000mg	\$85 ⁹⁰	TAXOTERE®	20mg	\$212 ¹⁰
FLUDARA®	50mg	\$179 ⁹⁵		80mg	\$839 ⁷⁵
GEMZAR®	200mg	\$69 ⁹⁵	VINCRISTINE®	1mg	\$4 ²⁵
	1gram	\$350 ²⁰		2mg	\$7 ²⁵
HYCANTIN®	4mg each	\$443 ⁴⁰	ZOFRAN®	2mg/mL 20mL	\$170 ^{43**}
	4mg (5/box)	\$2,217 ⁰⁰		32mg (premixed bag)	\$127 ^{98**}

INTRON-A®

*Universal contract only

These Prices Can't Be Beat!!!

10 million unit vial premix	\$93 ¹⁵	25 million unit vial premix	\$232 ⁸⁹
18 million unit vial premix	\$167 ⁶⁶	50 million unit vial powder	\$465 ⁷³

PRICES SUBJECT TO CHANGE UPON MANUFACTURER'S PRICE INCREASE

ASD ITEM #	MFG	NDC #	ONCOLOGY PHARMACEUTICALS	PKG SIZE	PKG PRICE	EACH PRICE	REDBOOK AWP	J CODE
291-181	PUJ	00008-0825-01	Solu Cortef 100mg vl	1	\$1.75	\$1.75	\$3.26	
291-179	PUJ	00008-0900-13	Solu Cortef 100 mg vl 2 ml	1	\$1.75	\$1.75	\$3.34	
291-187	PUJ	00008-0909-08	Solu Cortef 250 mg vl 2 ml	1	\$2.65	\$2.65	\$7.56	
291-153	PUJ	00008-0912-05	Solu Cortef 500 mg vl 4 ml	1	\$5.55	\$5.55	\$14.71	
291-344	PUJ	00008-0190-09	Solu Medrol 125 mg vl 2ml	1	\$2.65	\$2.65	\$5.31	
291-211	PUJ	00008-0887-01	Solu Medrol 500 mg vl	1	\$6.17	\$6.17	\$20.06	
291-280	PUJ	00008-0113-12	Solu Medrol 40 mg ADV 1 ml	1	\$1.60	\$1.60	\$2.00	
291-286	PUJ	00008-3389-01	Solu Medrol 1 g ADV 8 ml	1	\$11.02	\$11.02	\$32.19	
039-032	SKB	00108-5022-11	Tagamet 150mg/ml 8ml	10	\$111.00	\$11.10	\$128.60	J9999*
979-583	BMS	00015-3475-30	Taxol 6mg/ml 5ml	1	\$149.02	\$149.02	\$182.63	J9265
074-450	BMS	00015-3478-27	Taxol 100mg/17ml	1	\$496.75	\$496.75	\$608.76	J9265
587-691	BMS	00015-3479-11	Taxol 300mg MDV 50ml	1	\$1,490.22	\$1,490.22	\$1,826.30	J9265
665-885	RPR	00075-8001-20	Taxotere 20mg SDV	1	\$220.50	\$220.50	\$284.36	J9170
665-000	RPR	00075-8001-80	Taxotere 80mg SDV	1	\$882.00	\$882.00	\$1,137.43	J9170
034-637	LIL	00002-7241-18	Tazidime 6gm vl	6	\$434.70	\$72.45	NA	
976-472	SHN	00364-6610-54	Testost Cyp 200 mg vl 10 ml	1	\$13.99	\$13.99	\$26.15	J1080
976-498	SHN	00364-6617-20	Testost Ena 200mg vl 10ml	1	\$14.65	\$14.65	\$42.10	
324-319	CNN	49281-0800-83	Tetanus Tox A MDV 5 ml	1	\$23.08	\$23.08	\$20.75	J1670
673-640	MM	58408-0661-31	Thioplex 15MG/2ML	6	\$460.00	\$76.67	\$514.44	J9340
023-788	PUJ	00013-7336-91	Toposar 100mg	1	\$9.00	\$9.00	\$143.31	J9182
023-796	PUJ	00013-7336-94	Toposar 200mg	1	\$18.00	\$18.00	\$286.83	J9182
023-812	PUJ	00013-7336-88	Toposar 500mg	1	\$44.00	\$44.00	\$698.65	J9182
393-827	ROX	00054-4748-25	Torecan 10 mg Tabs	100	\$48.50	\$0.49	\$54.30	
393-835	ROX	00054-1701-07	Torecan 10 mg amp 2 ml	20	\$93.40	\$4.67	\$105.63	
241-497	PFI	00049-3900-28	Trovan IV 300mg SDV 60ml	1	\$48.06	\$48.06	NA	
535-559	CNN	11793-7522-01	Tubersol 5 TU 10 Test vl 1ml	1	\$15.23	\$15.23	\$22.08	J9999*
428-177	J+J	00045-0449-10	Tylenol X/S Disp Pack Cpl 2 UD	50	\$10.48	\$0.21	\$6.29	
783-409	ABB	00074-8533-01	Vancomycin 1 gm Add Vantage	10	\$76.00	\$7.60	\$693.14	
279-059	ALP	49669-1614-01	Venoglobul S 5% / 10 mg vl 200 ml	1	CALL	CALL	\$900.00	
097-253	ALP	49669-1623-01	Venoglobulin-S 10% 10gm	1	CALL	CALL	\$950.00	J1562
097-311	ALP	49669-1624-01	Venoglobulin-S 10% 20gm	1	CALL	CALL	\$1,900.00	J1562
106-112	ROC	00004-1999-01	Versed 1mg/ ml vl 5 ml	10	\$153.76	\$15.38	\$104.23	
481-584	BED	55390-0091-10	Vinblastine 10mg	10	\$72.80	\$7.28	\$212.50	J9360
955-666	FAU	61703-0310-18	Vinblastine 10mg	1	\$7.95	\$7.95	\$37.50	J9360
980-870	FUJ	00489-2780-30	Vinblastine 10mg Solution	1	\$9.00	\$9.00	\$43.23	J9360
312-439	PUJ	00013-7456-86	Vincasar 1mg	10	\$45.00	\$4.50	\$37.08	J9370
312-447	PUJ	00013-7466-86	Vincasar 2mg	10	\$70.00	\$7.00	\$74.13	J9375
955-716	FAU	61703-0309-06	Vincristine 1mg/ml 1ml	1	\$3.95	\$3.95	\$31.75	J9370
955-724	FAU	61703-0309-18	Vincristine 1mg/ml 2ml	1	\$6.95	\$6.95	\$36.25	J9375
313-593	GLS	81958-0101-1	Viscote 375mg 5ml	1	\$670.73	\$670.73	\$706.80	
062-224	ABB	00074-9158-01	Vit K10mg Amp 1ml	25	\$174.17	\$6.97	\$137.16	
080-416	BER	58337-0003-01	Vivitol Berna Capsule 4	1	\$31.02	\$31.02	\$34.17	
388-777	BMS	00015-3075-19	Vumon 50mg/ml	1	\$156.67	\$156.67	\$181.01	J9999*
083-998	NAB	60492-0061-01	WinRHo SDF 600iu 120mcg	1	\$56.02	\$56.02	\$120.00	J2790
086-892	NAB	60492-0082-01	WinRHo SDF 1500iu 300mcg	1	\$135.26	\$135.26	\$306.00	J2790
629-907	NAB	60492-0024-01	WinRHo SDF 6000iu 1000mcg	1	\$450.95	\$450.95	NA	J2790
140-079	ESI	00008-0170-01	Wydase Stabl 150 un vl 1 ml	1	\$8.00	\$8.00	\$8.26	J3470
457-622	ROC	00004-1100-51	Xeloda 150mg Tab	120	\$203.69	\$1.70	\$230.59	J9999
457-630	ROC	00004-1101-18	Xeloda 500mg Tab	240	\$1,357.92	\$5.66	\$1,537.27	J9999
560-441	AST	00186-0110-01	Xylocaine 1% MDV 20 ml	1	\$2.34	\$2.34	\$2.11	J2000
560-466	AST	00186-0120-01	Xylocaine 2% MDV 20 ml	1	\$2.61	\$2.61	\$2.39	J2000
292-136	PUJ	00009-0844-01	Zanosar 1gm	1	\$80.00	\$80.00	\$96.51	J9320
718-098	GLX	00173-0362-38	Zantac 25mg/ml 2ml	10	\$36.75	\$3.68	\$39.91	J9999*
489-740	GLX	00173-0363-01	Zantac 25mg/ml 6ml	1	\$8.90	\$8.90	\$9.26	J9999*
023-838	PUJ	00013-6715-62	Zincard 250mg	1	\$125.00	\$125.00	\$152.39	J1190
023-846	PUJ	00013-6725-99	Zincard 500mg	1	\$250.00	\$250.00	\$304.78	J1190
708-644	GLX	00173-6443-09	Zofran MDV 2mg/ml 20ml	1	\$167.09	\$167.09	\$244.43	J2406
583-780	GLX	00173-0461-00	Zofran pre-mix bags 32mg/50ml	6	\$766.00	\$128.00	\$208.41	J2406
762-607	GLX	00173-0469-00	Zofran oral sol 4 mg/5 ml sol 50 ml	1	\$120.00	\$120.00	\$134.60	
450-247	GLX	00173-0446-00	Zofran 4 mg Tab 30	1	\$350.00	\$350.00	\$396.30	
450-312	GLX	00173-0447-00	Zofran 8mg Tab 30	1	\$575.00	\$575.00	\$660.20	
303-586	ZNC	00310-0980-36	Zoladex Implant 3.6mg	1	\$363.51	\$363.51	\$451.18	J9202
036-855	ZNC	00310-0981-30	Zoladex Implant 10.8mg	1	\$1,150.54	\$1,150.54	\$1,353.57	J9202

MFG	ITEM #	DESCRIPTION	QTY	EXP	NET	AWP	J CODE
GLA	4241	ZANTAC 25MG/ML 10X2ML	10	Oct-99	\$ 36.75	\$ 39.91	
PHA	1070	ZINECARD 250mg	ea	Jun-00	\$ 125.00	\$ 152.39	J1190
PHA	1071	ZINECARD 500mg	ea	Jun-00	\$ 250.00	\$ 304.76	
GLA	4220	ZOFRAN 40mg 20ml	ea	Mar-99	\$ 165.00	\$ 244.43	J2405
GLA	4225	ZOFRAN 32mg BAGS	6	Aug-99	\$ 125.00	\$ 208.41	
Glaxo Contract Pricing will be honored.							
Non-Contract Customers call for Price							
GLA	4230	ZOFRAN 8mg TABLETS 3's	3	Oct-00	\$ 60.59	\$ 67.36	
GLA	4231	ZOFRAN 8mg TABLETS 30's	30	Sep-00	\$ 593.84	\$ 676.97	
GLA	4232	ZOFRAN 8mg TABLETS 100's	100	Aug-00	\$ 2,019.94	\$ 2,302.61	
ZEN	9113	ZOLADEX 3.6mg IMPLANT	ea	Oct-99	\$ 325.00	\$ 439.24	J9202
ZEN	9114	ZOLADEX 10.8 mg IMPLANT	ea	Jul-99	\$ 975.00	\$ 1,317.74	J9202

OTN

INVENTORY EXCEPTION UPDATES AWP SUMMARY SHEET HELP

Catalog Search Results

You searched for zofran, product name
Ondansetron HCl. Listed below are all of the
Ondansetron HCl products available through OTN.
Click on the catalog number to find more
information on each product. (AWPs, HCPCS
Codes, etc.)


CAT NO	DISTRIBUTOR OR MANUFACTURER	BRAND NAME	ITEM	UNIT SIZE	UNIT PRICE	NET PRICE
900-105	Glaxo Inc.	Zofran	Ondansetron HCl, oral susp 4mg/5mL	50 mL bd	138.10	136.72
900-100	Glaxo Inc.	Zofran Injection	Ondansetron HCl, solution (2mg/mL)	40 mg MDV	169.95	168.25
970-440	Glaxo Inc.	Zofran ODT	Ondansetron ODT 4mg	30/pk	406.60	402.53
970-043	Glaxo Inc.	Zofran Tablets	Ondansetron HCl, tablets, 4 mg	3 per bottle	40.65	40.24
970-410	Glaxo Inc.	Zofran Tablets	Ondansetron HCl, tablets, 4 mg	100 per bottle	1,355.15	1,341.60
970-810	Glaxo Inc.	Zofran Tablets	Ondansetron HCl, tablets, 8 mg	100 per bottle	2,257.55	2,234.97

[New Search](#)

* Net price reflects the amount charged if purchased under your payment terms of 1% 30 NET 60.

Items found in your contracts through OTN are listed in blue.

The prices shown above reflect all contracts and marketing programs in which you participated through OTN and are subject to the terms stipulated therein.



COPYRIGHT 1999 © OTN

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

3

Divider Title: _____

LEUCOVORIN CALCIUM

PROD/MFR	NDC	Wholesale	(GPO) DP	1999 AWP Red Book
(Abbott Hosp)				
INJ, IJ (VIAL, FLIPTOP)				
10mg/ml, 10ml.....	00074-4541-02	3.95 /FI 4.00 /OTN 3.60 /OS		9.98
(VIAL, FLIPTOP 30 ML)				
10 mg/ml, 25ml.....	00074-4541-04	9.95 /FI 10.00 /OTN 7.50 /ASD 7.25 /OS		24.94
(Bedford)				
PDI, IJ (VIAL)				
50 mg. 10s ea.....	55390-0051-10	2.75 /FI 3.05 /OTN 2.25 /ASD 3.00 /OS		18.44
100 mg, 10s ea.....	55390-0052-10	2.95 /FI 4.00 /OTN 3.00 /ASD,OS		35.00
200mg, ea.....	55390-0053-01	7.75 /FI 9.50 /OTN 7.75 /ASD,OS		78.00
(Gensia)				
PDI,IJ (P.F. VIAL)				
100 mg, ea.....	00703-5140-01	4.90 /OTN 2.79 /ASD,OS		38.63
350 mg, ea.....	00703-5145-01	21.00 /OTN 14.00 /ASD 12.50/OS		85.75
(Immunex)				
PDI, IJ (P.F.)				
350 mg, ea.....	58406-0623-07	19.00 /OTN 12.25 /FI 12.50 /OS		137.94



1-800-624-0152

Valid from 3/1/99 to 3/28/99

**MARCH
1999****FLORIDA INFUSION™ / NationsDrug™**

THIS MONTH'S SPECIALS ROAR IN LIKE A LION!

5-FU 500mg (10/box) \$11⁴⁵ *
 (Pharmacies not eligible) 1gram (10/box) \$26⁵⁰
 2.5gram \$6⁰⁰ *
 5gram \$12⁹⁵ *

ADRIAMYCIN® 50mg RDF (powder) \$36⁰⁰
 50mg PFS (liquid) \$38⁹⁵
 200mg PFS (liquid) \$148⁹⁵

ANZEMET® 20mg/mL 5mL SDV \$73⁵²

AREDLA® 30mg 4/box (Ciba) \$779⁹⁵ *
 90mg Vial (Ciba) \$549⁹⁵ *

BLEOMYCIN® 15unit Vial \$158⁰⁰
 30unit Vial \$330⁰⁰

CAMPTOSAR® 40mg Vial \$182⁵⁵ *
 100mg Vial \$459⁹⁵ *

CYTARABINE® 500mg Vial (powder) \$8²⁵
 500mg MDV (liquid) \$8⁵⁰
 1gm Vial (powder) \$16⁹⁵ *
 2gm Vial (powder) \$35²⁰

DEXFERRUM® 100mg/2mL Vial 10/box \$234⁰⁰

DOXIL® 2mg/mL 10mL SDV \$533⁹⁵ *

DOXORUBICIN® 50mg Lyoph (powder) \$33⁰⁰
 (Bedford) 50mg (liquid) \$34⁰⁰
 200mg (liquid) \$139⁹⁵

ETHYOL® (powder) 500mg 10mL Vial 3/box \$898⁹⁵ *

ETOPOSIDE® 100mg Inj. MDV \$7⁵⁰
 (Bedford) 500mg Inj. MDV \$38⁵⁰
 1000mg Inj. MDV \$79⁹⁵

FLUDARA® 50mg Vial \$185⁰⁰

GEMZAR® 200mg Vial \$69⁵⁰
 1gram Vial \$347⁹⁵ *

HERCEPTIN® 440mg MDV \$1,837⁵⁵

HYCANTIN® 4mg Vial \$467⁵⁰
 4mg Vial 5/Box \$2,336⁵⁵

INTRON-A® 3mill unit Syt/Sol 6/box \$165⁹⁵ *
 3mill unit Vial pwd/premix \$27⁴⁵ *
 5mill unit Syt/Sol 6/box \$276⁵⁴ *
 5mill unit Vial pwd/premix \$46⁹⁰ *
 10mill unit Syt/Sol 6/box \$553⁰⁷ *
 10mill unit Vial pwd/premix \$92¹⁰ *

INTRON-A® 18mill unit MDV pwd/premix \$165⁹⁵ *
 (Cost'd) 25mill unit MDV pwd/premix \$230⁴⁰ *
 50mill unit Vial powder \$460⁸⁵ *

KYTRIL® 1mg/mL 1mL Inj. Vial \$132³²
 1mg/mL 4mL \$529²⁶ *

LEUCOVORIN® 100mg Vial (Bedford) \$2⁹⁵
 (Powder) 200mg Vial (Bedford) \$7⁹⁵
 350mg Vial (Immunex) \$14²⁵

LEUKINE® 250mcg (5/box) \$555⁰⁰
 500mcg (5/box) \$1,111²⁰

LEUSTATIN® 1mg/mL 10mL Vial \$464⁰⁰

MITOMYCIN® 5mg Vial (Bedford) \$37⁰⁰ *
 20mg Vial (Bedford) \$124⁹⁵ *

NEOSAR® 100mg Vial \$37⁵ *
 200mg Vial \$47⁵ *
 500mg Vial \$6⁹⁵ *
 1000mg Vial \$9⁹⁵ *
 2000mg Vial \$19⁹⁵ *

NEUMEGA® 5mg SD Vial \$183⁷²
 5mg SD Vial (7/box) \$1,286⁰⁰

NEUTREXIN® 25mg Vial (50/box) \$2,692⁰⁷

NOVANTRONE® 20mg/10mL Vial \$659⁹⁵ *
 25mg/12.5mL Vial \$820⁰⁰ *
 30mg/15mL Vial \$990⁰⁰ *

PROCRT® 10,000u/mL (6/box) \$564⁰⁰
 (Certified physicians only) 10,000u/mL (25/box) \$2,350⁰⁰
 20,000u/mL 1&2mL (6/box) \$1,128⁰⁰
 40,000u/mL (4/box) \$1,504⁰⁰

RITUXAN® 100mg 10mL SDV \$343⁸²
 500mg 50mL SDV \$1,735⁹⁰

ROCEPHIN® 250mg Vial (10/box) \$111⁵¹
 500mg Vial (10/box) \$202¹⁶
 1gram Vial (10/box) \$345⁹⁰
 2gram Vial (10/box) \$687⁴⁵
 10gram Bulk Vial \$337³³

TAXOTERE® 20mg SDV w/Diluent \$222⁷⁵
 80mg SDV w/Diluent \$891⁰¹

VINBLASTINE® 10mg (powder) \$7⁹⁰
 (Pharmacies not eligible) 10mg (liquid) MDV \$9⁹⁵

VINCRIStINE® 1mg Solution Vial \$3⁹⁵
 2mg Solution Vial \$6⁹⁵

***New Lower Prices**

PRICES SUBJECT TO CHANGE UPON MANUFACTURER'S PRICE INCREASE

CN

IDC	MFG	Item #	Description	U/M	EXP	NET	AWP	J Code
00007-4201-05	SKB	600-205	HYCANTIN 4MG 5'S	EA	Sep-00	2,347.75	2,741.75	J9350
00007-4201-01	SKB	600-207	HYCANTIN 4MG SINGLES	EA	Sep-00	469.55		
00015-0830-50	BMS	195-414	HYDREA 500MG CAP 100'S	EA	Dec-00	117.30	141.93	
00013-2516-86	PHA	500-051	IDAMYCIN 10MG POWDER	EA	Nov-00	550.00	639.69	
00013-2526-86	PHA	500-052	IDAMYCIN 20MG POWDER	EA		1,100.00	1,270.40	
00013-2506-94	PHA	500-050	IDAMYCIN 5MG POWDER	EA	May-00	275.00	319.85	J9211
00013-2556-67	PHA	500-054	IDAMYCIN PFS 10MG	EA	Jul-99	550.00		
00013-2556-67	PHA	500-055	IDAMYCIN PFS 20MG	EA	May-00	1,100.00	1,279.40	
00013-2546-86	PHA	500-053	IDAMYCIN PFS 5MG	EA	Jul-99	275.00		
00015-3554-27	BMS	195-442	IFEX 10 X 1GM	EA	Aug-00	1,830.00	2,154.31	
00015-0556-05	BMS	195-437	IFEX 1GM	EA	Jul-01	70.00		
00015-3564-15	BMS	195-416	IFEX 2X3GM COMBO	EA	May-00	1,099.00	1,292.52	
00015-0557-41	BMS	195-443	IFEX 3GM	EA	Mar-01	127.40		
00015-3556-26	BMS	195-441	IFEX 5X1GM	EA	May-00	757.00	891.55	J9208
	MCN	888-922	IMMUNE GLOBULIN (HUMAN) IM 2ML	EA		33.00		
00364-3012-47	sc Inv	888-023	INFED 100MG 10X2ML	EA	Jan-00	245.00	349.59	J1760
00085-0571-02	SCH	580-110	INTRON-A 10MIL POWDER	EA	Sep-00	93.00	116.44	
00085-1110-01	SCH	580-118	INTRON-A 18MIL POWDER	EA	Sep-00	167.40	209.58	
00085-0285-02	SCH	580-125	INTRON-A 25MIL POWDER	EA	Jul-00	232.50	291.11	
00085-0539-01	SCH	580-150	INTRON-A 50MIL POWDER	EA	Apr-01	465.00	582.17	
00085-1179-01	SCH	580-010	INTRON-A HSAF 10MIL ALPHA 2B	EA	Aug-99	93.00	116.44	
00085-1179-02	SCH	580-610	INTRON-A HSAF 10MIL SYR 6'S	EA	Apr-99	558.00	698.62	
00085-1168-01	SCH	580-018	INTRON-A HSAF 18MIL ALPHA 2B	EA	May-99	165.00	209.58	
00085-1133-01	SCH	580-025	INTRON-A HSAF 25MIL ALPHA 2B	EA	Oct-99	232.50	291.11	
00085-1184-01	SCH	580-003	INTRON-A HSAF 3MIL ALPHA 2B	EA	Sep-99	27.90	34.93	J9214
00085-1184-02	SCH	580-603	INTRON-A HSAF 3MIL SYR 6'S	EA	Dec-99	167.40	209.58	
00085-1191-01	SCH	580-005	INTRON-A HSAF 5MIL ALPHA 2B	EA	Jul-99	46.50	58.21	
00085-1191-02	SCH	580-605	INTRON-A HSAF 5MIL SYR 6'S	EA	Sep-99	279.00	349.31	
00085-1254-01	SCH	580-210	INTRON-A HSAF 6X10MIU PEN	EA	Jun-99	558.00	698.62	
00085-1242-01	SCH	580-203	INTRON-A HSAF 6X3MIU PEN	EA	May-99	167.40	209.58	
00085-1235-01	SCH	580-205	INTRON-A HSAF 6X5MIU PEN	EA	May-99	279.00		
00029-4149-01	SKB	600-201	KYTRIL 1MG VIAL	EA	Apr-00	132.50	186.10	J1626
00029-4152-01	SKB	600-204	KYTRIL 4MG MDV	EA	Nov-00	529.00	744.35	
00075-4151-39	SKB	600-203	KYTRIL TAB 1MG 2'S	EA	Jul-00	72.80	89.70	
00173-0638-93	GLX	290-250	LEUCOVORIN 100MG "GLAXO"	EA	Apr-99	3.05		J0640
55390-0052-10	BED	170-100	LEUCOVORIN 100MG BEDFORD	EA	Sep-01	3.00	35.00	
00703-5140-01	GEN	270-440	LEUCOVORIN 100MG GENSIA	EA	Nov-00	2.79		
55390-0053-01	BED	170-200	LEUCOVORIN 200MG BEDFORD	EA	Nov-00	7.75	78.00	
00555-0485-27	BAR	160-025	LEUCOVORIN 25MG TABS 25'S	EA	Feb-00	296.80	600.00	
00703-5145-01	GEN	270-450	LEUCOVORIN 350MG GENSIA	EA	Jan-00	14.00		
58406-0623-33	IMM	320-660	LEUCOVORIN 350MG IMMUNEX	EA	Nov-00	15.00	137.94	
55390-0051-10	BED	170-005	LEUCOVORIN 50MG BEDFORD	EA	Jun-01	3.00	18.44	
00555-0484-02	BAR	160-005	LEUCOVORIN 5MG TABS 100'S	EA	Mar-00	140.00		
00074-4541-02	ABB	110-600	LEUCOVORIN SOLN 100MG ABBOTT	EA	Apr-00	3.60		
00074-4541-04	ABB	110-601	LEUCOVORIN SOLN 250MG ABBOTT	EA	May-00	7.25		
00073-0635-35	GLX	290-253	LEUKERAN 2MG 50'S TABS	EA	Sep-99	66.00	68.71	
58406-0002-33	IMM	320-670	LEUKINE 250MG 5'S	EA	Apr-01	549.00	630.20	
58406-0050-30	IMM	320-673	LEUKINE 500MG 5'S SOLUTION	EA	Sep-99	1,099.00	1,260.33	CALL*
59676-0201-01	JOM	330-810	LEUSTATIN 10MG VIAL	EA	Apr-00	465.00	516.00	J9065
00045-0069-51	MCN	888-204	LEVAQUIN 500MG IV	EA	Jul-00	36.99	39.60	
00517-0625-25	ARL	130-105	LIDOCAINE 1% 50CC	EA	Aug-00	1.25	3.00	J2000

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

4

Divider Title: _____

KYTRIL

PROD/MFR	NDC	Wholesale	(GPO) DP	1999 AWP Red Book
(SK Beecham Pharm)				
INJ, IJ (S.D.V.)				
1 mg/ml, 1 ml.....	00029-4149-01	138.80/FI 140.20/OS 144.65/OTN 132.50/ASD		186.10
(M.D.V.)				
1 mg/ml, 4 ml.....	00029-4152-01	555.18/FI 578.50/OTN 529.00/ASD 560.00/OS		744.35

C:\MyFiles\update\Kytril.wpd



INVENTORY EXCEPTION UPDATES	AWP SUMMARY SHEET	HELP
-----------------------------	-------------------	------

Catalog Search Results

You searched for kytril, product name Kytril.
Listed below are all of the Kytril products
available through OTN. Click on the catalog
number to find more information on each
product. (AWPs, HCPCS Codes, etc.)

CAT NO	DISTRIBUTOR OR MANUFACTURER	BRAND NAME	ITEM	UNIT SIZE	UNIT PRICE	NET PRICE
900-200	Smithkline Beecham Pharm.	Kytril	Granisetron HCl, solution (1 mg/mL)	1 mL	144.65	143.20
900-202	Smithkline Beecham Pharm.	Kytril	Granisetron HCl, solution (1 mg/mL)	1 mL	79.15	78.36
970-202	Smithkline Beecham Pharm.	Kytril	Granisetron HCl, tablets, 1 mg	2 per bottle	79.15	78.36
970-200	Smithkline Beecham Pharm.	Kytril	Granisetron HCl, tablets, 1 mg	2 per bottle	79.15	78.36

[New Search](#)

* Net price reflects the amount charged if purchased under your payment terms of **1% 30 NET 60**.

Items found in your contracts through OTN are listed in blue.

The prices shown above reflect all contracts and marketing programs in which you participated through OTN and are subject to the terms stipulated therein.



COPYRIGHT 1999 © OTN

PRICE LIST

KUTAPRESSININ120CC	108.25	MEVACOR20MGTABLETS60/BTL	125.20	OXIPORVHCLOTION1.9OZ	11.45
KYTRIL1MGTABLETS20/BOX	888.35*	MIACALCIN(CALCITONIN)NASALSPRAY2BTL	49.90	PANHEMATIN313MGVIAL	259.75
KYTRIL4MLVIAL MDV	503.60*	MITOMYCIN5MGVIAL BEDFORD	49.95*	PAPAVERINEINJ.30MG/ML10MLVIAL	5.95
KYTRILINJECTION1MG/ML1MLVIAL	125.90*	MITOMYCIN20MGVIAL BEDFORD	152.95*	PARAPLATIN50MGVIAL	80.15
LASIX20MGTABLETS100'S	17.20	MMR-2VACCINE10VIAL TRAY	293.85	PARAPLATIN150MGVIAL	240.15
LEUCOVORIN50MGVIAL BEDFORD	2.75*	MMR-2VACCINESINGLEDOSSEVIAL	33.90	PARAPLATIN450MGVIAL	720.75
LEUCOVORIN100MGVIAL BEDFORD	3.25*	MONOCID1GRAMVIAL	20.00	PENICILLINGPOT5MILLUNIT10/BOX	18.85
LEUCOVORIN200MGVIAL BEDFORD	8.50*	MORRHUATESODIUM5%30ML	31.50	PENICILLINGSOD5MILLUNIT10/BOX	78.05
LEUCOVORIN350MGVIAL IMMUNEX	15.95*	MULTITESTCMISKINTESTANTIGENS	145.30	PENICILLIN-GPOT20MILLUNIT5/10/BOX	9.25
LEUCOVORINLIQUID100MGVIAL ABBOTT	3.95*	MUMPSKINTEST1ML10TESTS	101.25	PENICILLIN-GPOT20MILLUNIT5/10/BOX	50.00
LEUCOVORINLIQUID250MGVIAL ABBOTT	9.95*	MUMPSVAXVACCINE(MUMPS)SDV	18.25	PENTAMIDINE300MGVIAL	29.00
LEUCOVORINTABS5MG30'S	45.00*	MUSE125MCGURETHRALSUPP6/BX	103.50	PEPCIDI.V.20MG/2MLSDV10/BOX	35.05
LEUCOVORINTABS5MG100'S	130.00*	MUSE250MCGURETHRALSUPP6/BX	108.50	PHENYTOIN100MG/2MLSDVIAL 25/BX	40.75
LEUCOVORINTABS15MG24'SIMMUNEX	180.90*	MUSE500MCGURETHRALSUPP6/BX	116.10	PIPRACIL4GMVIAL 10/BOX	218.50
LEUCOVORINTABS25MG25'S	280.00*	MUSE1000MCGURETHRALSUPP6/BX	124.90	PLATINOLAC50MGVIAL	167.50
LEUKERAN2MGTABLETS50'S	59.55	MUSTARGEN10MGVIAL	9.90	PLATINOLAC100MGVIAL	345.25
LEUKINE-GM-CSF250MCG5/BX	514.00*	MUTAMYCIN5MGVIAL	111.58	PNEUMOVAX-23(PNEUMOCOCCAL)5DOSEVIAL	58.35
LEUKINE-GM-CSFLIQUID500MCG5/BX	1,028.43*	MVI-12MULTIVITAMININFUSION10MLCOVIAL	3.25	PNU-IMUNE-23(PNEUMOCOCCAL)5SYRINGES	64.25
LEUSTATIN(2-CD4)1MG/ML10MLVIAL	447.25	MVI-12MULTIVITAMININFUSION2X5ML25/BX	70.00	POLIOVACCINEINACTIVATEDIPOL0.5MLSYR	18.20
LIDOCAINE1%50MG21X1-1/2ABBOJECT	2.90	MVI-12MULTIVITAMININFUSION50MLBX/102	42.00	POLIOVACCINEIPOL5MLMDV10DOSES	163.50
LIDOCAINE2%100MG/5ML21GAX1-1/2ABBO	2.90	MYAMBUTOL400MGTABLETS100/BTL	171.30	POLYMXINBSULFATE500000UNITS	4.77
LIDOCAINE2%JELLY30GMTUBE	14.50	MYCIBUTIN150MGCAPSULES100/BOTTLE	367.55	POLYMXINBSULFATE500000UNITS	4.77
LIDOCAINETOPICALSOLUTION4%50ML	8.50	NAFCIL10GRAMBULKVIAL 10/BOX	95.00	PRIOSEC20MGCAPS30/BTL	108.45
LINCOCIN300MG/ML10MLVIAL	16.80	NAFCIL1GMVIAL 10/BOX	10.65	PRIMACOR100MLBAG#P27710/CASE	1,169.00
LINCOCIN300MG/ML10MLVIAL	10.20	NAFCIL2GRAMVIAL 10/BOX	17.80	PRIMAXIN500MGADD-VANTAGEVIAL 25/BOX	622.95
LOVENOXINJ.30MG/0.3MLSYRINGE10/BOX	155.30	NALBUPHINE10MG/ML10MLMDV	4.95	PRIMAXIN500MGVIAL 25/BOX	610.90
LUPRONDEPOTKIT22.5MG	1,387.75	NALBUPHINE20MG/ML10MLMDV	12.25	PROCARDIA10MGCAPSULES100/BTL	59.45
LUPRONDEPOTKIT3.75MG	397.00	NALOXONE0.4MG/ML10MLMDV	4.95	PROCHLORPERAZINE5MG/ML10MLMDV	2.95
LUPRONDEPOTKIT30MG	1,886.50	NAVELBINE10MG/ML1MLVIAL	53.83**	PROCHLORPERAZINE5MG/MLMDV25X2ML	52.40
LUPRONDEPOTKIT7.5MG	462.50	NAVELBINE10MG/ML5MLVIAL	270.22**	PROCRIT(EPOETINALFA)2000U/ML25X1ML	520.00
LUPRONDEPOT-3MONTH11.25MGKIT	1,149.00	NEBUPENT300MG15MLVIAL	36.00	PROCRIT(EPOETINALFA)2000U/ML6X1ML	124.80
YSODREN500MGTABLETS100/BTL	208.95	NEOSAR(CYCLOPHOSPHAMIDE)100MGVIAL	3.95*	PROCRIT(EPOETINALFA)3000U/ML25X1ML	780.00
MAGNEVIST10MLVIAL	57.95	NEOSAR(CYCLOPHOSPHAMIDE)200MGVIAL	4.95*	PROCRIT(EPOETINALFA)3000U/ML8X1ML	187.20
MAGNEVIST15MLVIAL	84.75	NEOSAR(CYCLOPHOSPHAMIDE)500MGVIAL	7.25*	PROCRIT(EPOETINALFA)4000U/ML25X1ML	1,040.00
MAGNEVIST20MLVIAL	104.75	NEOSAR(CYCLOPHOSPHAMIDE)1GRAMVIAL	10.95*	PROCRIT(EPOETINALFA)4000U/ML8X1ML	249.60
MATULANE50MGCAPSULES100/BTL	63.80	NEOSAR(CYCLOPHOSPHAMIDE)2GRAMVIAL	21.90*	PROCRIT(EPOETINALFA)10000U/ML25X1ML	2,360.00*
MAXIPIME1GRAMVIAL 10/BOX	142.80	NEOSTIGMIN1MG/ML10MLVIAL	2.70	PROCRIT(EPOETINALFA)10000U/ML8X1ML	564.00*
MAXIPIME2GRAMVIAL 10/BOX	283.40	NEO-SYNEPHRINE1%1MLAMPULE25/BOX	191.00	PROCRIT(EPOETINALFA)20000U/ML8/BOX	1,128.00*
MEFOXIN2GRAMPIGGY-BACK10/BOX	185.65	NEOSARINE2%20MLSDV	18.80	PROCRIT(EPOETINALFA)20000U/2ML8/BOX	1,128.00*
MEGACE40MGTABLETS100'S	108.00	NEUMEGASMGSDVIAL 7/BX	1,295.00*	PROLASTIN1000MGVIAL	165.00
MEGACEORALSUSPENSION8OZ.BOTTLE	113.70	NEUMEGASMGSDVIAL	185.00*	PROLEUKIN22MILLI.U.VIAL	412.90
MENOMUNEAC/VW-1351DOSEVIAL	82.55	NEUPOGEN(300MCG)1.0MLVIAL 10/BOX	1,348.50	PROMETHAZINE25MG/ML10MLMDVSTERIS	8.75
MEPHROSUSPENSION750MG/5ML210ML	539.95	NEUPOGEN(480MCG)1.6MLVIAL 10/BOX	2,159.50	PROMETHAZINE25MG/ML1MLAMPULE25/BX	14.25
MERREM1GMADD-VANTAGE10/BX	489.45	NEUTREXIN25MGVIAL 50/BX	2,818.00	PROMETHAZINE50MG/ML10MLMDVSTERIS	8.80
MERUVAXVACCINE(RUBELLA)10DOSETRAY	128.95	NIFEDIPINE10MGCAPSULES100/BTL	5.15	PROMETHAZINE50MG/ML1MLAMPULE25/BX	17.85
MERUVAXVACCINE(RUBELLA)SDV	14.85	NIPENT(PENTOSTATIN)10MG/5MLVIAL	1,339.80	PROPULSID10MGTABLETS100/BTL	70.25
MESNEX1000MG10MLMDV	139.40	NITRO-DURO.1MG/HR30/BOX	41.80	PROPYLTHIOURACIL50MGTAB100/BTL	5.75
METHOTREXATE50MG/2MLMDVIMMUNEX	3.60	NITROLINGUALSPRAY0.4MG14.49GM	25.40	PROSCAR5MGTABLET30/BTL	57.30
METHOTREXATE50MG/2MLP/FBEDFORD	2.90	NIZORALTABLETS100/BTL	298.30	PROSCAR5MGTABLET100/BTL1	91.00
METHOTREXATE50MG/2MLPFSIMMUNEX	3.50	NOLVADEX10MGTABLETS60/BTL	93.30	PROTAMINE10MG/ML5MLVIAL 25/BOX	93.25
METHOTREXATE1000MGVIAL IMMUNEX	49.40	NORVIR100MGCAPS168/BX	257.60	PROVENTIL(ALBUTEROL)25X3ML	40.85
METHOTREXATE100MG/4MLP/FBEDFORD	4.25	NORVIRORALSOLUTION80MG/ML240MLBTL	257.60	PROVENTILINHALER17GM	28.80
METHOTREXATE100MG/4MLP/FIMMUNEX	4.90	NOVANTRONE20MG/10MLVIAL	884.86*	PURINETHOL50MGTABLET250/BT	553.75
METHOTREXATE2.5MGTABLETS100/BTL	129.60	NOVANTRONE25MG/12.5MLVIAL	837.50*	PURINETHOL50MGTABLETS25'S	59.45
METHOTREXATE200MG/8MLP/FBEDFORD	5.80	NOVANTRONE30MG/15MLVIAL	1,004.80*	QUININESULFATE280MGTABLETS100/BTL	7.80
METHOTREXATE200MG/8MLP/FIMMUNEX	6.50	NUBAIN10MG/ML1MLAMPULE10/BOX	16.10	RABIESVACCINE1DOSESQB	120.40
METHOTREXATE250MG/10MLMDVIMMUNEX	9.50	NUBAIN20MG/ML10MLVIAL	33.90	RABIESVACCINERABAVERTNKTCHIRON	114.50
METHOTREXATE250MG/10MLPFSBEDFORD	5.80	OCUSERTPILO408/BX	43.40	RANITIDINE300MGTABLET100/BTL	53.75
METHYLENEBLUE1%1MLAMPULE25'SA/R	188.87	OCUVITETABLETS60/BTL	7.35	REBETRON800/MDV	471.50
METHYLENEBLUE1%1MLSDV10/BX	70.00	OCUVITETABLETS120/BTL	10.50	REBETRON800/PAK	3471.50
METHYLPREDNISOLONEACETATE40MG/ML5ML	8.55	ONCASPARPEG-LASPARAGINASE750U/ML5ML	1,158.40	REBETRON1000/MDV	583.00
METHYLPREDNISOLONEACETATE40MG/ML10ML	9.70	ONCOVIN1MGVIAL (LILLY)	31.74	REBETRON1000/PAK	3575.50
METHYLPREDNISOLONEACETATE80MG/ML5ML	9.70	ONCOVIN2MGVIAL (LILLY)	63.45	REBETRON1200/MDV	638.00
METOCLOPRAMIDESMG/ML10MLVIAL 25/BOX	39.00	ONCOVIN5MGVIAL (LILLY)	143.19	REBETRON1200/PAK	3638.00
METOCLOPRAMIDESMG/ML2MLVIAL 25/BOX	12.50	OPHTHETICO.5%OPHTHALMIC SOLUTION15ML	10.85	RECOMBIVAX2.5MCG/0.5ML5MLSDV	14.30
METOCLOPRAMIDESMG/ML30MLVIAL 10/BOX	43.00	OXACILLIN1GRAMVIAL BMS10/BX	11.80	RECOMBIVAX2.5MCG/0.5ML3MLMDV	84.30
METOPROLOL TARTRATE1MG/ML3X5ML	12.70	OXACILLIN1GRAMVIAL MARSAM10/BX	11.80	RECOMBIVAX10MCG/ML1MLSDV	45.20
METRONIDAZOLE500MG/100MLBAGABBOTT	3.20	OXACILLIN2GRAMVIAL BMS10/BX	16.50	RECOMBIVAX10MCG/ML3MLMDV	132.45

ASD ITEM #	MFG	NDC #	ONCOLOGY PHARMACEUTICALS	PKG SIZE	PKG PRICE	EACH PRICE	REDBOOK AWP	J CODE
082-180	PUJ	00013-2538-78	Idamycin 5mg PFS	1	\$287.00	\$287.00	\$319.85	J9211
082-198	PUJ	00013-2548-88	Idamycin 10mg PFS	1	\$534.00	\$534.00	\$639.89	J9211
082-552	PUJ	00013-2558-87	Idamycin 20mg PFS	1	\$1,068.00	\$1,068.00	\$1,279.40	J9211
119-081	BMS	00015-3558-28	Ifex 1gm/Mesnex 1gm	5/3	\$785.25	NA	\$892.98	J9208/9209
119-802	BMS	00015-3554-27	Ifex 1gm/Mesnex 1gm	10/10	\$1,849.12	NA	\$2,157.78	J9208/9209
119-891	BMS	00015-3584-15	Ifex 3gm/Mesnex 1gm	2/6	\$1,109.42	NA	\$1,294.59	J9208/9209
685-174	SKB	58180-0840-11	Infanrix 0.5ml SDV	10	\$137.50	\$13.75	\$207.50	
048-284	SHN	00384-3012-47	Infed 50mg/ml 2ml	10	\$231.53	\$23.15	\$377.04	J1760
687-248	AMG	55513-0554-08	Infergen 9mcg/ .3 vl	8	\$185.15	\$30.86	NA	
688-442	AMG	55513-0582-08	Infergen 15mcg/ .5 vl	8	\$308.57	\$51.43	NA	
030-890	LY	00002-8215-01	Insulin Hum R 100 UN vl 10 ml	1	\$19.42	\$19.42	\$19.84	
091-587	SCH	00085-0847-03	Intron-A, lyophilized 3 million IU	1	\$29.42	\$29.42	\$34.93	J9214
091-595	SCH	00085-0120-02	Intron-A, lyophilized 5 million IU	1	\$49.00	\$49.00	\$58.22	J9214
091-603	SCH	00085-0571-02	Intron-A, lyophilized 10 million IU	1	\$97.03	\$97.03	\$116.44	J9214
942-375	SCH	00085-1110-01	Intron-A, lyophilized 18 million IU	1	\$174.85	\$174.85	\$203.47	J9214
091-611	SCH	00085-0285-02	Intron-A, lyophilized 25 million IU	1	\$242.59	\$242.59	\$291.11	J9214
181-388	SCH	00085-0539-01	Intron-A, lyophilized 50 million IU	1	\$485.80	\$485.80	\$582.17	J9214
517-292	SCH	00085-1184-01	Intron-A HSAF 3mmv/0.5ml vl	1	\$29.42	\$29.42	\$34.93	J9214
859-387	SCH	00085-1184-02	Intron-A HSAF 3mmv/0.5ml syr	6	\$178.52	\$29.42	\$209.52	J9214
681-272	SCH	00085-1191-01	Intron-A HSAF 5mmv/0.5ml vl	1	\$49.00	\$49.00	\$58.22	J9214
683-393	SCH	00085-1191-02	Intron-A HSAF 5mmv/0.5ml syr	6	\$294.00	\$49.00	\$349.32	J9214
684-730	SCH	00085-1179-01	Intron-A HSAF 10mmv/1ml vl	1	\$97.03	\$97.03	\$116.44	J9214
687-477	SCH	00085-1179-02	Intron-A HSAF 10mmv/1ml syr	6	\$582.18	\$97.03	\$698.64	J9214
688-848	SCH	00085-1188-01	Intron-A HSAF 18mmv/3.8ml MDV	1	\$174.85	\$174.85	\$209.58	J9214
672-083	SCH	00085-1133-01	Intron-A HSAF 25mmv/3.2ml vl	1	\$242.59	\$242.59	\$291.11	J9214
051-288	SKB	00029-4149-01	Kytril 1mg/ml 1ml	1	\$132.50	\$132.50	\$177.40	J1826
198-935	SKB	00029-4152-01	Kytril 1mg/ml 4ml MDV	1	\$529.00	\$529.00	\$709.60	J1826
879-742	SKB	00029-4151-39	Kytril 1 mg TAB	2	\$73.44	\$36.72	\$85.50	J1826
879-379	SKB	00029-4151-05	Kytril 1mg TAB	20	\$734.30	\$36.72	\$855.00	J1826
193-783	GLX	00173-0260-10	Lanoxin 0.5 mg Amp 2 ml	10	\$23.15	\$2.32	\$24.25	
468-827	BED	55390-0051-10	Leucovorin 50mg	10	\$22.47	\$2.25	\$184.40	J0840
127-910	IMM	58408-0821-05	Leucovorin 50mg	1	\$1.50	\$1.50	\$21.53	J0840
471-060	BED	55390-0052-10	Leucovorin 100mg	10	\$30.00	\$3.00	\$350.00	J0840
309-765	GEN	00703-5140-01	Leucovorin 100mg	1	\$2.79	\$2.79	\$40.83	J0840
472-209	BED	55390-0053-01	Leucovorin 200mg	1	\$7.75	\$7.75	\$78.00	J0840
510-248	ABB	00074-4541-04	Leucovorin 250mg Liq	1	\$7.50			
118-448	IMM	58408-0823-33	Leucovorin 350mg	1	\$15.00	\$15.00	\$137.94	J0840
233-684	GEN	00703-5145-01	Leucovorin 350mg 25ml SDV	1	\$14.00	\$14.00	\$132.12	
919-233	ORT	05987-0201-01	Leustatin 1mg/ml 10ml	1	\$443.50	\$443.50	\$518.00	J9085
728-212	IMM	58408-0002-33	Leukine lyophilized 250mcg	5	\$525.00	\$105.00	\$630.20	J2820
511-782	IMM	58408-0050-30	Liquid Leukine 500mcg	5	\$1,030.00	\$206.00	\$1,280.20	J2820
583-841	JOM	00045-0089-51	Levaquin 500mg SDV 20ml	1	\$36.98	\$36.98	\$39.80	
589-036	JOM	00045-0088-01	Levaquin 500mg Bag 100ml	24	\$815.78	\$33.99	NA	
171-348	SNF	00024-1123-02	Levophed 0.1 % Amp 4 ml	10	\$108.44	\$10.84	NA	
081-119	ABB	00074-4276-01	Lido 1% FTV 20ml	25	\$16.24	\$0.65	\$81.75	J2000
731-838	ABB	00074-4277-01	Lido 2% FTV 20ml	25	\$21.00	\$0.84	\$81.75	J2000
522-037	IMS	00548-3013-00	Lido 2 % Jel 10 ml	25	\$179.48	\$7.18	\$9.82	
288-449	PUJ	00009-0555-01	Lincocin 300 mg/ml vl 2 ml	1	\$6.13	\$6.13	\$5.88	
298-855	G/L	00182-1807-01	Lorazepam 1mg Tab	100	\$3.50	\$0.04	\$23.25	
124-024	ABB	00074-6780-01	Lorazepam 2mg/ml 10ml	25	\$863.75	\$26.55	\$2,042.50	J2080
124-313	ABB	00074-6778-01	Lorazepam 2mg/ml 1ml	25	\$102.27	\$4.09	\$272.53	J2080
987-298	RPR	00075-0824-30	Lovenox 30 mg Syg .3 ml	10	\$155.40	\$15.54	\$188.01	
740-449	TAP	00300-3829-01	Lupron Depot Kit 7.5 mg	1	\$480.49	\$480.49	\$540.63	J9217
587-586	TAP	00300-3336-01	Lupron Depot Kit 22.5 mg	1	\$1,441.44	\$1,441.44	\$1,621.89	J9217
343-816	TAP	00300-3673-01	Lupron Depot Kit 30 mg	1	\$1,921.91	\$1,921.91	\$2,162.52	J9217
205-112	AST	00188-1199-10	M.V.I. 12 Dual Pkg MDV 50 ml	10	\$242.00	\$24.20	\$289.84	
431-825	ABB	00074-2188-01	Magnesium Sulfate 50% FTV 10ml	25	\$21.58	\$0.88	\$52.55	J3475
338-103	GEN	00703-5377-03	Magnesium Sulfate 50% SDV 50ml	10	\$21.60	\$2.16	\$55.75	J3475
528-954	ABB	00074-2188-03	Magnesium Sulfate 50% FTV 50ml	25	\$57.88	\$2.32	\$243.73	J3475
084-887	ABB	00074-4031-01	Mannitol 25% (12.5gm) 50ml	25	\$29.63	\$1.19	\$132.25	J2150
059-493	CNN	49281-0489-01	Menomune DS ACYW 135 vl	1	\$82.25	\$82.25	NA	
119-184	BMS	00015-3563-02	Mesnex 100mg/ml 10ml MDV	1	\$142.23	\$142.23	\$167.60	J9209
119-222	BMS	00015-3563-03	Mesnex 100mg/ml 10ml MDV	10	\$1,422.29	\$142.23	\$1,678.00	J9209
082-810	IMM	58408-0873-01	Methotrex Sod 20mg P/F vl 20 ml	1	\$4.50	\$4.50	\$5.03	
083-831	IMM	58408-0871-05	Methotrex Sod 1gm P/F	1	\$39.20	\$39.20	\$61.44	
082-877	IMM	58408-0881-14	Methotrexate 50mg (w/ preservative)	1	\$3.00	\$3.00	\$4.75	J9260
081-356	IMM	58408-0881-17	Methotrexate 250mg (w/ preservative)	1	\$7.00	\$7.00	\$20.48	J9260
474-999	BED	55390-0031-10	Methotrexate 50mg LPF	10	\$23.00	\$2.30	\$88.80	J9260
081-810	IMM	58408-0883-15	Methotrexate 50mg LPF	1	\$2.00	\$2.00	\$4.75	J9260
475-840	BED	55390-0032-10	Methotrexate 100mg LPF	10	\$31.00	\$3.10	\$87.50	J9260
081-828	IMM	00205-5326-18	Methotrexate 100mg LPF	1	\$3.50	\$3.50	\$8.50	J9260
476-184	BED	55390-0033-10	Methotrexate 200mg LPF	10	\$40.00	\$4.00	\$175.00	J9260
081-844	IMM	58408-0883-12	Methotrexate 200mg LPF	1	\$5.00	\$5.00	NA	

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

5

Divider Title: _____

DEXTROSE W/SODIUM CHLORIDE

PROD/MFR	NDC	Wholesale	(GPO) DP	1999 AWP Red Book
(Abbott Hosp)				
5%-0.45%, 250 ml . . .	00074-7926-02	1.93 /TRI 2.00 /FI 1.48 /OS		12.07
500 ml	00074-7926-03	1.93 /TRI 2.10 /OTN 1.97 /ASD 2.00 /FI 1.78 /OS		12.07
1000 ml	00074-7926-09	2.25 /TRI 3.20 /OTN 2.94 /ASD 2.25 /FI 2.67 /OS		14.36
5%-0.9%, 250 ml	00074-7941-02	1.93 /TRI		12.07
500 ml	00074-7941-03	1.93 /TR 2.10 /OTN 1.61 /ASD 2.00 /FI 1.59 /OS		12.07
1000 ml	00074-7941-09	1.36 /BB 3.05 /OTN 1.88 /ASD 2.25 /FI 2.65 /OS		14.35
(Baxter)				
5%-0.45%, 250 ml . .	00338-0085-02	2.93 /TRI 2.00 FI		9.94
500 ml	00338-0085-03	1.80 /TRI 2.00/FI		9.93
1000 ml	00338-0085-04	2.25 /FI		11.80
5%-0.9%, 250 ml	00338-0089-02	2.93 /TRI		9.94
500 ml	00338-0089-03	2.00 /FI		9.94
1000 ml	00338-0089-04	2.25 /FI		11.81
(McGaw)				
5%-0.45%, 250 ml . .	00264-7612-20	1.78 /TRI 2.00 /FI		11.01
500 ml	00264-7612-10	1.70 /TRI 2.00 /FI		11.34
1000 ml	00264-7612-00	1.95 /TRI 2.25 /FI 1.36 /ASD		13.81
5%-0.9%, 250 ml	00264-7610-20	1.78 /TRI		10.99
500 ml	00264-7610-10	1.61 /TRI 2.00 /FI		11.32
1000 ml	00264-7610-00	1.95 /TRI 2.25 /FI		13.81

OTN

INVENTORY EXCEPTION UPDATES | AWP SUMMARY SHEET | HELP

Catalog Search Results

You searched for dextrose, product name Dextrose/Saline Solution. Listed below are all of the Dextrose/Saline Solution products available through OTN. Click on the catalog number to find more information on each product. (AWPs, HCPCS Codes, etc.)

CAT NO	DISTRIBUTOR OR MANUFACTURER	BRAND NAME	ITEM	UNIT SIZE	UNIT PRICE	NET PRICE
710-500	Abbott Laboratories	LifeCare	Dextrose 5% in 0.45% Sodium Chloride	500 mL IV bag	2.10	2.08
720-500	Abbott Laboratories	LifeCare	Dextrose 5% in 0.9% Sodium Chloride	500 mL IV bag	2.10	2.08
720-500	Abbott Laboratories	LifeCare	Dextrose 5% in 0.9% Sodium Chloride	1000 mL IV bag	3.45	3.42

[New Search](#)

* Net price reflects the amount charged if purchased under your payment terms of **1% 30 NET 60**.

Items found in your contracts through OTN are listed in blue.

The prices shown above reflect all contracts and marketing programs in which you participated through OTN and are subject to the terms stipulated therein.



COPYRIGHT 1999 © OTN

ASD #	MFG	PRODUCT #	ITEM DESCRIPTION	PKG SIZE	PKG PRICE	EACH PRICE
015-719	MCG	00264-7612-00	Dextrose 5%/ 45% Sod Chl 1000cc	12	\$18.30	\$1.36
018-267	MCG	00264-7510-20	Dextrose 5% 250ml	24	\$42.86	\$1.79
018-275	MCG	00264-7510-10	Dextrose 5% 500ml	24	\$42.86	\$1.79
336-032	MCG	00264-7510-00	Dextrose 5% 1000ml	12	\$27.60	\$2.30
699-538	ABB	00074-1772-48	Nitroglycerin Sets	48	\$582.85	\$12.14
707-895	ABB	00074-4524-48	IVEX-HP Filter Sets	48	\$145.80	\$3.04
IV ADMINISTRATION SETS						
703-561	ABB	00074-1857-48	Venuset 72" w/Cair Clamp NV ("1857")	48	\$49.68	\$1.04
724-856	ABB	00074-1859-48	Venuset 78" w/Cair Clamp NV ("1859")	48	\$52.93	\$1.10
050-922	ABB	00074-1861-58	Venuset Secondary Piggyback ("1861")	48	\$55.80	\$1.16
703-811	ABB	00074-1881-48	Venuset 78" w/Cair Clamp Vented ("1881")	48	\$56.16	\$1.17
106-021	ABB	00074-1819-48	Venuset Twinsite w/Cair Clamp NV ("1819")	48	\$80.52	\$1.68
703-355	ABB	00074-1832-58	Secondary Piggyback	48	\$64.20	\$1.34
917-567	ABB	00074-1818-48	Non-vented 78" with Twin Y site	48	\$125.30	\$2.61
723-841	ABB	00074-1883-68	70" Microdrip	48	\$70.05	\$1.46
733-972	ABB	00074-1718-48	Transfer Sets	48	\$135.00	\$2.81
702-498	ABB	00074-1671-02	Dial-a-flow sets	48	\$218.30	\$4.55
202-804	ABB	00074-2679-48	IVEX Filter Sets .22 micron	48	\$113.16	\$2.36
EXTENSION SETS						
707-976	ABB	00074-4612-04	Microbore Set with Locking "T"	120	\$197.64	\$1.65
824-797	ABB	00074-4438-02	IV Extension Sets 7-SL	50	\$99.48	\$1.99
570-812	ABB	00074-4481-01	30" Extension Sets	48	\$57.54	\$1.20
061-093	ABB	00074-4429-48	20" Extension Sets	48	\$45.23	\$0.94
SOLUSETS						
699-405	ABB	00074-4965-68	Microdrip 100ml Burette 100x 60	20	\$100.00	\$5.00
762-427	ABB	00074-1882-68	Microdrip 150ml Burette 150x 60	20	\$85.18	\$4.26
I.V. SOLUTIONS						
704-544	ABB	00074-7984-36	Sod. Chl. 0.9% LC Bags 50ml	80	\$98.88	\$1.24
114-504	ABB	00074-7984-37	Sod. Chl. 0.9% LC Bags 100ml	80	\$98.88	\$1.24
966-622	ABB	00074-7983-61	Sod. Chl. 0.9% LC Bags 150ml	32	\$43.46	\$1.36
704-536	ABB	00074-7983-02	Sod. Chl. 0.9% LC Bags 250ml	24	\$34.92	\$1.46
704-411	ABB	00074-7983-03	Sod. Chl. 0.9% LC Bags 500ml	24	\$37.25	\$1.55
704-429	ABB	00074-7983-09	Sod. Chl. 0.9% LC Bags 1000ml	12	\$31.50	\$2.63
702-092	ABB	00074-1584-01	Sod. Chl. 0.9% 250ml Glass	12	\$37.50	\$3.13
061-275	ABB	00074-1583-03	Sod. Chl. 0.9% 50ml Partial Fill Glass	12	\$43.92	\$3.66
884-991	ABB	00074-7985-03	Sod. Chl. 0.45% LC Bags 500ml	24	\$1.58	\$0.07
709-931	ABB	00074-7923-36	Dextrose 5% LC Bags 50ml	80	\$98.88	\$1.24
709-956	ABB	00074-7923-37	Dextrose 5% LC Bags 100ml	80	\$98.88	\$1.24
918-649	ABB	00074-7922-61	Dextrose 5% LC Bags 150ml	32	\$44.80	\$1.40
703-629	ABB	00074-7922-02	Dextrose 5% LC Bags 250ml	24	\$34.80	\$1.45
701-490	ABB	00074-7922-03	Dextrose 5% LC Bags 500ml	24	\$36.00	\$1.50
701-565	ABB	00074-7922-09	Dextrose 5% LC Bags 1000ml	12	\$28.08	\$2.34
724-351	ABB	00074-1523-01	Dextrose 5% 50ml Partial Fill Glass	12	\$45.75	\$3.81
701-821	ABB	00074-1522-02	Dextrose 5% 250ml Glass	12	\$43.50	\$3.63
702-043	ABB	00074-1522-03	Dextrose 5% 500ml Glass	12	\$52.20	\$4.35
703-801	ABB	00074-7926-03	Dextrose 5% / 0.45% Sod Chl LC Bags 500ml	24	\$47.25	\$1.97
703-827	ABB	00074-7926-09	Dextrose 5% / 0.45% Sod Chl LC Bags 1000ml	12	\$35.25	\$2.94
703-942	ABB	00074-7941-03	Dextrose/ Sod Chl 5%/ 9% 500ml	24	\$38.52	\$1.61
703-959	ABB	00074-7941-09	Dextrose/ Sod Chl 5%/ 9% 1000ml	12	\$22.50	\$1.88
665-018	ABB	00074-7953-03	Lactated Ringers Bags 500ml	24	\$47.74	\$1.99
704-098	ABB	00074-7953-09	Lactated Ringers Bags 1000ml	12	\$56.70	\$4.73
SMALL VOLUME PARENTALS						

I.V. SOLUTIONS - ABBOTT



DESCRIPTION	#/case	Price	DESCRIPTION	#/case	Price
D5W or NS 50-100 mL	96	124.00	DS 1/2 NS 250mL	24	48.00
D5W or NS 150 mL	36	48.00	DS 1/2 NS 500mL	24	48.00
D5W or NS 250 mL	36	48.00	D5W-NS 500mL	24	48.00
D5W or NS 500 mL	24	36.00	D5W-NS 1000mL	12	27.00
D5W or NS 1000 mL	12	27.00	D5W-1/2 NS 1000mL	12	27.00


ABBOTT DROP SHIP PROGRAM - SAVE 5%

Florida Infusion can arrange direct shipments from your local Abbott warehouse of orders of 10 cases or more. You may **mix and match** any of the items listed here. The two advantages to our direct drop ship program are a 5% off-invoice discount and faster delivery - usually within 1 to 3 days - from the local warehouse. If you wish to take advantage of this program, call your account manager at **1-800-624-0152** and they will set up your account as a drop ship account. This process usually takes 2 to 3 days and it requires only a copy of your DEA license. Some of the Abbott items you can purchase to make up a 10 case order: I.V. Solutions, Administration Sets, Extension Sets, Diluents (Normal Saline or Sterile Water for Injection in 10, 20, 30, 50 and 100cc's), Mannitol, Butterflies® and Empty Evacuated Containers.

I.V. SOLUTIONS-BAXTER-MCGAW



DESCRIPTION	#/case	Price	DESCRIPTION	#/case	Price
D5WorNS 50-100mL	96	124.00	DS 1/2 NS 250mL	24	48.00
D5WorNS 150 mL	36	48.00	DS 1/2 NS 500mL	24	48.00
D5WorNS 250 mL	36	48.00	D5W-NS 500mL	24	48.00
D5WorNS 500 mL	24	36.00	D5W-NS 1000mL	12	27.00
D5WorNS 1000 mL	12	27.00	D5W-1/2 NS1000mL	12	27.00



TAXOL I.V. BAGS

WE STOCK **McGaw** EXCEL IV CONTAINERS. THESE I.V. BAGS DO NOT CONTAIN DEHP AND ARE COMPATIBLE WITH TAXOL® AND TAXOTERE® INFUSION.

D5Wor 0.9% NACL 100cc 64/cs **\$92⁸⁰**

D5Wor 0.9% NACL 250cc 24/cs **\$36⁰⁰**

D5Wor 0.9% NACL 500cc 24/cs **\$36⁰⁰**

D5Wor 0.9% NACL 1000cc 12/cs **\$27⁰⁰**

TAXOL ACCESSORIES

370-183	MCG	Saline 250cc bags	L8002	24	\$ 1.58
370-184	MCG	Saline 500cc bags	L8001	24	\$ 1.80
370-185	MCG	Saline 1000cc bags	L8000	12	\$ 1.80
370-187	MCG	D5W 250cc bags	L5102	24	\$ 1.58
370-188	MCG	D5W 500cc bags	L5101	24	\$ 1.80
370-189	MCG	D5W 1000cc bags	L5100	12	\$ 1.80
888-800	CHUR	Administration Sets with Filter	AMS-975	ea	\$ 3.57
888-801	CHUR	Administration Sets with Filter	AMS-975	cs/50	\$ 145.00
110-050	ABB	Nitroglycerin Sets	1772-48	ea	\$ 11.95
110-051	ABB	IVEX-HP Filter Sets	4524-58	ea	\$ 3.09

IV SOLUTIONS AND SUPPLIES

110-142	ABB	D5W 50cc Partial-Fill glass	1523-01	12	\$ 48.00
110-144	ABB	D5W 250cc glass	1522-02	12	\$ 48.00
110-146	ABB	D5W 500cc glass	1522-03	12	\$ 48.00
110-100	ABB	D5W 50cc Partial-Fill bags	7923-36	80	\$ 99.00
110-102	ABB	D5W 100cc Partial-Fill bags	7923-37	80	\$ 99.00
110-104	ABB	D5W 150cc bags	7922-61	32	\$ 44.41
110-106	ABB	D5W 250cc bags	7922-62	24	\$ 34.04
110-108	ABB	D5W 500cc bags	7922-34	24	\$ 34.98
110-110	ABB	D5W 1000cc bags	7922-39	12	\$ 29.53
110-116	ABB	D5W .45% Saline 250cc bags	7926-62	24	\$ 35.39
110-118	ABB	D5W .45% Saline 500cc bags	7926-34	24	\$ 42.61
110-120	ABB	D5W .45% Saline 1000cc bags	7926-39	12	\$ 31.97
110-122	ABB	D5W .9% Saline 500cc bags	7941-34	24	\$ 38.10
110-132	ABB	D5W .9% Saline 1000cc bags	7941-39	12	\$ 31.79
110-412	ABB	Saline 250cc glass	1583-02	12	\$ 36.97
110-414	ABB	Saline 50cc Partial-Fill glass	1584-01	12	\$ 45.00
110-400	ABB	Saline 50cc Partial-Fill bags	7984-36	80	\$ 99.00
110-402	ABB	Saline 100cc Partial-Fill bags	7984-37	80	\$ 99.00
110-404	ABB	Saline 150cc bags	7983-61	32	\$ 43.06
110-406	ABB	Saline 250cc bags	7983-62	24	\$ 34.49
110-408	ABB	Saline 500cc bags	7983-34	24	\$ 41.25
110-410	ABB	Saline 1000cc bags	7983-39	12	\$ 29.08
110-430	ABB	Saline .45% (Half-Strength) 500cc bags	7985-34	24	\$ 40.35
110-432	ABB	Saline .45% (Half-Strength) 1000cc bag	7985-39	12	\$ 29.98
110-460	ABB	Lactated Ringers 500cc bags	7953-34	24	\$ 44.41
110-462	ABB	Lactated Ringers 1000cc bags	7953-39	12	\$ 33.59

SMALL VOLUME PARENTARALS

110-200	ABB	Bacteriostatic Water 30cc (Preserved)	3977-03	25	\$ 10.22
110-201	ABB	Sterile Water 10cc (No Preservative)	4887-10	25	\$ 8.08
110-202	ABB	Sterile Water 20cc (No Preservative)	4887-20	25	\$ 9.98
110-203	ABB	Sterile Water 50cc (No Preservative)	4887-50	25	\$ 17.50
110-204	ABB	Sterile Water 100cc (No Preservative)	4887-99	25	\$ 30.42
110-209	ABB	Bacteriostatic Saline 10cc (Preserved)	1966-07	25	\$ 8.95
110-210	ABB	Bacteriostatic Saline 30cc (Preserved)	1966-07	25	\$ 10.46
110-211	ABB	Sterile Saline 10cc (No Preservative)	4888-10	25	\$ 8.08
110-212	ABB	Sterile Saline 20cc (No Preservative)	4888-20	25	\$ 10.70

ASD #	MFG	PRODUCT #	ITEM DESCRIPTION	PKG SIZE	PKG PRICE	EACH PRICE
283-838	BD	305186	DISP R/B 19G X1 NDL	100	\$7.53	\$0.08
285-098	BD	305175	DISP R/B 20G X1 NDL	100	\$7.53	\$0.08
284-604	BD	305176	DISP R/B 20G X1.5 NDL	100	\$7.53	\$0.08
285-270	BD	305185	DISP R/B 21G X1 NDL	100	\$7.53	\$0.08
285-298	BD	305187	DISP R/B 21G X1.5 NDL	100	\$7.53	\$0.08
285-262	BD	305155	DISP R/B 22G X1 NDL	100	\$7.53	\$0.08
285-080	BD	305156	DISP R/B 22G X1.5 NDL	100	\$7.53	\$0.08
285-892	BD	305125	DISP R/B 25G X1 NDL	100	\$7.87	\$0.08
283-952	BD	305109	DISP R/B 27G X1/2 NDL	100	\$7.53	\$0.08
281-170	BD	305144	USE 23G X 1 NDL (SHORT BEVEL)	100	\$8.81	\$0.09
287-433	BD	305188	SGL 19G X 1 NDL	100	\$7.87	\$0.08
859-637	BD	305178	SGL 20G X 1 NDL	100	\$7.53	\$0.08
281-972	BD	305183	THINWALL 23G X 1 NDL	100	\$7.87	\$0.08
281-980	BD	305184	THINWALL 23G X1.5 NDL	100	\$7.87	\$0.08
287-284	BD	305185	FILL 18X 1-1/2 NDL	100	\$7.53	\$0.08
289-074	BD	305180	IV THINWALL 21G X 1.5 NDL	100	\$7.87	\$0.08
SYRINGE/NEEDLE COMBINATIONS						
488-148	TER	SS01T2518	W/NDL 1CC 25g x 5/8"	100	\$10.00	\$0.10
491-898	TER	SS03L2125	W/NDL 3CC 21g x 1"	100	\$9.50	\$0.10
489-880	TER	SS03L2138	W/NDL 3CC 21g x 1.5"	100	\$9.50	\$0.10
491-712	TER	SS03L2325	W/NDL 3CC 23g x 1"	100	\$9.50	\$0.10
490-185	TER	SS03L2518	W/NDL 3CC 25g x 5/8"	100	\$9.50	\$0.10
488-870	TER	SS10L2025	W/NDL 10CC 20g x 1"	100	\$19.00	\$0.19
284-588	BD	309626	TB SYG/NDL 25G X 5/8 1ML	100	\$18.00	\$0.18
284-059	BD	309623	P/P TB SYG 27G X 1/2 1ML	100	\$18.00	\$0.18
281-501	BD	329410	INSULIN 28G X 1/2 SYG 100 UN	100	\$23.42	\$0.23
273-474	BD	329411	INSULIN 29G X 1/2 SYG 1ML	100	\$25.22	\$0.25
285-809	BD	309578	P/P SYG/ND 20G X1 3ML	100	\$13.32	\$0.13
282-111	BD	309634	P/P SYG/ND 20G X1 5ML	100	\$25.97	\$0.26
282-152	BD	309644	P/P SYG/ND 20G X1 10ML	100	\$27.18	\$0.27
284-846	BD	309572	P/P SYG/ND 22G X1 3ML	100	\$13.32	\$0.13
282-095	BD	309632	P/P SYG/ND 21G X1 5ML	100	\$25.97	\$0.26
281-709	BD	309642	P/P SYG/ND 21G X1 10ML	100	\$27.18	\$0.27
283-887	BD	309574	P/P SYG/ND 22G X1.5 3ML	100	\$13.32	\$0.13
284-349	BD	309640	P/P SYG/ND 22G X1 L/L 10ML	100	\$27.18	\$0.27
284-638	BD	309571	P/P SYG/ND 23G X1 3ML	100	\$13.32	\$0.13
CATHETERS						
342-774	TER	2025CA	20G x 1	50	\$37.50	\$0.75
342-139	TER	2225CA	22G x 1	50	\$37.50	\$0.75
061-523	ABB	453508	Abbocath 18G x 1	100	\$104.40	\$1.04
446-898	ABB	453520	Abbocath 20G x 1 1/4	100	\$104.40	\$1.04
707-778	ABB	453524	Abbocath 24G x 3/4	100	\$121.20	\$1.21
CANNULAS						
272-983	BD	003385	INTERLINK Y-LK CANNUL	200	\$84.87	\$0.42
273-797	BD	303385	INTERLINK Y-LK CANNUL	1000	\$42.44	\$0.04
282-081	BD	303386	INTL CANN SYG	1000	\$244.38	\$0.24
273-518	BD	303367	INTL CANN ACCESS VL	100	\$307.91	\$3.08
348-359	BD	303369	T/LCK CANN SYG	100	\$495.08	\$4.95
TAXANE ACCESSORIES						
690-735	CHU		Taxol Admin. Set w/ Filter	10	\$36.00	\$3.60
640-815	MCG	00284-7800-20	Exel - Sod Chi .9% Bags 250cc	24	\$38.67	\$1.61
018-101	MCG	00284-7800-10	Exel - Sod Chi .9% Bags 500cc	24	\$41.80	\$1.74
337-485	MCG	00284-7800-00	Exel - Sod Chi .9% Bags 1000cc	12	\$23	\$1.94

ASD #	MFG	PRODUCT #	ITEM DESCRIPTION	PKG SIZE	PKG PRICE	EACH PRICE
015-719	MCG	00264-7812-00	Dextrose 5%/ 45% Sod Chl 1000cc	12	\$16.30	\$1.36
018-267	MCG	00264-7510-20	Dextrose 5% 250ml	24	\$42.86	\$1.79
018-275	MCG	00264-7510-10	Dextrose 5% 500ml	24	\$42.86	\$1.79
336-032	MCG	00264-7510-00	Dextrose 5% 1000ml	12	\$27.60	\$2.30
699-538	ABB	00074-1772-48	Nitroglycerin Sets	48	\$582.85	\$12.14
707-695	ABB	00074-4524-48	IVEX-HP Filter Sets	48	\$145.80	\$3.04
IV ADMINISTRATION SETS						
703-561	ABB	00074-1857-48	Venaset 72" w/Cair Clamp NV ("1857")	48	\$49.68	\$1.04
724-856	ABB	00074-1859-48	Venaset 78" w/Cair Clamp NV ("1859")	48	\$52.93	\$1.10
050-922	ABB	00074-1861-58	Venaset Secondary Piggyback ("1861")	48	\$55.80	\$1.16
703-811	ABB	00074-1881-48	Venaset 78" w/Cair Clamp Vented ("1881")	48	\$56.16	\$1.17
108-021	ABB	00074-1819-48	Venaset Twinsite w/Cair Clamp NV ("1819")	48	\$80.52	\$1.68
703-355	ABB	00074-1832-58	Secondary Piggyback	48	\$64.20	\$1.34
917-587	ABB	00074-1818-48	Non-vented 78" with Twin Y site	48	\$125.30	\$2.61
723-841	ABB	00074-1863-68	70" Microdrip	48	\$70.05	\$1.46
733-972	ABB	00074-1718-48	Transfer Sets	48	\$135.00	\$2.81
702-498	ABB	00074-1671-02	Dial-a-flow sets	48	\$218.30	\$4.55
202-804	ABB	00074-2679-48	IVEX Filter Sets .22 micron	48	\$113.16	\$2.36
EXTENSION SETS						
707-976	ABB	00074-4612-04	Microbore Set with Locking "T"	120	\$197.64	\$1.65
824-797	ABB	00074-4438-02	IV Extension Sets 7-SL	50	\$99.48	\$1.99
570-812	ABB	00074-4481-01	30" Extension Sets	48	\$57.54	\$1.20
061-093	ABB	00074-4429-48	20" Extension Sets	48	\$45.23	\$0.94
SOLUSETS						
699-405	ABB	00074-4985-68	Microdrip 100ml Burette 100x 60	20	\$100.00	\$5.00
762-427	ABB	00074-1882-68	Microdrip 150ml Burette 150x 60	20	\$85.18	\$4.26
I.V. SOLUTIONS						
704-544	ABB	00074-7984-36	Sod. Chl. 0.9% LC Bags 50ml	80	\$98.88	\$1.24
114-504	ABB	00074-7984-37	Sod. Chl. 0.9% LC Bags 100ml	80	\$98.88	\$1.24
966-622	ABB	00074-7983-61	Sod. Chl. 0.9% LC Bags 150ml	32	\$43.48	\$1.36
704-538	ABB	00074-7983-02	Sod. Chl. 0.9% LC Bags 250ml	24	\$34.82	\$1.46
704-411	ABB	00074-7983-03	Sod. Chl. 0.9% LC Bags 500ml	24	\$37.25	\$1.55
704-429	ABB	00074-7983-08	Sod. Chl. 0.9% LC Bags 1000ml	12	\$31.50	\$2.63
702-092	ABB	00074-1584-01	Sod. Chl. 0.9% 250ml Glass	12	\$37.50	\$3.13
061-275	ABB	00074-1583-03	Sod. Chl. 0.9% 50ml Partial Fill Glass	12	\$43.92	\$3.66
864-991	ABB	00074-7985-03	Sod. Chl. 0.45% LC Bags 500ml	24	\$1.58	\$0.07
709-931	ABB	00074-7923-36	Dextrose 5% LC Bags 50ml	80	\$98.88	\$1.24
709-956	ABB	00074-7923-37	Dextrose 5% LC Bags 100ml	80	\$98.88	\$1.24
918-649	ABB	00074-7922-61	Dextrose 5% LC Bags 150ml	32	\$44.80	\$1.40
703-629	ABB	00074-7922-02	Dextrose 5% LC Bags 250ml	24	\$34.80	\$1.45
701-490	ABB	00074-7922-03	Dextrose 5% LC Bags 500ml	24	\$36.00	\$1.50
701-565	ABB	00074-7922-09	Dextrose 5% LC Bags 1000ml	12	\$28.06	\$2.34
724-351	ABB	00074-1523-01	Dextrose 5% 50ml Partial Fill Glass	12	\$45.75	\$3.81
701-821	ABB	00074-1522-02	Dextrose 5% 250ml Glass	12	\$43.50	\$3.63
702-043	ABB	00074-1522-03	Dextrose 5% 500ml Glass	12	\$52.20	\$4.35
703-801	ABB	00074-7926-03	Dextrose 5% / 0.45% Sod Chl LC Bags 500ml	24	\$47.25	\$1.97
703-827	ABB	00074-7926-09	Dextrose 5% / 0.45% Sod Chl LC Bags 1000ml	12	\$35.25	\$2.94
703-842	ABB	00074-7941-03	Dextrose/ Sod Chl 5%/ 8% 500ml	24	\$36.52	\$1.51
703-959	ABB	00074-7941-09	Dextrose/ Sod Chl 5%/ 9% 1000ml	12	\$22.50	\$1.88
865-018	ABB	00074-7953-03	Lactated Ringers Bags 500ml	24	\$47.74	\$1.99
704-098	ABB	00074-7953-09	Lactated Ringers Bags 1000ml	12	\$56.70	\$4.73
SMALL VOLUME PARENTALS						

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

6

Divider Title: _____

ALBUTEROL SULFATE

PROD/MFR	NDC	Wholesale	(GPO) DP	1999 AWP Red Book
(Dey)				
SOL, IH, 0.083%, 3 ml 25s UD.....	49502-0697-03	9.50 /BB 8.84 /MK		30.25
3 ml 30s UD.....	49502-0697-33	11.40 /BB 10.61 /MK		36.30
3 ml 60s UD.....	49502-0697-60	22.80 /BB 21.22 /MK		72.60
0.5%, 20 ml.....	49502-0196-20	6.50 /BB 5.32 /MK		14.99
(Schein)				
SOL, IH, 0.5%, 20ml.....	00364-2530-55	7.42 /BB 7.81 /MK		13.91
(Warrick)				
SOL, IH 0.083%, 3 ml 25s UD.....	59930-1500-08	10.00 /BB 10.53 /MK 6.95 /AND		30.25
3 ml 60s.....	59930-1500-06	24.00 /BB 25.26 /MK 16.50 /AND		72.60
0.5%, 20 ml.....	59930-1515-04	5.51 /BB 5.79 /MK		14.99

ITEM NUMBER	ITEM DESCRIPTION	VEN	UD	NDC NUMBER	AWP	COST
413179	ALBUTEROL .5% INH SOL 20ML SHN	00364-2530-55	9.28	7.4200		
437855	ALBUTEROL 2MG TAB 100 URL	00677-1359-01	2.33	1.6200		
447813	ALBUTEROL 4MG TAB 100 MYL	00378-0572-01	4.00	3.6400		
447920	ALBUTEROL 4MG TAB 500 MYL	00378-0572-05	14.82	13.9300		
466920	ALBUTEROL .5% INH SOL 20ML WAR	59930-1515-04	5.51	5.5000		
466938	ALBUTEROL .083% INH SOL 25X3ML WAR UD	59930-1500-08	10.64	10.0000		
466946	ALBUTEROL .083% INH SOL 60X3ML WAR UD	59930-1500-06	25.54	24.0000		
466953	ALBUTEROL 2MG/5MLS YR 160Z WAR	59930-1510-05	4.76	4.7500		
868257	ALBUTEROL .5% INH SOL 20ML QLT	00603-1006-43	6.19	4.9500		
807438	ALBUTEROL 2MG TAB 100 WAR	59930-1520-01	2.27	2.0600		
807693	ALBUTEROL 2MG TAB 500 WAR	59930-1520-02	9.25	8.6900		
807719	ALBUTEROL 4MG TAB 100 WAR	59930-1530-01	4.54	4.1300		
206102	ALBUTEROL 4MG TAB 500 WAR	59930-1530-02	19.10	17.3800		
940544	ALBUTEROL 2MG/5MLS YR 160Z APH	00472-0825-16	5.77	5.2500		
196493	ALBUTEROL .5% INH SOL 20ML DEY	49502-0196-20	8.13	6.5000		
708131	ALBUTEROL 90MCG RFINH 17GM DEY	49502-0303-27	7.19	5.7500		
523829	ALBUTEROL .083% SOL 30X3ML APH UD	00472-0831-30	10.50	8.4000		
960625	ALBUTEROL KIT 90MCG INH 17GM WAR	59930-1560-01	5.56	5.5500		
077420	ALBUTEROL KIT 90MCG INH 17GM Z/G	00172-4390-18	4.17	3.7500		
086918	ALBUTEROL KIT 90MCG INH 17GM DEY	49502-0303-17	7.50	6.0000		
961342	ALBUTEROL KIT 90MCG INH 17GM SHN	00364-2632-98	6.99	5.5900		
031559	ALBUTEROL KIT 90MCG INH 17GM NOV	55953-0051-53	6.90	5.7500		
420406	ALBUTEROL KIT 90MCG INH 17GM SID	50111-0801-31	5.88	4.7000		
960476	ALBUTEROL RFL 90MCG INH 17GM WAR	59930-1560-02	5.21	5.2000		
078253	ALBUTEROL RFL 90MCG INH 17GM Z/G	00172-4390-19	4.17	3.7500		
842500	ALBUTEROL SUL 0.5% INHLSOL 20ML B-L	24208-0347-20	5.60	4.4800		
035774	ALBUTEROL USP 2MG TAB 100 SID	50111-0491-01	2.38	1.9000		
035865	ALBUTEROL USP 4MG TAB 100 SID	50111-0492-01	2.31	1.8500		
035881	ALBUTEROL USP 4MG TAB 500 SID	50111-0492-02	8.44	6.7500		
416503	ALCAINE .5% SOL 15ML ALC	00998-0016-15	16.00	12.8000		
285015	ALCOHOL TRPL SWB 25 CLI	-	5.14	4.1100		
702217	ALCOHOL HM 70%ISO BXLIQ 1GL BL	00395-1249-28	8.36	6.2700		
757211	ALCOHOL HM 70%ISO BLLIQ 1GL BL	00395-1259-28	12.05	9.0400		
762641	ALCOHOL HM DENAT LIQ 1GL BL	00395-0037-28	23.43	17.5700		
728329	ALCOHOL HM 50%ISOP LIQ 160Z BL	00395-1245-16	.73	.5475		
719757	ALCOHOL HM 99%ISOPPKLIQ 1GL BL	00395-4204-28	12.79	9.5900		
719864	ALCOHOL HM 70%ISOPPKLIQ 160Z BL	00395-4202-16	.75	.5600		
708461	ALCOHOL HM 70%ET PPKLIQ 1PT BL	00395-4201-16	1.07	.8000		
709386	ALCOHOL HM 70%ISOPPKLIQ 1GL BL	00395-4202-28	7.91	5.9300		
031922	ALCOHOL DEHYD 98% AMP 10X1ML SOL	39769-0288-01	50.00	40.0000		
031930	ALCOHOL DEHYD 98% AMP 10X5ML SOL	39769-0289-05	206.25	165.0000		
061051	ALCOHOL DEHYD 98% AMP 10X1ML SOL	60267-0100-11	34.88	27.9000		
155564	ALCOHOL DEHYD 98% AMP 10X5ML HOP	60267-0200-22	117.50	94.0000		



BB's
AWP NET
Red Book
AWP

ITEM NUMBER	ITEM DESCRIPTION	VEN	UD	NDC	NUMBER	AWP	COST
862284	AKARPINE 1%	O/S	15ML	AKO	17478-0223-12	5.13	4.1000
862292	AKARPINE 2%	O/S	15ML	AKO	17478-0224-12	5.13	4.1000
862318	AKARPINE 4%	O/S	15ML	AKO	17478-0226-12	6.38	5.1000
347641	AKINETON 2MG	TAB	1000	KNO	00044-0120-04	220.22	183.5200
348342	AKINETON 2MG	TAB	100	KNO	00044-0120-02	29.76	24.8000
831685	AKNE-MYCIN 2%	ONT	25GM	HPT	48017-3501-01	19.14	15.9500
244327	AKORN ANTIOX	CPL	60	AKO	17478-0805-60	7.38	5.9000
862250	AKWA TEAR	SOL	15ML	AKO	17478-0060-12	3.69	2.9500
862466	AKWA TEAR	O/O	3.5GM	AKO	17478-0062-35	3.88	3.1000
626259	ALA SCALP HP 2%	LOT	10Z	DRL	00316-0140-01	7.71	6.1700
225029	ALAMAG	SUS	120Z	Z/G	00182-0809-39	1.95	1.4800
236158	ALAMAG	SUS	16L	Z/G	00182-0809-41	17.09	12.9900
220699	ALAMAG PLUS	SUS	120Z	Z/G	00182-6004-39	2.49	1.8900
572131	ALBALON 0.1%	O/S	15ML	ALL	11980-0154-15	17.73	14.1800
341982	ALBENZA 200MG	TAB	112	SKF	00007-5500-40	111.90	89.5200
129353	ALBERTO S/LN THICKGMSE		80Z	ALB	- -	2.46	2.0500
389536	ALBERTO S/LN XTRACONTRL MSE		80Z	ALB	- -	2.46	2.0500
391003	ALBOLENE SCN	CRM	120Z	NUM	87900-0387-22	8.52	7.1000
391029	ALBOLENE UNS	CRM	120Z	NUM	87900-0016-22	8.52	7.1000
391102	ALBOLENE UNS	CRM	60Z	NUM	87900-0016-40	5.28	4.4000
391128	ALBOLENE SCN	CRM	60Z	NUM	87900-0387-40	5.28	4.4000
466011	ALBUMARC DS 5%	VL	6X250ML	ARX	52769-0450-25	429.38	343.5000
466037	ALBUMARC DS 5%	VL	6X500ML	ARX	52769-0450-50	858.75	687.0000
379321	ALBUMIN 25%	VL	10X100ML	ARX	52769-0451-10	1,431.25	1,145.0000
379313	ALBUMIN DS 25%	VL	10X50ML	ARX	52769-0451-05	715.63	572.5000
306282	ALBUSTIX REAG	STP	100	BYR	00193-2191-21	33.06	26.4500
036467	ALBUTEIN DS 5%	SOL	250ML	ALP	49669-5211-01	112.50	90.0000
036475	ALBUTEIN DS 25%	SOL	50ML	ALP	49669-5213-02	112.50	90.0000
220871	ALBUTEIN DS 25%	SOL	100ML	ALP	49669-5213-03	225.00	180.0000
220889	ALBUTEIN DS 5%	SOL	500ML	ALP	49669-5211-02	225.00	180.0000
C29959	ALBUTEROL 2MG/5ML SYR		160Z	TEV	00093-0661-16	3.69	3.4700
033019	ALBUTEROL .083% INH	SOL	25X3ML	DEY UD	49502-0697-03	11.88	9.5000
039669	ALBUTEROL .083% INH	SOL	60X3ML	DEY UD	49502-0697-60	28.50	22.8000
051615	ALBUTEROL .083% INH	SOL	30X3ML	DEY UD	49502-0697-33	14.25	11.4000
195172	ALBUTEROL 4MG	TAB	100	TEV	00332-2228-09	5.24	4.1900
238196	ALBUTEROL .5% INH	SOL	20ML	Z/G	00182-6014-65	9.93	7.5500
21 38	ALBUTEROL .083% INH	SOL	25X3ML	UD	00182-8010-24	19.72	14.9900
30 698	ALBUTEROL 2MG	TAB	100	NOV	55953-0480-40	2.03	1.8500
30 004	ALBUTEROL 2MG	TAB	100	NOV	55953-0480-40	2.03	1.8500

DEP	ITEM NUMBER	ITEM DESCRIPTION	R	REGULAR COST	LIST / SUGGDT RETAIL	MIN ORD	UNIT	PKG QTY	DEP	ITEM NUMBER	ITEM DESCRIPTION	R	REGULAR COST	LIST / SUGGDT RETAIL	MIN ORD	UNIT	PKG QTY
AD	136-3803	ADALAT CC ER TAB 30MG	1000	R 772.93				58	AA	278-0088	ALBUTEROL SOL .083% Q/P 25X3ML	R	9.98*				24
AD	389-3751	ADALAT CC ER TAB 30MG UD	100	R 82.39				12	BE	277-3075	ALBUTEROL SOL .5% DEY 20ML	R	6.84*				72
AD	389-4171	ADALAT CC ER TAB 60MG	100	R 134.46				144	AA	131-7023	ALBUTEROL SOL 0.5% G/L 20ML	R	8.30*				36
AD	136-1433	ADALAT CC ER TAB 60MG	1000	R 1324.44				56	AA	110-3332	ALBUTEROL SOL 0.5% GEN 20ML	R	7.49				36
AD	389-4452	ADALAT CC ER TAB 60MG UD	100	R 141.18				12	AA	110-6475	ALBUTEROL SOL 0.5% Q/P 20ML	R	6.38*				24
AD	389-4742	ADALAT CC ER TAB 90MG	100	R 163.13				144	AA	218-5207	ALBUTEROL SOL 0.5% SCHE 20ML	R	7.81*				36
AD	389-6061	ADALAT CC ER TAB 90MG UD	100	R 171.30				12	AA	325-6120	ALBUTEROL SOL 0.5% WAR 20ML	R	8.79*				36
AD	140-6703	ADAPIN CAP 60MG	100	R 42.86				72	BE	161-5180	ALBUTEROL SOL 2ML UD DEY 25	R	10.00*				12
DB	123-8898	ADAPTER CATH TIP BAXA 13601	50	R 68.11*				CS	AA	118-0233	ALBUTEROL SOL 2ML UD DEY 30	R	12.00*				12
KD	386-8282	ADAPTER SPIKE BUR SA-2000	CS50	R 85.00				CS	AA	244-2119	ALBUTEROL SOL 2ML UD DEY 60	R	24.00*				12
KD	386-8225	ADAPTER SPIKE BUR SA1000	CS50	R 28.00				CS	AA	220-5144	ALBUTEROL SULF SOL .05% 20ML	R	8.81*				36
KD	129-9320	ADAPTER SPIKE BUR 356072	CS50	R 104.60				CS	AA	220-3834	ALBUTEROL SULF SOL .083% 3MLX25	R	10.86*				36
DB	123-8870	ADAPTER URETHRA BAXA 13501	50	R 88.11*				CS	AA	248-4106	ALBUTEROL SULF SYRP ALPH 180Z	R	6.83*				12
KD	240-6763	ADAPTER Y TYPE BUR SA2020Y	20	R 66.00				CS	AD	184-7417	ALBUTEROL SULF TAB 2MG WAR 1C	R	2.17*				36
JE	344-2548	ADDERALL TAB 5MG	100	X 33.76*				12	AD	184-8043	ALBUTEROL SULF TAB 2MG WAR SC	R	9.15*				12
JE	117-2856	ADDERALL TAB 10MG	100	X 65.08*				36	AD	184-8813	ALBUTEROL SULF TAB 4MG WAR 1C	R	4.35*				36
JE	117-3269	ADDERALL TAB 20MG	100	X 94.38*				36	AD	185-8562	ALBUTEROL SULF TAB 4MG WAR SC	R	18.29*				12
JE	321-8138	ADDERALL TAB 30MG	100	X 123.13*				12	AA	128-6818	ALBUTEROL SULF UD ASTR 60X3ML	R	62.11				20
DA	110-0080	ADEOCARD SDV 6MG	2ML	R 24.20				100	AA	128-5588	ALBUTEROL SULF UD ASTR 25X3ML	R	21.96				36
DA	118-8564	ADEOCARD SYR 6MG 2ML	5	R 128.00				5	AA	191-8958	ALBUTEROL SULF 0.5% ASTR 20ML	R	8.65				36
DA	118-6420	ADEOCARD SYR 12MG 4ML	5	R 250.60				5	AA	248-8803	ALBUTEROL SYRP 1GM GEN 160Z	R	4.99				12
DA	148-9350	ADEOCARD VIAL 3MG/ML	20ML	R 124.50				10	AA	181-1185	ALBUTEROL SYRP 2MG G/L 160Z	R	8.58*				12
DA	247-3122	ADEOCARD VIAL 3MG/ML	30ML	R 179.00				100	AA	221-0862	ALBUTEROL SYRP 2MG MNP 160Z	R	11.28				12
AA	111-6369	ADEXOL-DM	40Z	R 6.83				24	AA	240-0794	ALBUTEROL SYRP 2MG Q/P 160Z	R	3.58*				12
KD	223-6778	ADI VIAL STRL EMPTY 1QML AB 80	R	369.00				CS	AA	358-8878	ALBUTEROL SYRP 2MG SCHE 160Z	R	5.70*				12
KD	223-6321	ADI VIAL STRL EMPTY 5QML AB 80	R	303.60				CS	AA	131-6793	ALBUTEROL SYRP 2MG TEV 160Z	R	3.65*				12
JA	131-4413	ADIPEX-P CAP 37.5MG	100	D 95.64				24	AA	325-5890	ALBUTEROL SYRP 2MG WAR 160Z	R	3.80*				12
JA	127-7870	ADIPEX-P TAB	100	D 93.98				12	AA	327-5542	ALBUTEROL SYRP 2MG WAT 160Z	R	3.74				12
JA	118-3508	ADIPOST CAP	100	D 71.02				158	AD	362-0770	ALBUTEROL TAB 2MG GEN 100	R	2.85				24
KC	384-3681	ADMIN SET 4085-58 ABB	CS48	R 383.84				CS	AD	229-4593	ALBUTEROL TAB 2MG LED 500	R	16.07*				144
DA	138-7788	ADRENALIN AMP 1:1000 1ML	10	R 13.50				100	AD	188-8122	ALBUTEROL TAB 2MG MYLN 100	R	2.34*				144
DA	227-7598	ADRENALIN SOL 1:100 0.250Z	10	R 12.31				144	AD	188-8189	ALBUTEROL TAB 2MG MYLN 500	R	9.42*				144
DA	138-7760	ADRENALIN SOL 1:1000 10Z	R	9.18				100	AD	184-2184	ALBUTEROL TAB 2MG NOV 100	R	1.85				8
DA	138-7778	ADRENALIN SOL 1:1000 30ML	R	9.18				100	AD	184-2893	ALBUTEROL TAB 2MG NOV 500	R	7.20				8
IB	341-8118	ADRIAMYCIN PFS MOV 200MG 100ML	R	392.58				20	AD	148-8345	ALBUTEROL TAB 2MG Q/P 100	R	1.79*				24
IB	229-7950	ADRIAMYCIN PFS VIAL 10MG 5ML	R	20.03				10	AD	132-3435	ALBUTEROL TAB 2MG SID 100	R	2.00				36
IB	229-8735	ADRIAMYCIN PFS VIAL 20MG 10ML	R	40.08				10	AD	387-1328	ALBUTEROL TAB 2MG TEV 100	R	2.19				144
IB	229-8105	ADRIAMYCIN PFS VIAL 50MG 25ML	R	97.32				10	AD	387-1930	ALBUTEROL TAB 2MG TEV 500	R	8.75				144
IB	111-7389	ADRIAMYCIN PFS VL 75MG 37.5ML	R	147.21				10	AD	120-7978	ALBUTEROL TAB 2MG URL 100	R	1.83*				12
IB	389-1037	ADRIAMYCIN RDF MOV 150MG 75ML	R	280.32				10	AD	382-0705	ALBUTEROL TAB 4MG GEN 100	R	4.96				24
AB	137-0881	ADRIAMYCIN RDF VIAL 10MG 5ML	R	19.07				10	AD	229-4884	ALBUTEROL TAB 4MG LED 100	R	5.23*				144
AD	137-4537	ADRIAMYCIN RDF VIAL 50MG 25ML	R	92.85				96	AD	229-4833	ALBUTEROL TAB 4MG LED 500	R	24.88*				72
DD	343-1982	ADRUCL VIAL 2.5GM	5	R 60.00				6	AD	188-8262	ALBUTEROL TAB 4MG MYLN 100	R	3.83*				144
DD	246-3157	ADRUCL VIAL 500MG 10ML	10	R 12.92				10	AD	184-2966	ALBUTEROL TAB 4MG NOV 100	R	3.20				6
BA	163-8360	ADSORBOCARPINE 1% OT	15ML	R 11.80				12	AD	182-8829	ALBUTEROL TAB 4MG NOV 500	R	11.10				12
BA	163-8444	ADSORBOCARPINE 2% OT	15ML	R 12.10				12	AD	197-1217	ALBUTEROL TAB 4MG Q/P 100	R	2.62*				24
BE	163-8469	ADSORBOCARPINE 4% OT	15ML	R 12.90				12	AD	387-2490	ALBUTEROL TAB 4MG TEV 100	R	4.19				144
BE	218-8829	AEROBID INHALER SYSTEM	7GM	R 49.70				72	AD	387-4803	ALBUTEROL TAB 4MG TEV 500	R	15.94				48
BE	248-2255	AEROBID-M INHALER	7GM	R 49.70				72	AD	121-0046	ALBUTEROL TAB 4MG URL 100	R	2.89*				12
BE	228-4560	AEROCAMBER MDI SP (RX) 013601	R	23.20				144	AD	121-0375	ALBUTEROL TAB 4MG URL 500	R	12.60*				12
BE	219-6883	AEROCAMBERMASK LGE	013545	R 31.29				6	AD	243-5884	ALBUTEROL TB 2MG UD UDL	R	4.51				10
BE	345-0319	AEROCAMBERMASK MDI	013540	R 31.29				8	AD	243-8046	ALBUTEROL TB 4MG UD UDL	R	5.50				10
BE	219-6832	AEROCAMBERMASK SML	013535	R 31.29				6	BA	124-0332	ALCAINE DROP 0.5% DT	R	12.00				12
DA	271-2222	AGGRASTAT VL 12.5MG	50ML	R 350.00				144	DA	112-6748	ALCOHOL AMP 95% 1ML 3772 AB	R	258.50				4
AD	175-9186	AGRYLIN CAP 0.5MG	100	R 350.00				288	DA	278-8842	ALCOHOL DEH AMP 1ML A/R	R	65.00				10
AD	183-4355	AH-CHEW CHEW TAB	100	R 46.00				48	DA	214-0200	ALCOHOL DEH AMP 1ML SOLO	R	32.20				84
AD	133-9563	AH-CHEW O TAB	100	R 47.00				48	AD	112-7927	ALCOHOL DEH AMP 1ML TAY	R	38.54				10
AA	132-6396	AIRET SOL 3ML	26	R 41.26				4	DA	278-9154	ALCOHOL DEH AMP 5ML A/R	R	295.00				10
BA	134-9125	AK-CIDE OPH OINT	3.5GM	R 8.19*				72	DA	149-4772	ALCOHOL DEH AMP 98% 1ML HOP	R	27.90				30
BA	271-3238	AK-CIDE OPH SUSP	5ML	R 8.19*				72	DA	149-5019	ALCOHOL DEH AMP 98% 5ML HOP	R	94.00				30
BA	271-3279	AK-COM OPH SOL 0.1% 15ML	R	3.95*				144	DA	227-8838	ALCOHOL DEH 98% SDA 1ML MNP	R	81.20				10
BA	121-0509	AK-DEX OPH SOL 0.1% 5ML	R	4.84				144	DA	228-0022	ALCOHOL DEH 98% SDA 5ML MNP	R	388.70				10
BA	274-0751	AK-DILATE OPH SOL 2.5% 2ML	R	3.28				432	KA	384-3228	ALCOHOL-DEX SOL 5/5 1MM AB	R	63.18				CS
DA	277-2089	AK-FLUOR VIAL 10% 5ML LIGHT	12	R 53.24				80	AD	145-0881	ALDOCTAZIDE TAB 25MG	R	39.41				12
DA	125-7831	AK-FLUOR VIAL 25% 2ML	12	R 53.24				162	AD	121-8274	ALDOCTAZIDE TAB 50MG	R	89.24				120
BA	118-1892	AK-PENTOLATE OPH SOL 1% 2ML	R	4.18				432	AD	145-1004	ALDOCTONE TAB 25MG	R	36.57				12
BA	160-0204	AK-POLY-BAC OPH OINT 3.5GM	R	4.95*				144	AD	189-2350	ALDOCTONE TAB 25MG	R	173.83				3
BA	178-8538	AK-PRED OPH SOL 1% 5ML	R	4.64				144	AD	121-6217	ALDOCTONE TAB 50MG	R	64.22				72
BA	171-8960	AK-PRED OPH SOL 1% 15ML	R	6.83				144	AD	121-9823	ALDOCTONE TAB 50MG UD	R	87.27				10
BC	115-4962	AK-SPORE HC OTIC SOL	10ML	R 6.89				240	AD	193-0462	ALDOCTONE TAB 100MG	R	107.88				120
BC	115-4954	AK-SPORE HC OTIC SUSP	10ML	R 8.89				240	AD	194-5328	ALDOCTONE TAB 100MG UD	R	112.91				10
BA	115-6142	AK-SPORE OPH SOL	10ML	R 5.05				144	CA	228-8884	ALDARA CREAM 5% 0.25GM	R	90.00				24
BA	180-2531	AK-TOB STER O/S 0.3%	5ML	R 5.05				144	AD	135-6369	ALDOCLOR-250 TAB	R	48.87				48
BA	110-3847	AK-TROL OPH SUSP 0.1%	5ML	R 6.12				144	AD	118-8428	ALDOMET TAB 125MG	R	23.88				144
AD	131-6480	AKINETON TAB 2MG	100	R 24.80				12	AD	135-6393	ALDOMET TAB 250MG	R	30.40				48
CA	178-3512	AKNE-MYCIN OINT	25GM	R 16.95				12	AD	172-8512	ALDOMET TAB 500MG	R	55.55				48
CC	270-8931	ALA-SCALP LOT 2%	10Z	R 8.17				12	AD	222-9698	ALDORIL-030 TAB	R	77.71				48
BA	228-8842	ALBALON OPH SOL 0.1%	15ML	R 14.18				38	AD	222-8708	ALDORIL-050 TAB	R	83.58				48
AD	383-8871	ALBENZA TAB 200MG	11Z	R 81.44				38	AD	135-6401	ALDORIL-15 TAB	R	41.48				48
DA	165-4722	ALBUMIN VIAL 25% 100ML TAY	10	R 3650.00				162	AD	135-6427	ALDORIL-25 TAB	R	48.87				48
DA	165-3377	ALBUMIN VIAL 25% 50ML TAY	10	R 1825.00				48	AH	382-3321	ALESSE-21 PILPAK	R	86.92				36
AA	187-8717																

ANDA GENERICS PRESENTS

RETAIL PHARMACY REBATE on **ALBUTEROL UNIT DOSE 0.083 %** from **DEY** Laboratories



REBATES:

Albuterol Unit-Dos

25's - \$.25/carton

30's - \$.35/carton

60's - \$.60/carton

Substantial Savings Available

- Offer Begins February 1, 1998 and Ends March 31, 1998
- Daily minimum: 12 cartons/order • Daily maximum: 144 cartons/order
- Purchase must be initiated through ANDA GENERICS
- Proof of purchase in the form of an invoice, must be mailed directly to Dey at the address listed below, or faxed to 707.224.0495 (attention: Rebate Program)
- Rebate will be mailed directly to you in 4-6 weeks after receipt of invoice
- No returns, excluding freight damage within 3 days

To get more details, call ANDA GENERICS today

1800-331-2632
Ext #4550



Depend on Quality.
Depend on Dey.

DEY Laboratories
2751 Napa Valley Corporate Drive
Napa, CA 94558

09-422-0240D V08 Printed U.S.A.
© 1998 DEY Laboratories

Notice required by law: Where any remuneration, including a discount, rebate or promotion may directly or indirectly involve Medicare or a State health care program, Federal requirements including mandatory disclosure may apply. This statement constitutes required notice to all parties under 42 U.S.C. §1320a-7b(b) and 42 C.F.R. §1001.952. DEY reserves the right to change the program without prior notification.

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

7

Divider Title: _____

ACYCLOVIR SODIUM

PROD/MFR	NDC	Wholesale	(GPO) DP	1999 AWP Red Book
(App)				
INJ, IJ (VIAL)				
50 mg/ml, 10 ml.....	63323-0325-10	15.00/MK		22.82
20 ml.....	63323-0325-20	28.00/MK		42.59
PDI, 15, 500 mg ea. ...	63323-0105-10	37.15/MK		56.51
1000 mg.....	63323-0110-20	75.13/MK		113.05
(Abbott Hosp)				
(VIAL, FLIPTOP)				
500 mg, 10s.....	00074-4427-01	306.10 /BB		997.50
		392.00 /MK		1,995.00
(VIAL, FLIPTOP)				
1000 mg, 10s.....	00074-4452-01	612.20 /BB		
		788.00 /MK		
(Bedford)				
PDI, IJ (S.D.V.)				
500 mg, 10s.....	55390-0612-10,	175.00 /BB		528.00
		224.00 /ASD		
		222.00 /FI		
1000 mg 10s.....	55390-0613-20	350.00 /BB		1,056.00
		448.00 /ASD		
		444.00 /FI		
		365.00/OS		
(Faulding)				
PDI, IJ				
500 mg, 10s.....	61703-0311-20	89.00 /FI		490.04
1000 mg, 10s.....	61703-0311-43	179.50 /FI		954.00
(Fujisawa /APP)				
PDI, IJ (VIAL)				
500 mg 10s.....	63323-0325-10	150.00 /BB		
500 mg 10s.....	63323-0105-10	371.50 /BB,MK		
1000 mg 10s.....	63323-0325-20	280.00 /BB,MK		
1000 mg 10s.....	63323-0110-20	751.80 /BB,MK		
(Gensia)				
PDI, IJ (VIAL)				
500 mg 10s.....	00703-8104-03	100.00 /BB		125.00
1000 mg 10s.....	00703-8105-03	186.00 /BB		232.50

ASD ITEM #	MFG	NDC #	ONCOLOGY PHARMACEUTICALS	PKG SIZE	PKG PRICE	EACH PRICE	REDBOOK AWP	J CODE
158-505	ABB	00074-6111-01	Abbokinase 5,000	1	\$51.48	\$51.48	\$58.26	J3364
159-921	ABB	00074-6145-02	Abbokinase 9,000	1	\$89.78	\$89.78	\$98.13	J3364
805-242	BED	55390-0812-10	Acyclovir 500mg v1 10ml	10	\$224.00	\$22.40	\$528.00	J9999
805-127	BED	55390-0813-20	Acyclovir 1gm v1 20ml	10	\$448.00	\$44.80	\$1,056.00	J9999
310-847	PUJ	00013-1138-91	Adriamycin PFS 10mg	10	\$74.00	\$7.40	\$51.21	J9000
311-050	PUJ	00013-1148-94	Adriamycin PFS 20mg	1	\$14.80	\$14.80	\$102.43	J9000
311-258	PUJ	00013-1158-79	Adriamycin PFS 50mg	1	\$37.00	\$37.00	\$258.08	J9010
257-493	PUJ	00013-1176-87	Adriamycin PFS 75mg	1	\$56.70	\$56.70	\$384.89	J9000
311-282	PUJ	00013-1188-83	Adriamycin PFS 200mg	1	\$148.00	\$148.00	\$1,003.75	J9000
310-334	PUJ	00013-1088-91	Adriamycin RDF 10mg	10	\$71.60	\$7.16	\$48.78	J9000
310-831	PUJ	00013-1108-79	Adriamycin RDF 50mg	1	\$35.79	\$35.79	\$243.80	J9010
310-880	PUJ	00013-1118-83	Adriamycin RDF 150mg	1	\$108.00	\$108.00	\$716.78	J9000
311-340	PUJ	00013-1038-91	Adrucil 500mg	10	\$14.17	\$1.42	\$2.50	J9190
311-464	PUJ	00013-1048-94	Adrucil 2.5gm v1 50 ml	5	\$33.73	\$6.75	\$12.50	J9190
311-472	PUJ	00013-1058-94	Adrucil 5gm	5	\$85.00	\$13.00	\$25.00	J9190
957-480	ABB	00013-1058-94	Adrucil 5gm	5	\$55.00	\$11.00		
394-528	GLX	00173-0130-93	Alkeran IV 50mg SDV	1	\$277.29	\$277.29	\$325.03	J9245
148-429	GLX	00173-0045-35	Alkeran 2mg Tab 50	1	\$78.92	\$78.92	\$92.77	J8600
425-728	GEN	00703-9785-01	Amphoteric B 50 mg v1	1	\$15.00	\$15.00	\$38.50	K0453
311-882	PUJ	00013-1405-44	Amphocin 50 mg v1	1	\$18.00	\$18.00	\$34.54	K0453
321-497	SEQ	81471-0115-12	Amphotec 50 mg v1 20 ml	1	\$75.60	\$75.60	\$93.33	K0453
350-074	SEQ	81471-0110-12	Amphotec 100 mg v1 50 ml	1	\$129.60	\$129.60	\$160.00	K0453
924-217	HMR	0088-1208-32	Anzemet 100mg v1 5ml	1	\$71.00	\$71.00	\$149.88	J1260
071-829	P-D	00071-4525-03	Aplisol TU 10 test v1 1ml	1	\$16.18	\$16.18	\$15.40	
089-508	MSD	00008-7780-84	Aquamephyton 10 mg AMP 1 ml	6	\$28.22	\$4.70	\$30.59	J3430
089-532	MSD	00008-7782-03	Aquamephyton 10mg v1 5ml	1	\$20.20	\$20.20	\$20.43	J3430
158-091	NOV	00083-2801-04	Aredia IV Inf v1 30mg	4	\$778.17	\$194.54	\$872.98	J2430
294-116	NOV	00083-2809-01	Aredia IV Inf v1 90mg	1	\$549.90	\$549.90	\$821.75	J2430
137-729	ESI	00008-0581-04	Ativan 2 mg/ml 1 ml	1	\$8.83	\$8.83	\$9.85	J2080
754-897	FUJ	00489-1234-25	Atropine Sulf 0.4 mg SDV 1 ml	25	\$17.92	\$0.72	\$1.12	J0480
585-158	BGN	59827-0001-03	Avonex Admin Pk 30mcg v1	4	\$795.20	\$198.80	\$852.00	J1830
388-249	BMS	00015-3012-38	BicNU 100mg	1	\$83.83	\$83.83	\$95.73	J9050
387-597	BMS	00015-3010-20	Blenoxane 15u	1	\$255.88	\$255.88	\$304.80	J9040
985-358	PUJ	00013-1818-78	Bleomycin 15 units	1	\$159.00	\$159.00	\$309.98	J9040
984-922	PUJ	00013-1838-88	Bleomycin 30 units	1	\$318.00	\$318.00	\$618.91	J9040
979-559	PUJ	00009-7529-02	Camptosar 40mg	1	\$182.58	\$182.58	\$208.72	J9208
987-032	PUJ	00009-7529-01	Camptosar 100mg	1	\$456.44	\$456.44	\$551.93	J9208
143-580	SCH	00085-0568-05	Celestone SUS 8 mg/ml MDV 5 ml	1	\$24.70	\$24.70	\$23.15	J0704
484-834	BED	55390-0281-10	Cerubidine (Daunorubicin HCL) 20mg	10	\$1,354.39	\$135.44	\$1,685.00	J9150
426-585	ABB	00074-7445-01	Cimetidine Inj. 150mg/ml 8ml	10	\$32.50	\$3.25	\$200.33	J9999*
939-884	ABB	00074-7444-01	Cimetidine 150mg/ml FTV 2ml	10	\$13.50	\$1.35	NA	J9999
248-385	BYR	00028-8554-83	Cipro IV 400 mg Bag 200 ml	24	\$872.00	\$28.00	\$720.29	
562-496	AST	00188-1451-04	Clindamy Phos 600mg SDV 4ml	25	\$48.60	\$1.94	\$250.00	
562-548	AST	00188-1451-05	Clindamy Phos 900 mg 8 ml	25	\$87.20	\$2.89	\$75.00	
040-800	SKB	00007-3348-15	Compazine SPN 15 mg CAP	50	\$87.57	\$1.35	\$85.70	J0780
040-485	SKB	00007-3343-01	Compazine 5mg/ml MDV 10ml	1	\$28.18	\$28.18	NA	
041-038	SKB	00007-3352-18	Compazine 10mg/2ml v1 2ml	25	\$150.00	\$6.00	NA	
090-506	MSD	00008-3298-22	Cosmegen 0.5mg vial	1	\$12.00	\$12.00	\$12.60	J9120
754-770	FUJ	00489-1044-25	Cyanocobalamin 100mcg/ml 1ml	25	\$31.92	\$1.28	\$1.78	
581-583	ARL	00517-0130-01	Cyanoco 1000mcg/ml v1 30ml	1	\$1.98	\$1.98	\$1.58	J3420
488-122	BED	55390-0131-10	Cytarabine 100mg Lyophilized	10	\$30.00	\$3.00	\$62.50	J9100
490-318	BED	55390-0132-10	Cytarabine 500mg Lyophilized	10	\$80.00	\$8.00	\$250.00	J9110
543-397	FAU	81703-0304-25	Cytarabine 500mg Solution MDV	5	\$57.50	\$11.50	\$143.85	J9110
491-860	BED	55390-0133-01	Cytarabine 1gm Lyophilized	1	\$17.00	\$17.00	\$50.00	J9100
493-726	BED	55390-0134-01	Cytarabine 2gm Lyophilized	1	\$35.00	\$35.00	\$98.90	J9110
297-978	PUJ	00009-0373-01	Cytosar-U 100mg	1	\$3.00	\$3.00	NA	
292-987	PUJ	00009-0473-01	Cytosar-U 500mg	1	\$8.50	\$8.50	NA	
289-850	PUJ	00009-3295-01	Cytosar-U 1gm	1	\$17.00	\$17.00	\$52.58	J9100
289-876	PUJ	00009-3298-01	Cytosar-U 2gm	1	\$34.00	\$34.00	\$102.90	J9100
824-445	ROC	00004-8940-03	Cytovene Ster 500 mg pwd 10 ml	25	\$817.44	\$32.70	\$870.00	
026-070	BMS	00015-0539-41	Cytosan 100mg	12	\$44.00	\$3.67	NA	
026-096	BMS	00015-0548-41	Cytosan 200mg	12	\$70.00	\$5.83	\$12.25	J9094
056-911	BMS	00015-0547-41	Cytosan 500mg	12	\$90.00	\$7.50	\$25.71	J9095
056-473	BMS	00015-0548-41	Cytosan 1gm	6	\$90.00	\$15.00	\$51.43	J9096
056-317	BMS	00015-0549-41	Cytosan 2gm	6	\$175.00	\$29.17	\$102.89	J9097
566-737	NEX	56148-0301-04	Daunoxome 2mg/ml 50ml	1	\$265.00	\$265.00	\$287.50	J9999*
255-570	ROR	00075-2451-01	DDAVP 4 mcg/ml AMP 1 ml	10	\$249.82	\$24.98	\$268.90	J2597
465-799	ORG	00052-0897-02	Deca Durab 100mg/ml 2ml v1	1	\$41.08	\$41.08	\$23.59	
288-563	PUJ	00009-0826-01	Depo Provera 400 mg VL 2.5 ml	1	\$98.91	\$98.91	\$101.28	
288-548	PUJ	00009-0828-02	Depo Provera 400 mg v1 10 ml	1	\$375.50	\$375.50	\$384.49	
288-670	PUJ	00009-0417-01	Depo Testot 200mg v1 1ml	1	\$22.44	\$22.44	\$11.59	
152-157	NOV	00083-3801-04	Desferal 500mg	4	\$48.27	\$11.57	\$44.78	J0895
045-419	GEN	00703-3524-01	Dexamethasone 10mg/ml 10ml	1	\$2.50	\$2.50	\$5.20	J1100


PRICE LIST

A WORD ABOUT PRICING

We strive to provide our customers the lowest prices possible day in and day out. Due to printing deadlines, the prices shown in this catalog are being entered in advance of the publication date and, due to potential manufacturer's price increases, may change by the time you receive this newsletter or during the period these prices are offered. We invite you to call at any time for a current price quote. (*) Denotes monthly special. (**) Denotes Universal contracts only.

ABBOKINASE25000U5ML VIAL	439.50	ASCORBICACID50ML VIAL	5.00	CEE-NU100MGCAPS20'S	280.30
ABBOKINASEOPENCATH5000U1.0ML VIAL	52.45	ATRACURRUMBESYLATE10MG/ML10MLMOV10BX ...	168.00	CEE-NU100MGCAPS20'S	516.25
ABBOKINASEOPENCATH5000U1.8ML VIAL	91.45	ATROPINE0.4MG/ML1ML VIAL 25/BOX	8.27	CEFAZOLIN10GMVIAL 100ML10/BOX	103.00
ABELCET5MG/ML20ML VIAL	153.70	ATROPINE0.4MG/ML20MLMOV	0.82	CEFAZOLIN1GMVIAL 10MLBMS	1.45
ACETAMINOPHENUNISERT120MG12/BOX	5.90	ATROPINESULFATE1MG/10ML21X1-1/2ABBOJ	2.90	CEFAZOLIN500MGVIAL 10ML	0.95
ACETAMINOPHENUNISERT325MG12/BOX	6.50	ATROVENT0.02%INH SOL2.5ML25/BX	48.90	CEFZOX1GRAMVIAL	10.63
ACETAMINOPHENUNISERT650MG12/BOX	8.90	ATTENUVAXVACCINE(MEASLES)10VIAL TRAY	114.70	CEFUROXIME1.5GRAMVIAL 10/BOX	78.25
ACTHARGELHP80U/ML5MLMOV	44.00	ATTENUVAXVACCINE(MEASLES)SDV	14.15	CEFUROXIME7.5GRAMBUKVIAL 10/BOX	372.70
ACTIGALL300MGCAPS100'S	236.75	AUGMENTIN500MG TABS20/BTL	57.95	CEFUROXIME750MGVIAL 10/BOX	38.25
ACTIMUNE3MILLIUNITS/5ML VIAL	110.00	AUROLATE(GOLDTHIOMALATE)50MG/ML10ML	108.05	CELESTONESOLUSPANSCVIAL	22.50
ACYCLOVIR500MG LIQUIDVIAL 10/BX	89.00	AVONEX30MCGADMINPK4-WK	795.17	CEPTAZ1GRAMVIAL 25/BOX	332.90
ACYCLOVIR1000MG LIQUIDVIAL 10/BX	179.50	AZATAM1GRAMVIAL 10/BOX	148.35	CERUBIDINE20MGVIAL 10/BOX	1,475.00
ADENOCARD6MG10/BOX	280.65	BACTROBAN OINTMENT2%15GM	15.25	CERUMENEXEARDROPS12ML	29.80
ADRENALIN1:10000MILLISTERI-VIAL	9.35	BACTROBAN OINTMENT2%30GM TUBE	28.75	CHLOROMYCETINSUCCINATE1GRAM10/BOX	41.80
ADRENALIN1:10000MILLI10/BOX/PD	14.30	BAYRHO-DIMMUNEGLOBULINFULLDOSE10/BX	620.00	CHOLERA VACCINE20MILLIMOVWYETH	32.00
ADRIAMYCINPFS10MGVIAL	8.95	BAYRHO-DIMMUNEGLOBULINFULLDOSESYR	82.00	CHORIONICGNADOTROPIN10000U10ML VIAL	15.75
ADRIAMYCINPFS20MGVIAL	16.95	BAYRHO-DIMMUNEGLOBULINMINIDOSE10/BX	184.00	CIMETIDINEHCL300MG/2ML8MLMOV25/BOX	103.80
ADRIAMYCIN PFS 50MG VIAL	39.95*	BAYTETSINGLESYRINGE	61.80	CIMETIDINEHCL300MG/2ML VIAL 25/BOX	42.75
ADRIAMYCINPFS75MGVIAL	62.50	BCGVACCINETICESTRAINORGANON	118.00	CIPRO600MG TABS100/BTL	335.00
ADRIAMYCIN PFS 200MG VIAL	148.50*	BENADRYL50MG/1MLAMPS10/BOX	14.22	CIPROLV.400MG/40ML VIAL	27.13
ADRIAMYCINRDF10MGVIAL	8.95	BENADRYL50MG/ML10MLMOV	8.83	CLAFORAN1GMVIAL 10/BOX1	05.75
ADRIAMYCINRDF20MGVIAL	16.80	BENADRYL50MG/MLSYRINGE22X1-1/4	2.90	CLAFORAN2GMVIAL 10/BOX	195.80
ADRIAMYCIN RDF 50MG VIAL	38.00*	BETAMETHASONE500PHOSPHATE3MG/ML5ML	9.00	CLAFORAN500MGVIAL 10/BOX	63.40
ADRIAMYCINRDF150MGVIAL	122.00	BLAXIN500MG TABLETS80/BTL	172.00	CLEMASTINEFUM.1.34MG TABLETS100/BTL	21.00
ADRUCLIS-FUJ5.5GMVIAL	7.95	BICILLINCR300000U/VIAL	15.95	CLINDAMYCIN150MGCAPSULES100/BTL	89.00
ADRUCLIS-FUJ5.0GMVIAL	14.25	BICILLINCR800000UTUBEX10X1ML	58.30	CLINDAMYCIN300MG/2ML VIAL 25/BOX	28.75
ADVLAPLET3200MG100/BTL	9.45	BICILLINCR1200000UTUBEX10X2ML	110.55	COMBIVIR TABLETS90/BTL	458.80
ALBUMIN(BUMINATE)25%50ML10/BOX	750.00	BICILLINCR2400000USYRINGE10X4ML	238.70	COMPazine10MG TABLETS100/BTL	73.20
ALBUMIN(PLASBUMIN)25%100MLCUTTER	210.00	BICILLINCR900/300TUBEX2ML10/BX	115.00	COMPazine15MG SPANSULES50/BTL	88.35
ALBUTEROL0.083%INHALSOL3ML25/BX	8.80	BICILLINLA300000U/VIAL	23.80	COMPazine5MG/ML10MLMOV	30.30
ALBUTEROL0.5%20MLINHALSOL	5.50	BICILLINLA600000UTUBEX10X1ML	80.05	CORTROSYN25MG/2ML VIAL 10/BOX	145.75
ALBUTEROLINHALER17GM	8.95	BICILLINLA1200000UTUBEX10X2ML	138.80	COSMEGEN500MCGVIAL	11.35
ALCOHOL DEHYDRATEDAMPS 5ML10/BX	180.00	BICILLINLA2400000USYRINGE10X4ML	283.80	CYANOCOBOLAMIN(B12)1000MCG/ML25X1ML	19.00
ALFERON-NSU/VIAL	148.50	BICIN(CARMUSTINE)100MGVIAL	79.70	CYANOCOBOLAMIN(B12)1000MCG/ML30ML	1.55
ALKERAN2MG50TABLETS	82.44	BLENOXANE(BLEOMYCIN)15U/VIAL	253.43	CYTARABINE 100MG LIQUID SDV	3.95*
ALKERAN50MCGSDV	277.28	BLENOXANE(BLEOMYCIN)30U/VIAL	506.85	CYTARABINE 100MG VIAL POWDER	3.30*
ALPROSTADIL500MCG/1MLAMPS/BX	838.00	BLEOMYCIN 15U VIAL	158.00*	CYTARABINE 500MG VIAL POWDER	8.25*
ALTERNAGELLIQUID12OZ	5.35	BLEOMYCIN 30U VIAL	330.00*	CYTARABINE 1GM VIAL POWDER	18.70*
AMIKACIN500MG/2ML VIAL BEDFORD10/BX	86.00	BRETHINEIN1MG/ML10/BOX	21.20	CYTARABINE 2GM VIAL POWDER	35.20*
AMIKACIN1000MG/4ML VIAL BEDFORD10/BX	118.00	BRETYLIUMTOSYLATE50MG/ML10MLABOJECT	4.00	CYTARABINE VIAL LIQUID MOV 500MG	8.95*
AMIKIN(AMIKACIN)1000MG/4ML VIAL 10/BX	148.00	BROMPHENIRAMINEMALEATE10MG/ML10ML	11.65	CYTOSAR-U(ARA-C)100MGVIAL UP JOHN	4.95
AMIKIN(AMIKACIN)500MG/2ML VIAL 10/BOX	72.00	BUMEX1MG/4ML VIAL 10/BOX	28.80	CYTOSAR-U(ARA-C)500MGVIAL UP JOHN	15.00
AMINOPHYLLIN250MG/10ML VIAL	0.47	BUPIVACAINE0.5%10ML VIAL	2.80	CYTOSAR-U(ARA-C)1000MGVIAL UP JOHN	28.25
AMINOPHYLLIN500MG/20ML VIAL	0.58	BUPIVACAINE0.5%W/PL10ML VIAL	4.80	CYTOSAR-U(ARA-C)2000MGVIAL UP JOHN	32.50
AMPICILLIN250MG10/BOX	5.05	CALCUIEX1MCG/ML1MLAMPULE100/CASE10	27.00	CYTOVENE250MGCAPSULES180/BX	840.85
AMPICILLIN500MG10/BOX	8.15	CALCUIEX2MCG/ML1MLAMPULE100/CASE19	12.50	CYTOVENE500MGVIAL 25/BOX	772.85
AMPICILLIN1000MG10/BOX	7.10	CALCIMAR(CALCITONIN)200U/ML2MLMOV	48.20	CYTOXAN25MG TABS100'S	182.00
AMPICILLIN1000MG10/BOX	7.10	CALCITONIN200U/ML2ML VIAL	22.90	CYTOXAN50MG TABS100'S	298.95
AMPICILLIN2000MG10/BOX	11.05	CALCIUMCHLORIDE10%18GAX3-1/2ABOJECT	3.40	CYTOXANLYOPHILIZED100MGVIAL BRISTOL	5.35
ANZEMET (DOLASETRON) 20MG/ML 5ML SDV	71.80*	CALCIUMCHLORIDE10%21GAX1-1/2ABOJECT	2.90	CYTOXANLYOPHILIZED200MGVIAL BRISTOL	10.20
AQUAMEPHYTON10MG/ML1MLAMPULE5/BOX	28.20	CAMPITOSAR 100MG/5ML VIAL	494.00*	CYTOXANLYOPHILIZED500MGVIAL BRISTOL	21.40
AQUAMEPHYTON10MG/ML5ML VIAL MOV	20.15	CAMPITOSAR 40MG/2ML VIAL	174.00*	CYTOXANLYOPHILIZED1000MGVIAL BRISTOL	42.80
AREDA (PAMIDRONATE) 30MG VIAL 4/BX CIBA	742.00*	CANDIN1ML VIAL	44.20	CYTOXANLYOPHILIZED2000MGVIAL BRISTOL	85.80
AREDA (PAMIDRONATE) 60MG VIAL CIBA	382.80*	CARNITOR1GM5MLAMPULE5/BOX	158.00	DALALONEP.16MG/ML5ML VIAL	22.40
AREDA (PAMIDRONATE) 90MG VIAL CIBA	525.80*	CAVERJECT10MCGSYSTEM8/BX	100.20	DANOCRINE50MGCAPSULES100/BTL	122.05
ARISTOCORTFORTE40MG/ML1ML VIAL	8.62	CAVERJECT10MCGVIAL 8/BX	85.15	DANOCRINE200MGCAPSULES100/BTL	302.85
ARISTOCORTFORTE40MG/ML5ML VIAL	11.25	CAVERJECT20MCGSYSTEM8/BX	128.05	DAPSONE25MG TABLETS100/BTL	18.30
ARISTOSPAN20MG/ML1ML VIAL	8.15	CAVERJECT20MCGVIAL 8/BX	114.25	DARANIDE50MG TABLETS100/BTL	48.95
STOSPAN20MG/ML5ML VIAL	19.85	CEE-NU10MGCAPS20'S	88.30		

H.I.V. DRUGS


**FOSCAVIR**

12/case
 250ml **\$732⁰⁰**
 500ml **\$1,460⁰⁰**

**CYTOVENE**

500mg vial 25/box


\$754⁰⁰

**ACYCLOVIR** ←


1000mg vial 10/box 500mg vial 10/box

\$444⁰⁰

\$222⁰⁰




ZOVIRAX
 500mg vial
\$49.05



NEBUPENT
 300mg/15mL
\$36.00




PENTAMIDINE
 300mg
\$29.00



ZOVIRAX TABS
 200mg 100's **\$95.60**
 400mg 100's **\$193.00**
 800mg 100's **\$365.60**




EPIVIR TABS RETROVIR CAPS
 150mg 60's 100mg 100's ... **\$138.00**
\$199.10 300mg 60's **\$253.20**




CYTOVENE CAPS
 250mg 180's
\$625.00




DIFLUCAN TABS
 100mg 30's
\$184.95




NIZORAL TABS
 200mg 100's
\$268.10



MYCOBUTIN
 150mg 100's
\$339.85



HIVID TABS
 750mg 100's
\$210.75



MEPRON TABS
 250mg 200's
\$480.11

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

8

Divider Title: _____

REQUEST FOR INFORMATION FOR NEW DRUG PRODUCT
OR FOR ADDITIONAL INFORMATION OF PRODUCTS CURRENTLY
INCLUDED IN THE TEXAS DRUG CODE INDEX


A product added to the Texas Vendor Drug Program must bear the labeler code, as defined by the FDA, of the party, with the exception of a bonafide full-service drug wholesaler, making the final sale to the provider.

Manufacturers or distributors having one or more of their pharmaceuticals included in the program are responsible for submitting notification of any changes pertaining to any of the 16 points above not later than such revisions are scheduled to occur to:

Texas Department of Human Services
Martha McNeill, R.Ph., Product Manager
Vendor Drug Program (Mail Code Y-915)
Post Office Box 149030
Austin, Texas 78714-9030

I certify that the information submitted is correct to the best of my knowledge and that this product is not now in violation of either Federal or State Law. I also agree to inform the Texas Department of Human Services, in writing, of any changes in formulation, product status, price or availability as herein described, within fifteen (15) days of such change.

DIANE GERST
Responsible Person (Type or Print)


Signature

MANAGER, REGULATORY AFFAIRS
Title

POST OFFICE BOX 19791 IRVINE CA 92713-9791
Address City State Zip

McGAW, INC. (714) 660-2689
Company Name Telephone

Note: Do not use the abbreviation N/A in answering any of the questions on this application. Also, all liquids are to be listed as milliliters.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001a. form	re: Information for New Drug Product (partial) (1 page)	n.d.	P6/b(6)

COLLECTION:

Clinton Presidential Records
Domestic Policy Council
Devorah Adler
OA/Box Number: 20468

FOLDER TITLE:

Fraud and Drugs

2012-0463-S

rc754

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

9. Does your finished dosage form (tablet, capsule, etc.) carry a visible identifying logo?
X Yes ____ No. If yes, please enclose a picture of schematic drawing.

Label Enclosed

10. Is this product now marketed under an approved NDA or ANDA? **NDA 19-635**

Submit a copy of the FDA letter of approval of the NDA or ANDA, or, if not applicable, a copy of the FDA letter of approval for marketing. **Attached**

11. Is this product listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)? **YES**

If so, what is it's rating? **AP**

If not, why?

12. Name and address of representative covering the Austin area; if applicable:

Nancy Robinson,

P6/(b)(6)

[001a]

13. Attach a copy of your sales agreement with retail pharmacists (contract, policy, etc.)

General Ordering Information Enclosed

14. Include a copy of file care, package insert, or material for physicians.

Package Insert Enclosed

15. Attach a copy of your Vendor Liability Insurance:

- a. Included, OR
b. Previously submitted or unchanged. (Do not need to resubmit)

16. Do you sell to distributors, repackagers, or relabelers, other than full-service drug wholesalers, who in turn sell your products to the retail trade bearing your NDC number?

If yes, attach a listing. **NO**

REQUEST FOR INFORMATION FOR NEW DRUG PRODUCT
OR FOR ADDITIONAL INFORMATION OF PRODUCTS CURRENTLY
INCLUDED IN THE TEXAS DRUG CODE INDEX

Requests for consideration of a preparation for addition to the Texas Vendor Drug Program must cover the following points:

1. Name of drug:
 - a. Your private brand name, if applicable: *0.9%*
 - b. Generic name: **0.9% Sodium Chloride Injection-~~USP~~**
2. Name and address of Firm: **McGaw Inc., 2525 McGaw Avenue, Post Office Box 19791 Irvine, CA 92713-9791.**
3. Name and address of manufacturer of drug: **Same as #2**
4. Drug description:
 - a. Dosage Form: **Injection**
 - b. Strength: **0.9% Sodium Chloride**
 - c. Formula:
 - d. Recommended daily dose: **See Enclosed Package Insert**
 - e. Maximum daily dose:
5. Size of packages (50's, 100's, etc.) and National Drug Code for each.

250 mL - NDC 0264-7800-20 **1000 mL - NDC 0264-7800-00**

500 mL - NDC 0264-7800-10

40542950 *200*

listed 4/6/93
6. Price: (a., b., and c. must be completed). In addition, attach copies of price lists - one set of price lists is sufficient for multiple submittals.
 - a. Published List Price: **\$7.18 per 250/500 mL, \$7.81 per 1000 mL**
 - b. Price to wholesaler and/or distributor: 00002872 *ml* 00001430 *ml* 00000708 *ml*
 - c. Direct price to pharmacy:
 - d. Special price to institutional pharmacy, i.e., (Nursing Home, Home Health Care, etc):
 - e. Special price to chain warehouse:
7. Is the drug legend or OTC? **Legend**
8. DEA schedule of the drug, if applicable. **Not a controlled substance**

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

9

Divider Title: _____



August 2, 1994

TEXAS DEPT. OF HEALTH
RECEIVED

AUG 09 1994

Martha McNeill, R.Ph., Product Manager
Texas Department Of Health
Vendor Drug Program
(Mail Code - Y-915)
1100 West 49th Street
Austin, TX 78756-3174

VENDOR DRUG PROGRAM

Dear Ms. McNeill:

I am writing to introduce myself as Manager of Pricing Strategy for Schein Pharmaceutical, Inc. As part of our company's restructuring, all pricing information will be supplied through my office.

Enclosed is Schein's product listing, updated as of August 1, 1994. This list replaces all prior pricing information. Please update your files as soon as possible. As always, all pricing information is provided to you on a confidential basis for your use only.

If you have any questions, you may reach me at the above address or through my direct dial number: 201-593-5669. I look forward to working with you in the future.

Sincerely,

A handwritten signature in black ink, appearing to read "Lisa Recchia", written over a horizontal line.

Lisa Recchia
Manager, Pricing Strategy

LR/mvl
(tx-dept)

comp. 8/12/94
llk & km

WAC X 1.111 = D

Schein Pharmaceutical Inc.
PRODUCT LISTING

SCHEIN	PRODUCT LISTING				
NDC#					
00364-	DESCRIPTION	STRENGTH	SIZE	AWP	WAC
7347-10	Trimethobenzamide Suppos	100mg	10	6.04	3.50
7348-10	Trimethobenzamide Suppos	200mg	10	7.43	4.22
0649-01	Trimethoprim Tabs	100mg	100	22.80	10.70
7105-72	Triple Antibiotic Ointment	Combo	1/2oz	1.58	0.95
7105-56	Triple Antibiotic Ointment	Combo	1oz	2.25	1.35
7284-37	Triple Sulfa Vaginal Cream	Combo	2.75 oz	6.70	3.35
0846-01	Trivitamin Fluoride Chewable Tabs	1mg	100	5.00	3.08
0783-57	Trivitamin Fluoride Drops	0.25mg	50ml	3.90	2.25
0782-57	Trivitamin Fluoride Drops	0.5mg	50ml	4.50	2.25
0822-01	Valproic Acid Caps	250mg	100	24.50	12.96
2139-16	Valproic Acid Syrup, USP	250mg	Pint	37.27	24.25
2472-33	Vancomycin Inj	500mg	10x10ml	70.00	59.50
2473-91	Vancomycin Inj	1gm	10x30ml	140.41	117.01
2111-01	Verapamil Tabs	80mg	100	21.75	3.65
2111-90	Verapamil Tabs	80mg	100UD	34.25	20.48
2111-05	Verapamil Tabs	80mg	500	95.95	17.25
2111-02	Verapamil Tabs	80mg	1000	134.65	34.50
2112-01	Verapamil Tabs	120mg	100	28.50	5.25
2112-90	Verapamil Tabs	120mg	100UD	37.50	22.28
2112-05	Verapamil Tabs	120mg	500	110.95	24.95
2112-02	Verapamil Tabs	120mg	1000	215.00	46.95
2590-01	Verapamil HCL Ext. Release Tabs	180mg	100	97.80	53.50
2567-01	Verapamil HCL Ext. Release Tabs	240mg	100	113.70	58.75
2262-54	Vit B Complex w/ C & B12 (Lyophilized) Inj MDV	Combo	10ml	8.78	5.27
6579-56	Water For Inj Bacteriostatic MDV		30ml	2.25	1.31

geh

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

10

Divider Title: _____

Hospital Products Division

Abbott Laboratories
One Abbott Park Road
Abbott Park, Illinois 60064-3500

December 22, 1992

Martha McNeill, R.Ph.
Texas Department of Human Services
Vendor Drug Program, Mail Code Y-915
P.O. Box 149030
Austin, Texas 78714-9030

Dear Ms. McNeill:

Enclosed you will find the Request For Information form that your office requested for our list number 07923-23, 5% Dextrose Injection, U.S.P. in Partial-Fills. Also enclosed is a supplementary price list as well as the NDA approval letter and a statement as to our liability insurance. In the event that you need additional information, please feel free to contact either myself at (708) 937-8980 or the local sales representative identified in the questionnaire.

Sincerely,



Mark W. Sebree
Manager, Contract Administration

cc: C. Marcaccio NJB 29

REQUEST FOR INFORMATION FOR NEW DRUG PRODUCT
OR FOR ADDITIONAL INFORMATION OF PRODUCTS CURRENTLY
INCLUDED IN THE TEXAS DRUG CODE INDEX

Texas Department of Health
Austin, Texas

Requests for consideration of a preparation for addition to the Texas Vendor Drug Program must cover the following points:

1. Name of drug. 5% dextrose injection, U.S.P. in partial-fills
 - a. Your private brand name, if applicable:
 - b. Generic name:
2. Name and address of firm: Abbott Laboratories
1 Abbott Park Rd.
Abbott Park, IL 60064-3500
3. Name and address of manufacturer of drug: Abbott Laboratories
1 Abbott Park Rd.
Abbott Park, IL 60064-3500
4. Drug description:
 - a. Dosage Form: I.V. Solution
 - b. Strength: 5%
 - c. Formula: N.A
 - d. Recommended daily dose: Variable
 - e. Maximum daily dose: Variable
5. Size of packages (50's, 100's, etc.) and National Drug Code for each.

25 ml

50 ml

100 ml

0074-07923-20 - 40 0499 00 010 0050 VL

0074-07923-13 - 40 0499 01 010 00250 VL

0074-07923-23 - 40 0499 06 010 00250 VL
6. Price: (a., b., and c. must be completed) In addition, attach copies of price lists- one set of price lists is sufficient for multiple submittals.
 - a. Average of suggested wholesale price to pharmacy: *Direct Price* \$260.16 per case of 48 *00542000*
 - b. Price to wholesaler and/or distributor: - \$260.16 per case of 48 *00542000*
 - c. Direct price to pharmacy: \$260.16 per case of 48 *00542000*
 - d. Special price to institutional pharmacy, i.e., (Nursing Home, Home Health Care, etc.): \$368.64 per case of 48 *00768000*
 - e. Special price to chain warehouse:

Handwritten:
1-4-93
1-4-93

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001b. form	re: Information for New Drug Product (partial) (1 page)	n.d.	P6/b(6)

COLLECTION:

Clinton Presidential Records
Domestic Policy Council
Devorah Adler
OA/Box Number: 20468

FOLDER TITLE:

Fraud and Drugs

2012-0463-S

rc754

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

7. Is the drug legend or OTC? Legend
8. DEA schedule of the drug, if applicable. N.A.
9. Does your finished dosage form (tablet, capsule, etc.) carry a visible identifying logo? ___ Yes ☒ No If yes, please enclose a picture of schematic drawing.
10. Is this product now marketed under an approved NDA or ANDA? Yes
- Submit a copy of the FDA letter of approval of the NDA or ANDA, or, if not applicable, a copy of the FDA letter of approval for marketing.
11. Is this product listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)? Yes
- If so, what is it's rating? AP
- If not, why? _____
12. Name and address of representatives covering the Austin area; if applicable:
Jerry Johnson

P6(b)(6)

 [001b]
13. Attach a copy of your sales agreement with retail pharmacists (contract, policy, etc.)
Not Applicable
14. Include a copy of file card, package insert, or material for physicians.
Included
15. Attach a copy of your Vendor Liability Insurance:
- a. Included, or
- b. Previously submitted or unchanged. (Do not need to resubmit.)
16. Do you sell to distributors, repackagers, or relabelers, other than full-service drug wholesalers, who in turn sell your products to the retail trade bearing your NDC number? No
- If yes, attach a listing.

REQUEST FOR INFORMATION FOR NEW DRUG PRODUCT
OR FOR ADDITIONAL INFORMATION OF PRODUCTS CURRENTLY
INCLUDED IN THE TEXAS DRUG CODE INDEX

A product added to the Texas Vendor Drug Program must bear the labeler code, as defined by the FDA, of the party, with the exception of a bonafide full-service drug wholesaler, making the final sale to the provider.


Manufacturers or distributors having one or more of their pharmaceuticals included in the program are responsible for submitting notification of any changes pertaining to any of the 16 points above not later than such revisions are scheduled to occur to:

Texas Department of Human Services
Martha McNeill, R.Ph., Product Manager
Vendor Drug Program (Mail Code Y-915)
P. O. Box 149030
Austin, Texas 78714-9030

I certify that the information submitted is correct to the best of my knowledge and that this product is not now in violation of either Federal or State Law. I also agree to inform the Texas Department of Human Services, in writing, of any changes in formulation, product status, price or availability as herein described, within fifteen (15) days of such change.

Mark Sebree

Responsible Person (Type or Print)


Signature

Manager, Contract Administration

Title

1 Abbott Park Road	Abbott Park	IL	60064-3500
Address	City	State	Zip

Abbott Laboratories	708 937-8980
Company Name	Telephone

Note: Do not use the abbreviation N/A in answering any of the questions on this application. Also, all liquids are to be listed as milliliters.

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a tabbed divider. Given our digitization capabilities, we are sometimes unable to adequately scan such dividers. The title from the original document is indicated below.

11

Divider Title: _____

Texas Department of Human Services

INTERIM
COMMISSIONER
Burton F. Railford

February 13, 1992

BOARD MEMBERS
Cassandra C. Carr
Chairman, Austin
David Herndon
Vice Chairman, Austin
Bob Gever
El Paso
Yava D. Scott
Houston
Paula Gomez
Brownsville

Catherine G. Specht
Director, Sales Administration
General Healthcare Division
Baxter Healthcare Corporation
One Parkway North, Suite 100
Deerfield, IL 60015

Dear Ms. Specht:

This will advise you that your application for inclusion of the drug (see attached list) on the list of drug products for which the Texas Vendor Drug Program will reimburse pharmacies on Medicaid prescriptions has been approved. The effective date for this approval is January 1, 1992.

Thank you for your submission of this application. Your cooperation in keeping me informed of any changes to your product line, including changes in cost to wholesalers and retail/chain pharmacies, is hereby requested and required.

Sincerely,

Martha McNeill, R.Ph.

Martha McNeill, R.Ph.
Product Manager
Vendor Drug Program
(Mail Code Y-915)

MM:jb

Enclosure

REQUEST FOR INFORMATION FOR NEW DRUG PRODUCT
OR FOR ADDITIONAL INFORMATION OF PRODUCTS CURRENTLY
INCLUDED IN THE TEXAS DRUG CODE INDEX

Requests for consideration of a preparation for addition to the Texas Vendor Drug Program must cover the following points:

1. Name of drug. *5%, Dextrose and 0.9% Sodium Chloride Injection, USP*
 - a. Your private brand name, if applicable:
 - b. Generic name: *5%, Dextrose and 0.9% Sodium Chloride Injection, USP*
2. Name and address of firm:

Baxter Healthcare Corporation
General Healthcare Division
One Parkway North Suite 100
Deerfield, IL 60015-0851
3. Name and address of manufacturer of drug:

Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015
4. Drug description:
 - a. Dosage Form: *Liquid*
 - b. Strength:
 - c. Formula: *5%, Dextrose, 0.9% Sodium Chloride*
 - d. Recommended daily dose: *ml's as appropriate*
 - e. Maximum daily dose: *ml's*
5. Size of packages (50's, 100's, etc.) and National Drug Code for each.

<i>250 ml</i>	<i>0336-0089-02-24</i>	<i>40 04 93 10 090 001</i>
<i>500 ml</i>	<i>0336-0089-03-18</i>	<i>40 04 93 10 090 002</i>
<i>1000 ml</i>	<i>0336-0089-04-12</i>	<i>40 04 93 10 090 003</i>
6. Price: (a., b., and c. must be completed) In addition, attach copies of price lists- one set of price lists is sufficient for multiple submittals.
 - a. Average of suggested wholesale price *in each* to pharmacy:

<i>250 ml</i>	<i>8.75</i>
<i>500 ml</i>	<i>8.75</i>
<i>1000 ml</i>	<i>10.51</i>
 - b. Price to wholesaler and/or distributor *in each*:

<i>250 ml</i>	<i>5.30</i>
<i>500 ml</i>	<i>5.30</i>
<i>1000 ml</i>	<i>6.37</i>
 - c. Direct price to pharmacy:
 - d. Special price to institutional pharmacy, i.e., (Nursing Home, Home Health Care, etc.):
 - e. Special price to chain warehouse:

LOT
281062
NDC 0338-0009-02

EXP
250 mL

Baxter

**5% Dextrose and
0.9% Sodium Chloride
Injection USP**

50

EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP
900 mg SODIUM CHLORIDE USP pH 4.5 (3.5 TO 6.5)
MEq/L SODIUM 154 CHLORIDE 154
HYPERTONIC OSMOLARITY 580 mOsm/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER

100

ADDITIVES MAY BE INCOMPATIBLE
CONSULT WITH PHARMACIST IF
AVAILABLE WHEN INTRODUCING
ADDITIVES USE ASEPTIC TECHNIQUE
MIX THOROUGHLY DO NOT STORE
DOSAGE INTRAVENOUSLY AS DIRECTED
BY A PHYSICIAN SEE DIRECTIONS
CAUTIONS MUST NOT BE USED IN
SERIES CONNECTIONS DO NOT USE
UNLESS SOLUTION IS CLEAR
FEDERAL (USA) LAW PROHIBITS
DISPENSING WITHOUT PRESCRIPTION

150

200

Vialflex® CONTAINER PL 146® PLASTIC

BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

7-25-1-147

LOT

EXP

281063
NDC 0338-0089-03

500 mL

1- **Baxter** -1

— 5% Dextrose and —

2- 0.9% Sodium Chloride -2
Injection USP —3- EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP -3
800 mg SODIUM CHLORIDE USP pH 4.0 (3.5 TO 6.5)
mEq/L SODIUM 154 CHLORIDE 154
HYPERTONIC OSMOLARITY 560 mOsm/L (CALC)
STERILE NONPYROGENIC SINGLE DOSE CONTAINER— ADDITIVES MAY BE INCOMPATIBLE CONSULT -
WITH PHARMACIST IF AVAILABLE WHEN
INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUE
MIX THOROUGHLY DO NOT STORE4- DOSAGE INTRAVENOUSLY AS DIRECTED BY A -4
PHYSICIAN SEE DIRECTIONSCAUTIONS MUST NOT BE USED IN SERIES
CONNECTIONS DO NOT USE UNLESS SOLUTION IS
CLEARFEDERAL (USA) LAW PROHIBITS DISPENSING
WITHOUT PRESCRIPTION

Vialflex® CONTAINER

PL 146® PLASTIC

BAXTER HEALTHCARE CORPORATION

DEERFIELD IL 60015 USA

MADE IN USA

7-25-1-148

LOT
ZB1064
NDC 0338-0089-04

EXP

1000 mL

1-	Baxter	-1
2-	5% Dextrose and	-2
3-	0.9% Sodium Chloride	-3
4-	Injection USP	-4
5-	EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP 900 mg SODIUM CHLORIDE USP pH 4.0 (3.5 TO 6.5) mEq/L SODIUM 154 CHLORIDE 154 HYPERTONIC OSMOLARITY 560 mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE CONTAINER	-5
6-	ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE	-6
7-	DOSAGE INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY DISCARD IF LEAKS ARE FOUND	-7
8-	MUST NOT BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS SOLUTION IS CLEAR FEDERAL (USA) LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C) UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT	-8
9-	Vialflex® CONTAINER PL 146® PLASTIC BAXTER HEALTHCARE CORPORATION DEERFIELD IL 60015 USA MADE IN USA	-9

7-25-1-149

REQUEST FOR INFORMATION FOR NEW DRUG PRODUCT
OR FOR ADDITIONAL INFORMATION OF PRODUCTS CURRENTLY
INCLUDED IN THE TEXAS DRUG CODE INDEX

Requests for consideration of a preparation for addition to the Texas Vendor Drug Program must cover the following points:

1. Name of drug. *5% Dextrose Injection, USP Dextrose 5% in Water*
 - a. Your private brand name, if applicable:
 - b. Generic name: *5% Dextrose in Water*
2. Name and address of firm: *Baxter Healthcare Corporation
General Healthcare Division
One Parkway North Suite 100
Deerfield, IL 60015-0851*
3. Name and address of manufacturer of drug: *Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015*
- Drug description:
 - a. Dosage Form: *Liquid*
 - b. Strength:
 - c. Formula: *5% Dextrose*
 - d. Recommended daily dose: *ml's as appropriate*
 - e. Maximum daily dose: *ml's*
5. Size of packages (50's, 100's, etc.) and National Drug Code for each.
1A0062 250 ml 0396 0016 02 12 4004 99 02 090 0025
1A0063 500 ml 0396 0016 03 12 4004 99 03 090 0025
6. Price: (a., b., and c. must be completed) In addition, attach copies of price lists- one set of price lists is sufficient for multiple submittals.
 - a. Average of suggested wholesale price to pharmacy: *(in each)*

250 ml	8.33
500 ml	8.33
 - b. Price to wholesaler and/or distributor: *(in each)*

250 ml	5.05
500 ml	5.05
 - c. Direct price to pharmacy:
 - d. Special price to institutional pharmacy, i.e., (Nursing Home, Home Health Care, etc.):
 - e. Special price to chain warehouse:

REQUEST FOR INFORMATION FOR NEW DRUG PRODUCT
OR FOR ADDITIONAL INFORMATION OF PRODUCTS CURRENTLY
INCLUDED IN THE TEXAS DRUG CODE INDEX

Requests for consideration of a preparation for addition to the Texas Vendor Drug Program must cover the following points:

1. Name of drug. *Lactated Ringers Injection, USP*
 - a. Your private brand name, if applicable:
 - b. Generic name: *Lactated Ringers Injection, USP*
2. Name and address of firm: *Baxter Healthcare Corporation
General Healthcare Division
One Parkway North Suite 100
Deerfield, IL 60015-0851*
3. Name and address of manufacturer of drug: *Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015*
4. Drug description:
 - a. Dosage Form: *Liquid*
 - b. Strength:
 - c. Formula: *Lactated Ringers*
 - d. Recommended daily dose. ml's as appropriate
 - e. Maximum daily dose: ml's
5. Size of packages (50's, 100's, etc.), and National Drug Code for each.
2B2322 250 ml 0338-0117-02 24 40 0450 02 090 00250
2B2323 500 ml 0338-0117-03 18 250
2B2324 1000 ml 0338-0117-04 12 333
6. Price: (a., b., and c. must be completed) In addition, attach copies of price lists- one set of price lists is sufficient for multiple submittals.
 - a. Average of suggested wholesale price *in eaches* to pharmacy:

{	250 ml	9.41
	500 ml	9.40
	1000 ml	10.79
 - b. Price to wholesaler and/or distributor: *in eaches*

{	250 ml	5.70
	500 ml	5.70
	1000 ml	6.54
 - c. Direct price to pharmacy:
 - d. Special price to institutional pharmacy, i.e., (Nursing Home, Home Health Care, etc.):
 - e. Special price to chain warehouse:

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001c. note	re:phone number (partial) (1 page)	12/30/1991	P6/b(6)

COLLECTION:

Clinton Presidential Records
Domestic Policy Council
Devorah Adler
OA/Box Number: 20468

FOLDER TITLE:

Fraud and Drugs

2012-0463-S

rc754

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

Effective: 12/30/91
Baxter

file

Dear Martha,

Attached is a print-out showing new prices (dp and amp) for codes I have previously submitted on forms. The prices are effective immediately, so please change pricing in your database.

Also included is another batch of new forms for our mini and premix solutions. The pricing on those forms is effective immediately.

Please feel free to call me if you have questions —

at Baxter office :

at my office at my home :

[001c]

(708)-940-4173



Sincerely,

Sharon Porter

**VENDOR DRUG PROGRAM
RECEIVED**

JAN 2 - 1992

Texas Dept. of Human Services
Austin, Texas

comp. 1/02/92
JEP

code	description	ndc number	ml	case quantity	case price		each price	
					dp	amp	dp	amp
280163	10% Dextrose	0338-0023-03	500	18	\$112.50	162.22	\$6.25	\$9.01
280164	10% Dextrose	0338-0023-04	1000	12	\$88.20	126.14	\$7.35	\$10.51
281163	10% Dextrose and 0.9% NaCl	0338-0095-03	500	18	\$132.12	200.88	\$7.34	\$11.16
281164	10% Dextrose and 0.9% NaCl	0338-0095-04	1000	12	\$98.40	149.90	\$8.20	\$12.49
SODIUM CHLORIDE INJECTIONS								
281313	0.45% Sodium Chloride	0338-0043-03	500	18	\$105.66	147.74	\$5.87	\$8.21
281314	0.45% Sodium Chloride	0338-0043-04	1000	12	\$79.80	110.74	\$6.65	\$9.23
281322	0.9% Sodium Chloride	0338-0044-02	250	12	\$66.12	96.62	\$5.51	\$8.05
281321	0.9% Sodium Chloride	0338-0049-01	150	36	\$193.32	277.92	\$5.37	\$7.72
281322	0.9% Sodium Chloride	0338-0049-02	250	24	\$128.88	234.96	\$5.37	\$9.79
281323	0.9% Sodium Chloride	0338-0049-03	500	18	\$96.66	178.22	\$5.37	\$9.79
281324	0.9% Sodium Chloride	0338-0049-04	1000	12	\$69.72	136.98	\$5.81	\$11.24
281353	3% Sodium Chloride	0338-0054-03	500	18	\$103.68	159.70	\$5.76	\$8.75
281373	5% Sodium Chloride	0338-0056-03	500	18	\$114.30	165.78	\$6.35	\$9.21
REPLACEMENT SOLUTIONS								
282303	Lactated Ringer's Injection	0338-0105-03	500	18	\$114.12	165.24	\$6.34	\$9.18
282304	Lactated Ringer's Injection	0338-0105-04	1000	12	\$89.16	125.71	\$7.43	\$10.48
282322	Lactated Ringer's Injection	0338-0117-02	250	24	\$151.92	223.78	\$6.33	\$9.32
282323	Lactated Ringer's Injection	0338-0117-03	500	18	\$113.94	167.76	\$6.33	\$9.32
282324	Lactated Ringer's Injection	0338-0117-04	1000	12	\$87.12	125.71	\$7.26	\$10.48
282063	5% Dextrose and Ringer's Inj.	0338-0111-03	500	18	\$117.72	174.74	\$6.54	\$9.71
282064	5% Dextrose and Ringer's Inj.	0338-0111-04	1000	12	\$109.68	151.92	\$9.14	\$12.66